AU641361B2
(en)
*
|
1988-05-02 |
1993-09-23 |
Zynaxis Technologies, Incorporated |
Compounds, compositions and method for binding bio-affecting substances to surface membranes of bio-particles
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
US6214804B1
(en)
|
1989-03-21 |
2001-04-10 |
Vical Incorporated |
Induction of a protective immune response in a mammal by injecting a DNA sequence
|
US6867195B1
(en)
|
1989-03-21 |
2005-03-15 |
Vical Incorporated |
Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
|
CA2489769A1
(en)
*
|
1989-03-21 |
1990-10-04 |
Philip L. Felgner |
Expression of exogenous polynucleotide sequences in a vertebrate
|
US6706694B1
(en)
|
1990-03-21 |
2004-03-16 |
Vical Incorporated |
Expression of exogenous polynucleotide sequences in a vertebrate
|
US6228844B1
(en)
|
1991-11-12 |
2001-05-08 |
Vical Incorporated |
Stimulating vascular growth by administration of DNA sequences encoding VEGF
|
US5543389A
(en)
*
|
1990-11-01 |
1996-08-06 |
State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization |
Covalent polar lipid-peptide conjugates for use in salves
|
US5256641A
(en)
*
|
1990-11-01 |
1993-10-26 |
State Of Oregon |
Covalent polar lipid-peptide conjugates for immunological targeting
|
US5543390A
(en)
|
1990-11-01 |
1996-08-06 |
State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University |
Covalent microparticle-drug conjugates for biological targeting
|
US5827819A
(en)
*
|
1990-11-01 |
1998-10-27 |
Oregon Health Sciences University |
Covalent polar lipid conjugates with neurologically active compounds for targeting
|
US6605712B1
(en)
*
|
1990-12-20 |
2003-08-12 |
Arch Development Corporation |
Gene transcription and ionizing radiation: methods and compositions
|
US6156304A
(en)
*
|
1990-12-20 |
2000-12-05 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Gene transfer for studying and treating a connective tissue of a mammalian host
|
US20020123476A1
(en)
*
|
1991-03-19 |
2002-09-05 |
Emanuele R. Martin |
Therapeutic delivery compositions and methods of use thereof
|
US7202225B1
(en)
*
|
1993-10-15 |
2007-04-10 |
Emanuele R Martin |
Therapeutic delivery compositions and methods of use thereof
|
US5693769A
(en)
*
|
1991-12-13 |
1997-12-02 |
Transcell Technologies, Inc. |
Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
|
US5795870A
(en)
*
|
1991-12-13 |
1998-08-18 |
Trustees Of Princeton University |
Compositions and methods for cell transformation
|
EP0625207A1
(en)
*
|
1991-12-17 |
1994-11-23 |
The Regents Of The University Of California |
Gene therapy for cystic fibrosis transmembrane conductance regulator activity (cftr)
|
US6627615B1
(en)
|
1991-12-17 |
2003-09-30 |
The Regents Of The University Of California |
Methods and compositions for in vivo gene therapy
|
US5858784A
(en)
*
|
1991-12-17 |
1999-01-12 |
The Regents Of The University Of California |
Expression of cloned genes in the lung by aerosol- and liposome-based delivery
|
US5756353A
(en)
*
|
1991-12-17 |
1998-05-26 |
The Regents Of The University Of California |
Expression of cloned genes in the lung by aerosol-and liposome-based delivery
|
CA2128616A1
(en)
*
|
1992-01-23 |
1993-08-05 |
Gary H. Rhodes |
Ex vivo gene transfer
|
US5885970A
(en)
*
|
1992-03-16 |
1999-03-23 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotides against human protein kinase C
|
US6113946A
(en)
*
|
1992-04-03 |
2000-09-05 |
The Regents Of The University Of California |
Self-assembling polynucleotide delivery system comprising dendrimer polycations
|
EP1236473A3
(en)
*
|
1992-04-03 |
2003-01-15 |
The Regents Of The University Of California |
Self-assembling polynucleotide delivery system
|
US5792751A
(en)
*
|
1992-04-13 |
1998-08-11 |
Baylor College Of Medicine |
Tranformation of cells associated with fluid spaces
|
US20020108136A1
(en)
*
|
1997-03-21 |
2002-08-08 |
Sri |
Transgenic animals produced by homologous sequence targeting
|
US6806084B1
(en)
*
|
1992-06-04 |
2004-10-19 |
The Regents Of The University Of California |
Methods for compositions for in vivo gene delivery
|
IL105914A0
(en)
*
|
1992-06-04 |
1993-10-20 |
Univ California |
Methods and compositions for in vivo gene therapy
|
JPH07502753A
(en)
*
|
1992-07-13 |
1995-03-23 |
ユーカリオン,インコーポレイティド |
Transvascular and intracellular transport of lipidated proteins
|
US7105574B1
(en)
|
1999-03-26 |
2006-09-12 |
Vical Incorporated |
Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
|
US5334761A
(en)
*
|
1992-08-28 |
1994-08-02 |
Life Technologies, Inc. |
Cationic lipids
|
IL107150A0
(en)
*
|
1992-09-29 |
1993-12-28 |
Isis Pharmaceuticals Inc |
Oligonucleotides having a conserved g4 core sequence
|
US5329029A
(en)
*
|
1992-11-05 |
1994-07-12 |
Wan Barbara Y |
Phosphatidylalkanolamine derivatives and their use in generating phospholipid conjugates
|
US5552155A
(en)
*
|
1992-12-04 |
1996-09-03 |
The Liposome Company, Inc. |
Fusogenic lipsomes and methods for making and using same
|
US5705655A
(en)
*
|
1992-12-17 |
1998-01-06 |
Megabios Corporation |
Amphiphilic nitrogen containing imidazolinium derivative compounds and uses
|
US5631237A
(en)
*
|
1992-12-22 |
1997-05-20 |
Dzau; Victor J. |
Method for producing in vivo delivery of therapeutic agents via liposomes
|
US6090925A
(en)
|
1993-03-09 |
2000-07-18 |
Epic Therapeutics, Inc. |
Macromolecular microparticles and methods of production and use
|
DK0809110T3
(en)
*
|
1993-03-09 |
2004-05-24 |
Baxter Int |
Macromolecular microparticles and methods of preparation
|
EP1624068A1
(en)
*
|
1993-06-01 |
2006-02-08 |
Life Technologies Inc. |
Genetic immunization with cationic lipids
|
US5578475A
(en)
*
|
1993-07-12 |
1996-11-26 |
Life Technologies, Inc. |
Composition and methods for transfecting eukaryotic cells
|
US5563111A
(en)
*
|
1993-08-03 |
1996-10-08 |
Kao Corporation |
Agricultural chemical composition comprising amine surfactants with at least one ester or amide linkage
|
US6348449B1
(en)
|
1993-09-21 |
2002-02-19 |
The Trustees Of The University Of Pennsylvania |
Methods of inducing mucosal immunity
|
AU691226B2
(en)
*
|
1993-11-24 |
1998-05-14 |
Megabios Corporation |
Amphiphilic derivatives of guanidine
|
JPH09505593A
(en)
*
|
1993-11-24 |
1997-06-03 |
メガバイオス・コーポレイション |
Amphiphilic derivatives of piperazine
|
US5665879A
(en)
*
|
1993-11-24 |
1997-09-09 |
Megabios Corporation |
Amphiphilic derivatives of piperazine
|
US6613351B1
(en)
*
|
1993-12-20 |
2003-09-02 |
Biotech Tools S.A. |
Compound capable of introducing at least one molecule into a cell
|
US5674908A
(en)
|
1993-12-20 |
1997-10-07 |
Life Technologies, Inc. |
Highly packed polycationic ammonium, sulfonium and phosphonium lipids
|
US5830686A
(en)
*
|
1994-01-13 |
1998-11-03 |
Calydon |
Tissue-specific enhancer active in prostate
|
US6057299A
(en)
*
|
1994-01-13 |
2000-05-02 |
Calydon, Inc. |
Tissue-specific enhancer active in prostate
|
US5928944A
(en)
*
|
1994-02-04 |
1999-07-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of adenoviral-medicated cell transfection
|
US6075012A
(en)
*
|
1994-02-11 |
2000-06-13 |
Life Technologies, Inc. |
Reagents for intracellular delivery of macromolecules
|
US6989434B1
(en)
|
1994-02-11 |
2006-01-24 |
Invitrogen Corporation |
Reagents for intracellular delivery of macromolecules
|
US5962427A
(en)
|
1994-02-18 |
1999-10-05 |
The Regent Of The University Of Michigan |
In vivo gene transfer methods for wound healing
|
US5942496A
(en)
|
1994-02-18 |
1999-08-24 |
The Regent Of The University Of Michigan |
Methods and compositions for multiple gene transfer into bone cells
|
US5763416A
(en)
|
1994-02-18 |
1998-06-09 |
The Regent Of The University Of Michigan |
Gene transfer into bone cells and tissues
|
US6074840A
(en)
|
1994-02-18 |
2000-06-13 |
The Regents Of The University Of Michigan |
Recombinant production of latent TGF-beta binding protein-3 (LTBP-3)
|
US6995008B1
(en)
|
1994-03-07 |
2006-02-07 |
Merck & Co., Inc. |
Coordinate in vivo gene expression
|
US6551618B2
(en)
|
1994-03-15 |
2003-04-22 |
University Of Birmingham |
Compositions and methods for delivery of agents for neuronal regeneration and survival
|
US5651981A
(en)
*
|
1994-03-29 |
1997-07-29 |
Northwestern University |
Cationic phospholipids for transfection
|
US5739118A
(en)
|
1994-04-01 |
1998-04-14 |
Apollon, Inc. |
Compositions and methods for delivery of genetic material
|
EP0759768A4
(en)
*
|
1994-04-07 |
2000-08-09 |
Proteinix Company |
Vasoactive intestinal polypeptide
|
AU2589095A
(en)
*
|
1994-05-16 |
1995-12-05 |
Washington University |
Cell membrane fusion composition and method
|
CA2194221C
(en)
*
|
1994-06-22 |
2001-01-02 |
Timothy D. Heath |
Cationic amphiphiles
|
US5777153A
(en)
*
|
1994-07-08 |
1998-07-07 |
Gilead Sciences, Inc. |
Cationic lipids
|
FR2722506B1
(en)
*
|
1994-07-13 |
1996-08-14 |
Rhone Poulenc Rorer Sa |
COMPOSITION CONTAINING NUCLEIC ACIDS, PREPARATION AND USES
|
DE4426429A1
(en)
*
|
1994-07-26 |
1996-02-01 |
Boehringer Ingelheim Int |
Method for introducing DNA into higher eukaryotic cells
|
US7592317B1
(en)
*
|
1994-08-11 |
2009-09-22 |
The University Of Chicago |
Constitutive gene expression in conjuction with ionizing radiation
|
AUPM747694A0
(en)
*
|
1994-08-16 |
1994-09-08 |
Commonwealth Scientific And Industrial Research Organisation |
Delivery of nucleic acids and peptides
|
US5892071A
(en)
*
|
1994-09-30 |
1999-04-06 |
The Reagents Of The University Of California |
Cationic transport reagents
|
US5527928A
(en)
*
|
1994-09-30 |
1996-06-18 |
Nantz; Michael H. |
Cationic transport reagents
|
US5837533A
(en)
|
1994-09-28 |
1998-11-17 |
American Home Products Corporation |
Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
|
US5753613A
(en)
*
|
1994-09-30 |
1998-05-19 |
Inex Pharmaceuticals Corporation |
Compositions for the introduction of polyanionic materials into cells
|
US5785992A
(en)
*
|
1994-09-30 |
1998-07-28 |
Inex Pharmaceuticals Corp. |
Compositions for the introduction of polyanionic materials into cells
|
US6911216B1
(en)
|
1994-10-12 |
2005-06-28 |
Genzyme Corporation |
Targeted delivery via biodegradable polymers
|
US5641665A
(en)
*
|
1994-11-28 |
1997-06-24 |
Vical Incorporated |
Plasmids suitable for IL-2 expression
|
US6071890A
(en)
*
|
1994-12-09 |
2000-06-06 |
Genzyme Corporation |
Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
|
US5767099A
(en)
*
|
1994-12-09 |
1998-06-16 |
Genzyme Corporation |
Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules
|
US5747471A
(en)
*
|
1994-12-09 |
1998-05-05 |
Genzyme Corporation |
Cationic amphiphiles containing steroid lipophilic groups for intracellular delivery of therapeutic molecules
|
US5650096A
(en)
*
|
1994-12-09 |
1997-07-22 |
Genzyme Corporation |
Cationic amphiphiles for intracellular delivery of therapeutic molecules
|
US5948767A
(en)
*
|
1994-12-09 |
1999-09-07 |
Genzyme Corporation |
Cationic amphiphile/DNA complexes
|
US6331524B1
(en)
|
1994-12-09 |
2001-12-18 |
Genzyme Corporation |
Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapy
|
US5910487A
(en)
*
|
1994-12-09 |
1999-06-08 |
Genzyme Corporation |
Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules
|
US6383814B1
(en)
|
1994-12-09 |
2002-05-07 |
Genzyme Corporation |
Cationic amphiphiles for intracellular delivery of therapeutic molecules
|
US5719131A
(en)
*
|
1994-12-09 |
1998-02-17 |
Genzyme Corporation |
Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
|
US5840710A
(en)
*
|
1994-12-09 |
1998-11-24 |
Genzyme Corporation |
Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
|
US5939401A
(en)
*
|
1994-12-09 |
1999-08-17 |
Genzyme Corporation |
Cationic amphiphile compositions for intracellular delivery of therapeutic molecules
|
US6630455B1
(en)
|
1995-01-13 |
2003-10-07 |
Vanderbilt University |
Methods for inducing mucosal immune responses
|
US5795587A
(en)
|
1995-01-23 |
1998-08-18 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
US6008202A
(en)
*
|
1995-01-23 |
1999-12-28 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
US5929043A
(en)
|
1995-01-31 |
1999-07-27 |
Pangene Corporation |
Recombinase mediated DNA therapies
|
US5830430A
(en)
|
1995-02-21 |
1998-11-03 |
Imarx Pharmaceutical Corp. |
Cationic lipids and the use thereof
|
US20020103147A1
(en)
*
|
1997-09-05 |
2002-08-01 |
Hammond H. Kirk |
Gene therapy for congestive heart failure
|
CN1136920C
(en)
|
1995-02-28 |
2004-02-04 |
加利福尼亚大学董事会 |
Gene transfer-mediated angiogenesis therapy
|
US20030148968A1
(en)
*
|
1995-02-28 |
2003-08-07 |
Hammond H. Kirk |
Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
|
US6752987B1
(en)
|
1995-02-28 |
2004-06-22 |
The Regents Of The University Of California |
Adenovirus encoding human adenylylcyclase (AC) VI
|
US5962428A
(en)
*
|
1995-03-30 |
1999-10-05 |
Apollon, Inc. |
Compositions and methods for delivery of genetic material
|
US6242434B1
(en)
*
|
1997-08-08 |
2001-06-05 |
Bone Care International, Inc. |
24-hydroxyvitamin D, analogs and uses thereof
|
US20040043971A1
(en)
*
|
1995-04-03 |
2004-03-04 |
Bone Care International, Inc. |
Method of treating and preventing hyperparathyroidism with active vitamin D analogs
|
US20020183288A1
(en)
*
|
1995-04-03 |
2002-12-05 |
Bone Care International, Inc. |
Method for treating and preventing hyperparathyroidism
|
JPH11504631A
(en)
*
|
1995-04-25 |
1999-04-27 |
バイカル インコーポレイテッド |
Single vial formulation of DNA / lipid complex
|
US6420549B1
(en)
|
1995-06-06 |
2002-07-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide analogs having modified dimers
|
JPH11507352A
(en)
|
1995-06-07 |
1999-06-29 |
ジンタ・インコーポレイテッド |
New carbamate-based cationic lipids
|
US5869040A
(en)
*
|
1995-06-07 |
1999-02-09 |
Biogen, Inc |
Gene therapy methods and compositions
|
EP0832271B8
(en)
*
|
1995-06-07 |
2005-03-02 |
INEX Pharmaceuticals Corp. |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
US5759519A
(en)
*
|
1995-06-07 |
1998-06-02 |
Gen-Probe Incorporated |
Method for the intracellular delivery of biomolecules using thiocationic lipids
|
US5994315A
(en)
*
|
1995-06-07 |
1999-11-30 |
East Carolina University |
Low adenosine agent, composition, kit and method for treatment of airway disease
|
US5711964A
(en)
*
|
1995-06-07 |
1998-01-27 |
United States Of America |
Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D
|
US20030069173A1
(en)
*
|
1998-03-16 |
2003-04-10 |
Life Technologies, Inc. |
Peptide-enhanced transfections
|
US5756352A
(en)
*
|
1995-06-07 |
1998-05-26 |
Gen-Probe Incorporated |
Thiocationic lipid-nucleic acid conjugates
|
US7422902B1
(en)
|
1995-06-07 |
2008-09-09 |
The University Of British Columbia |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
US5739271A
(en)
*
|
1995-06-07 |
1998-04-14 |
Gen-Probe Incorporated |
Thiocationic lipids
|
US5705385A
(en)
*
|
1995-06-07 |
1998-01-06 |
Inex Pharmaceuticals Corporation |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
US6051429A
(en)
*
|
1995-06-07 |
2000-04-18 |
Life Technologies, Inc. |
Peptide-enhanced cationic lipid transfections
|
KR19990022597A
(en)
*
|
1995-06-07 |
1999-03-25 |
다니엘 엘. 캐시앙, 헨리 엘. 노르호프 |
Thiocationic lipids, pharmaceutical compositions and methods of using the same
|
US5851548A
(en)
*
|
1995-06-07 |
1998-12-22 |
Gen-Probe Incorporated |
Liposomes containing cationic lipids and vitamin D
|
JPH11507815A
(en)
|
1995-06-07 |
1999-07-13 |
ジンタ・インコーポレイテッド |
Phosphonate-based cationic lipids
|
US5981501A
(en)
*
|
1995-06-07 |
1999-11-09 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating plasmids in lipid bilayers
|
AU5979296A
(en)
*
|
1995-06-07 |
1996-12-30 |
Life Technologies, Inc. |
Peptide-enhanced cationic lipid transfections
|
DE19521412A1
(en)
*
|
1995-06-14 |
1996-12-19 |
Boehringer Mannheim Gmbh |
New cationic and polycationic amphiphiles, reagents containing them and their use
|
US5931809A
(en)
*
|
1995-07-14 |
1999-08-03 |
Depotech Corporation |
Epidural administration of therapeutic compounds with sustained rate of release
|
US6339173B1
(en)
|
1996-07-22 |
2002-01-15 |
Promega Biosciences, Inc. |
Amide-based cationic lipids
|
US6020526A
(en)
*
|
1995-07-21 |
2000-02-01 |
Genta, Incorporated |
Amide-based cationic lipids
|
US5855911A
(en)
*
|
1995-08-29 |
1999-01-05 |
Board Of Regents, The University Of Texas System |
Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
|
NO953680D0
(en)
*
|
1995-09-18 |
1995-09-18 |
Hans Prydz |
Cell cycle Enzymes
|
US6120794A
(en)
*
|
1995-09-26 |
2000-09-19 |
University Of Pittsburgh |
Emulsion and micellar formulations for the delivery of biologically active substances to cells
|
AU7078396A
(en)
*
|
1995-09-27 |
1997-04-30 |
Regents Of The University Of California, The |
Polyfunctional cationic cytofectins, formulations and methods for generating active cytofectin:polynucleotide transfection complexes
|
US5869715A
(en)
*
|
1995-09-27 |
1999-02-09 |
The Reagents Of The University Of California |
Polyfunctional cationic cytofectins
|
US6086913A
(en)
*
|
1995-11-01 |
2000-07-11 |
University Of British Columbia |
Liposomal delivery of AAV vectors
|
EP0863749A2
(en)
|
1995-11-30 |
1998-09-16 |
Vical Incorporated |
Complex cationic lipids
|
US6537776B1
(en)
|
1999-06-14 |
2003-03-25 |
Diversa Corporation |
Synthetic ligation reassembly in directed evolution
|
US6126964A
(en)
*
|
1996-01-04 |
2000-10-03 |
Mirus Corporation |
Process of making a compound by forming a polymer from a template drug
|
AUPN741696A0
(en)
*
|
1996-01-05 |
1996-01-25 |
Commonwealth Scientific And Industrial Research Organisation |
Delivery of nucleic acids ii
|
US5789244A
(en)
*
|
1996-01-08 |
1998-08-04 |
Canji, Inc. |
Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
|
US6392069B2
(en)
*
|
1996-01-08 |
2002-05-21 |
Canji, Inc. |
Compositions for enhancing delivery of nucleic acids to cells
|
US7002027B1
(en)
*
|
1996-01-08 |
2006-02-21 |
Canji, Inc. |
Compositions and methods for therapeutic use
|
US20040014709A1
(en)
*
|
1996-01-08 |
2004-01-22 |
Canji, Inc. |
Methods and compositions for interferon therapy
|
AU2112697A
(en)
*
|
1996-02-09 |
1997-08-28 |
Pi-Wan Cheng |
Receptor ligand-facilitated delivery of biologically active molecules
|
US5783566A
(en)
*
|
1996-05-10 |
1998-07-21 |
California Institute Of Technology |
Method for increasing or decreasing transfection efficiency
|
WO1997034483A1
(en)
*
|
1996-03-18 |
1997-09-25 |
California Institute Of Technology |
Methods for increasing or decreasing transfection efficiency
|
US5994317A
(en)
*
|
1996-04-09 |
1999-11-30 |
Vical Incorporated |
Quaternary cytofectins
|
US5798250A
(en)
*
|
1996-04-15 |
1998-08-25 |
Icn Pharmaceuticals, Inc. |
Facilitating hepatitus virus infection in cell culture using a membrane stressor
|
JP2001507207A
(en)
*
|
1996-05-01 |
2001-06-05 |
イマアーレクス・フアーマシユーチカル・コーポレーシヨン |
Methods for delivering compounds to cells
|
KR100536983B1
(en)
*
|
1996-05-08 |
2006-06-29 |
니카 헬스 프로덕츠 리미티드 |
Some genes for delivery of genetic material
|
WO1997042819A1
(en)
*
|
1996-05-13 |
1997-11-20 |
Alberto Haces |
Cationic lipids for transfection of negatively charged or neutral molecules into living cells
|
US5980935A
(en)
*
|
1996-05-15 |
1999-11-09 |
Kirpotin; Dmitri |
Cationic lipids and methods of use therefor
|
US8323963B2
(en)
*
|
1996-05-29 |
2012-12-04 |
University Of Southern California |
Construction and use of genes encoding pathogenic epitopes for treatment of autoimmune disease
|
US6274136B1
(en)
|
1996-05-29 |
2001-08-14 |
University Of Southern California |
Construction and use of genes encoding pathogenic epitopes for treatment of autoimmune disease
|
US5935936A
(en)
*
|
1996-06-03 |
1999-08-10 |
Genzyme Corporation |
Compositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic molecules
|
US7812149B2
(en)
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
US9096636B2
(en)
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US6093816A
(en)
|
1996-06-27 |
2000-07-25 |
Isis Pharmaceuticals, Inc. |
Cationic lipids
|
WO1998000554A1
(en)
*
|
1996-07-03 |
1998-01-08 |
Genetics Institute, Inc. |
Protease fmh-1, an ice/ced-like protease
|
CA2261887C
(en)
*
|
1996-07-23 |
2007-10-02 |
Oregon Health Sciences University |
Covalent polar lipid conjugates with biologically-active compounds for use in salves
|
CA2271388C
(en)
*
|
1996-09-13 |
2007-11-06 |
The School Of Pharmacy, University Of London |
Liposomes encapsulating polynucleotides operatively coding for immunogenic polypeptides
|
US7384923B2
(en)
*
|
1999-05-14 |
2008-06-10 |
Lipoxen Technologies Limited |
Liposomes
|
WO1998014592A2
(en)
|
1996-10-01 |
1998-04-09 |
Geron Corporation |
Telomerase reverse transcriptase
|
US5861397A
(en)
*
|
1996-10-03 |
1999-01-19 |
Vical Incorporated |
Piperazine based cytofectins
|
US6977244B2
(en)
|
1996-10-04 |
2005-12-20 |
Board Of Regents, The University Of Texas Systems |
Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
|
FR2754828B1
(en)
*
|
1996-10-23 |
1998-12-24 |
Univ Toulouse |
ARTIFICIAL MEMBRANE STRUCTURE, METHOD AND POLYMER FOR PREPARING IT, METHOD FOR PREPARING THIS POLYMER, PARTICLE AND FILM COMPRISING THIS STRUCTURE
|
US6210707B1
(en)
*
|
1996-11-12 |
2001-04-03 |
The Regents Of The University Of California |
Methods of forming protein-linked lipidic microparticles, and compositions thereof
|
AU729655B2
(en)
*
|
1996-11-12 |
2001-02-08 |
Regents Of The University Of California, The |
Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery
|
US5965441A
(en)
*
|
1996-11-13 |
1999-10-12 |
The General Hospital Coporation |
HSV/AAV hybrid amplicon vectors
|
EP0958380A4
(en)
*
|
1996-12-06 |
2004-03-17 |
Univ California |
Macromolecule-lipid complexes and methods for making and using
|
WO1998024888A2
(en)
|
1996-12-06 |
1998-06-11 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Polypeptides encoded by a human lipase-like gene, compositions and methods
|
US7008776B1
(en)
|
1996-12-06 |
2006-03-07 |
Aventis Pharmaceuticals Inc. |
Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
|
US20020128240A1
(en)
*
|
1996-12-30 |
2002-09-12 |
Bone Care International, Inc. |
Treatment of hyperproliferative diseases using active vitamin D analogues
|
US6527716B1
(en)
|
1997-12-30 |
2003-03-04 |
Altea Technologies, Inc. |
Microporation of tissue for delivery of bioactive agents
|
US20030129194A1
(en)
*
|
1997-02-13 |
2003-07-10 |
Bone Care International, Inc. |
Targeted therapeutic delivery of vitamin D compounds
|
AU750451B2
(en)
*
|
1997-02-13 |
2002-07-18 |
Bone Care International, Inc. |
Targeted therapeutic delivery of vitamin D compounds
|
FR2760193B1
(en)
*
|
1997-02-28 |
1999-05-28 |
Transgene Sa |
LIPIDS AND COMPLEXES OF CATIONIC LIPIDS AND ACTIVE SUBSTANCES, IN PARTICULAR FOR THE TRANSFECTION OF CELLS
|
US5837283A
(en)
*
|
1997-03-12 |
1998-11-17 |
The Regents Of The University Of California |
Cationic lipid compositions targeting angiogenic endothelial cells
|
US7112338B2
(en)
*
|
1997-03-12 |
2006-09-26 |
The Regents Of The University Of California |
Cationic liposome delivery of taxanes to angiogenic blood vessels
|
US5965542A
(en)
*
|
1997-03-18 |
1999-10-12 |
Inex Pharmaceuticals Corp. |
Use of temperature to control the size of cationic liposome/plasmid DNA complexes
|
US5948653A
(en)
|
1997-03-21 |
1999-09-07 |
Pati; Sushma |
Sequence alterations using homologous recombination
|
US5925628A
(en)
*
|
1997-03-31 |
1999-07-20 |
Genzyme Corporation |
Cationic amphiphiles for intracellular delivery of therapeutic molecules
|
US5958894A
(en)
*
|
1997-04-04 |
1999-09-28 |
Megabios Corporation |
Amphiphilic biguanide derivatives
|
US6235310B1
(en)
|
1997-04-04 |
2001-05-22 |
Valentis, Inc. |
Methods of delivery using cationic lipids and helper lipids
|
US5912239A
(en)
*
|
1997-04-04 |
1999-06-15 |
Genzyme Corporation |
Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules
|
FR2761912B1
(en)
*
|
1997-04-14 |
1999-07-02 |
Capsulis |
PROCESS FOR ADHERING A PRODUCT TO A SURFACE
|
AU753781B2
(en)
|
1997-04-28 |
2002-10-31 |
Aventis Pharma S.A. |
Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
|
WO1998049350A1
(en)
*
|
1997-04-30 |
1998-11-05 |
Regents Of The University Of Minnesota |
In vivo use of recombinagenic oligonucleobases to correct genetic lesions in hepatocytes
|
US5948925A
(en)
*
|
1997-05-06 |
1999-09-07 |
Genzyme Corporation |
Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids
|
US5952516A
(en)
*
|
1997-05-08 |
1999-09-14 |
Genzyme Corporation |
Cationic amphiphiles containing multiplesteroid lipophilic groups
|
US5942634A
(en)
*
|
1997-05-09 |
1999-08-24 |
Genzyme Corporation |
Cationic amphiphiles for cell transfections
|
US6835395B1
(en)
|
1997-05-14 |
2004-12-28 |
The University Of British Columbia |
Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
|
US20030104044A1
(en)
*
|
1997-05-14 |
2003-06-05 |
Semple Sean C. |
Compositions for stimulating cytokine secretion and inducing an immune response
|
US6287591B1
(en)
*
|
1997-05-14 |
2001-09-11 |
Inex Pharmaceuticals Corp. |
Charged therapeutic agents encapsulated in lipid particles containing four lipid components
|
WO1999002192A1
(en)
|
1997-07-11 |
1999-01-21 |
Brandeis University |
Method of inducing apoptosis by reducing the level of thiamin
|
US20090239940A1
(en)
*
|
1997-07-22 |
2009-09-24 |
Del Monte Federica |
Treating heart failure and ventricular arrhythmias
|
EP1007673B1
(en)
|
1997-07-30 |
2008-12-17 |
Emory University |
Novel bone mineralization proteins, dna, vectors, expression systems
|
US7923250B2
(en)
|
1997-07-30 |
2011-04-12 |
Warsaw Orthopedic, Inc. |
Methods of expressing LIM mineralization protein in non-osseous cells
|
DE69838584T2
(en)
|
1997-08-04 |
2008-06-26 |
Cell Genesys, Inc., Foster City |
ENHANCERS OF HUMAN GLANDULAR CALLIQUE, VECTORS CONTAINING HIM, AND METHODS FOR ITS USE
|
WO1999008110A1
(en)
*
|
1997-08-08 |
1999-02-18 |
Newbiotics, Inc. |
Methods and compositions for overcoming resistance to biologic and chemotherapy
|
ES2167939T3
(en)
*
|
1997-08-13 |
2002-05-16 |
Biontex Lab Gmbh |
NEW POLYAMINS, ITS PREPARATION AND USES.
|
US6818627B1
(en)
|
1997-08-14 |
2004-11-16 |
The Trustees Of The University Of Pennsylvania |
Functional fragments of HIV-1 Vpr protein and methods of using the same
|
US7285288B1
(en)
|
1997-10-03 |
2007-10-23 |
Board Of Regents, The University Of Texas System |
Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
|
US7704962B1
(en)
|
1997-10-03 |
2010-04-27 |
Board Of Regents, The University Of Texas System |
Small oligonucleotides with anti-tumor activity
|
US6884842B2
(en)
|
1997-10-14 |
2005-04-26 |
Alnis Biosciences, Inc. |
Molecular compounds having complementary surfaces to targets
|
US6875606B1
(en)
*
|
1997-10-23 |
2005-04-05 |
The United States Of America As Represented By The Department Of Veterans Affairs |
Human α-7 nicotinic receptor promoter
|
US5998482A
(en)
*
|
1997-11-10 |
1999-12-07 |
David; Sunil A. |
Use of synthetic polycationic amphiphilic substances with fatty acid or hydrocarbon substituents as anti-sepsis agents
|
EP1987845B1
(en)
|
1997-11-20 |
2012-03-21 |
Vical Incorporated |
Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor.
|
WO1999027964A1
(en)
*
|
1997-12-01 |
1999-06-10 |
Cfy Biomedicals, Inc. |
Multivalent recombinant antibodies for treating hrv infections
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
US7179892B2
(en)
|
2000-12-06 |
2007-02-20 |
Neuralab Limited |
Humanized antibodies that recognize beta amyloid peptide
|
FR2772047B1
(en)
*
|
1997-12-05 |
2004-04-09 |
Ct Nat D Etudes Veterinaires E |
GENOMIC SEQUENCE AND POLYPEPTIDES OF CIRCOVIRUS ASSOCIATED WITH PIGLET LOSS DISEASE (MAP), APPLICATIONS TO DIAGNOSIS AND TO PREVENTION AND / OR TREATMENT OF INFECTION
|
US20010003580A1
(en)
|
1998-01-14 |
2001-06-14 |
Poh K. Hui |
Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
|
AU2324999A
(en)
*
|
1998-01-16 |
1999-08-02 |
California Pacific Medical Center Research Institute |
Methods and compositions for gene delivery
|
EP1045897B1
(en)
|
1998-01-23 |
2002-01-30 |
Newbiotics Inc. |
Enzyme catalyzed therapeutic agents
|
US7462605B2
(en)
*
|
1998-01-23 |
2008-12-09 |
Celmed Oncology (Usa), Inc. |
Phosphoramidate compounds and methods of use
|
US6410328B1
(en)
*
|
1998-02-03 |
2002-06-25 |
Protiva Biotherapeutics Inc. |
Sensitizing cells to compounds using lipid-mediated gene and compound delivery
|
WO1999047538A1
(en)
|
1998-03-19 |
1999-09-23 |
Human Genome Sciences, Inc. |
Cytokine receptor common gamma chain like
|
US6271209B1
(en)
*
|
1998-04-03 |
2001-08-07 |
Valentis, Inc. |
Cationic lipid formulation delivering nucleic acid to peritoneal tumors
|
US6043390A
(en)
|
1998-04-03 |
2000-03-28 |
The Regents Of The University Of California |
Pentaerythritol lipid derivatives and nucleic-acid complexes
|
DE69928244T2
(en)
|
1998-05-06 |
2006-08-10 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. |
INHIBITORS OF NF-KB ACTIVATION
|
US6225456B1
(en)
|
1998-05-07 |
2001-05-01 |
University Technololy Corporation |
Ras suppressor SUR-5
|
US6506889B1
(en)
|
1998-05-19 |
2003-01-14 |
University Technology Corporation |
Ras suppressor SUR-8 and related compositions and methods
|
SK287330B6
(en)
*
|
1998-05-29 |
2010-07-07 |
The Scripps Research Institute |
Methods and compositions useful for modulation of angiogenesis using tyrosine kinase Src
|
US6726925B1
(en)
|
1998-06-18 |
2004-04-27 |
Duke University |
Temperature-sensitive liposomal formulation
|
US6200598B1
(en)
*
|
1998-06-18 |
2001-03-13 |
Duke University |
Temperature-sensitive liposomal formulation
|
US20040077603A1
(en)
*
|
1998-08-28 |
2004-04-22 |
Wilhelm Stoffel |
Synthetic tear fluid
|
ES2394458T3
(en)
*
|
1998-09-09 |
2013-01-31 |
Genzyme Corporation |
Methylation of plasmid vectors
|
US6135976A
(en)
|
1998-09-25 |
2000-10-24 |
Ekos Corporation |
Method, device and kit for performing gene therapy
|
US6077709A
(en)
|
1998-09-29 |
2000-06-20 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Survivin expression
|
EP1829856A3
(en)
|
1998-11-12 |
2009-02-25 |
Invitrogen Corporation |
Transfection reagents
|
DE69918711T2
(en)
*
|
1998-11-25 |
2005-07-21 |
Gene Therapy Systems, Inc., San Diego |
AMPHIPHILE POLYAMINE COMPOUNDS
|
US6656498B1
(en)
|
1998-11-25 |
2003-12-02 |
Vanderbilt University |
Cationic liposomes for gene transfer
|
US20030035798A1
(en)
|
2000-08-16 |
2003-02-20 |
Fang Fang |
Humanized antibodies
|
US20020032164A1
(en)
|
1998-12-30 |
2002-03-14 |
Dale Roderic M. K. |
Antimicrobial compounds and methods for their use
|
US6441156B1
(en)
*
|
1998-12-30 |
2002-08-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Calcium channel compositions and methods of use thereof
|
US7868162B2
(en)
|
1998-12-30 |
2011-01-11 |
Lakewood-Amedex, Inc. |
Antimicrobial and antiviral compounds and methods for their use
|
US6627215B1
(en)
|
1998-12-30 |
2003-09-30 |
Oligos Etc. Inc. |
Devices for improved wound management
|
US6570003B1
(en)
*
|
2001-01-09 |
2003-05-27 |
Lexion Genetics Incorporated |
Human 7TM proteins and polynucleotides encoding the same
|
AU776150B2
(en)
*
|
1999-01-28 |
2004-08-26 |
Medical College Of Georgia Research Institute, Inc. |
Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
|
DE50000562D1
(en)
|
1999-02-25 |
2002-10-31 |
Von Strandmann Elke Pogge |
AGENTS FOR TREATING PIGMENTATION DISORDERS
|
CN1348332A
(en)
|
1999-03-03 |
2002-05-08 |
宾夕法尼亚大学理事会 |
Vaccines and gene therapy compositions and methods of making and using the same
|
US7393548B2
(en)
*
|
1999-03-22 |
2008-07-01 |
J.P. M.E.D. Ltd. |
Nano oil in glycerin emulsion
|
US6280977B1
(en)
|
1999-03-24 |
2001-08-28 |
Gene Therapy Systems |
Method for generating transcriptionally active DNA fragments
|
ATE272410T1
(en)
|
1999-03-26 |
2004-08-15 |
Vical Inc |
ADJUVANT COMPOSITIONS FOR INCREASE THE IMMUNE RESPONSE TO POLYNUCLEOTIDE-BASED VACCINES
|
US6379698B1
(en)
|
1999-04-06 |
2002-04-30 |
Isis Pharmaceuticals, Inc. |
Fusogenic lipids and vesicles
|
US7098192B2
(en)
|
1999-04-08 |
2006-08-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of STAT3 expression
|
US6696424B1
(en)
|
1999-05-28 |
2004-02-24 |
Vical Incorporated |
Cytofectin dimers and methods of use thereof
|
JP4723097B2
(en)
*
|
1999-05-28 |
2011-07-13 |
バイカル インコーポレイテッド |
Cytofectin dimer and method of use thereof
|
UA81216C2
(en)
|
1999-06-01 |
2007-12-25 |
|
Prevention and treatment of amyloid disease
|
US6943152B1
(en)
|
1999-06-10 |
2005-09-13 |
Merial |
DNA vaccine-PCV
|
US20010048940A1
(en)
*
|
1999-06-18 |
2001-12-06 |
Jennifer D. Tousignant |
Cationic amphiphile micellar complexes
|
FR2797402B1
(en)
|
1999-07-15 |
2004-03-12 |
Biomerieux Stelhys |
USE OF A POLYPEPTIDE FOR DETECTING, PREVENTING OR TREATING A CONDITION ASSOCIATED WITH A DEGENERATIVE, NEUROLOGICAL OR AUTOIMMUNE DISEASE
|
US6683061B1
(en)
|
1999-07-22 |
2004-01-27 |
Newbiotics, Inc. |
Enzyme catalyzed therapeutic activation
|
WO2001007088A2
(en)
|
1999-07-22 |
2001-02-01 |
Newbiotics, Inc. |
Methods for treating therapy-resistant tumors
|
US20030078499A1
(en)
*
|
1999-08-12 |
2003-04-24 |
Eppstein Jonathan A. |
Microporation of tissue for delivery of bioactive agents
|
US20050249794A1
(en)
*
|
1999-08-27 |
2005-11-10 |
Semple Sean C |
Compositions for stimulating cytokine secretion and inducing an immune response
|
AUPQ259399A0
(en)
*
|
1999-09-01 |
1999-09-23 |
Lustre Investments Pte Ltd |
Therapeutic agents
|
US6448388B1
(en)
|
2000-08-16 |
2002-09-10 |
Lexicon Genetics Incorporated |
Human proteases and polynucleotides encoding the same
|
US6716614B1
(en)
|
1999-09-02 |
2004-04-06 |
Lexicon Genetics Incorporated |
Human calcium dependent proteases, polynucleotides encoding the same, and uses thereof
|
US20080003673A1
(en)
*
|
1999-09-02 |
2008-01-03 |
Alejandro Abuin |
Novel human proteases and polynucleotides encoding the same
|
US20030166902A1
(en)
*
|
2001-02-20 |
2003-09-04 |
Yi Hu |
Novel human protease and polynucleotides encoding the same
|
US20050153323A1
(en)
*
|
2000-07-28 |
2005-07-14 |
Yi Hu |
Novel human proteases and polynucleotides encoding the same
|
US20020151047A1
(en)
*
|
2001-01-08 |
2002-10-17 |
Yi Hu |
Novel human protease and polynucleotides encoding the same
|
US20030050464A1
(en)
*
|
2000-07-28 |
2003-03-13 |
Yi Hu |
Novel human proteases and polynucleotides encoding the same
|
EE200200127A
(en)
*
|
1999-09-09 |
2003-04-15 |
The Regents Of The University Of California |
Delivering taxanes to angiogenic blood vessels with cationic liposomes
|
US20020107382A1
(en)
*
|
2000-09-27 |
2002-08-08 |
Friddle Carl Johan |
Novel human protease inhibitor proteins and polynucleotides encoding the same
|
US6867291B1
(en)
*
|
2000-09-15 |
2005-03-15 |
Lexicon Genetics Incorporated |
Human hemicentin proteins and polynucleotides encoding the same
|
US6790660B1
(en)
*
|
2001-09-18 |
2004-09-14 |
Lexicon Genetics Incorporated |
Human kielin-like proteins and polynucleotides encoding the same
|
US6541252B1
(en)
|
2000-05-19 |
2003-04-01 |
Lexicon Genetics Incorporated |
Human kinases and polynucleotides encoding the same
|
US6841377B1
(en)
*
|
2001-06-13 |
2005-01-11 |
Lexicon Genetics Incorporated |
Human kinase and polynucleotides encoding the same
|
US6864079B2
(en)
|
2001-04-06 |
2005-03-08 |
Lexicon Genetics Incorporated |
Human kinase and polynucleotides encoding the same
|
US6720173B1
(en)
|
1999-11-08 |
2004-04-13 |
Lexicon Genetics Incorporated |
Human kinase protein and polynucleotides encoding the same
|
US6734009B2
(en)
|
2000-12-27 |
2004-05-11 |
Lexicon Genetics Incorporated |
Human kinases and polynucleotides encoding the same
|
US20080050809A1
(en)
*
|
1999-09-28 |
2008-02-28 |
Alejandro Abuin |
Novel human kinases and polynucleotides encoding the same
|
US6759527B2
(en)
|
2001-03-20 |
2004-07-06 |
Lexicon Genetics Incorporated |
Human kinase and polynucleotides encoding the same
|
US6586230B1
(en)
*
|
2000-10-27 |
2003-07-01 |
Lexicon Genetics Incorporated |
Human kinase and polynucleotides encoding the same
|
US6511840B1
(en)
|
2000-06-15 |
2003-01-28 |
Lexicon Genetics Incorporated |
Human kinase proteins and polynucleotides encoding the same
|
US6797510B1
(en)
|
2001-05-24 |
2004-09-28 |
Lexicon Genetics Incorporated |
Human kinases and polynucleotides encoding the same
|
US6734010B2
(en)
*
|
2001-05-09 |
2004-05-11 |
Lexicon Genetics Incorporated |
Human kinases and polynucleotides encoding the same
|
US7892541B1
(en)
|
1999-09-30 |
2011-02-22 |
Tumor Biology Investment Group, Inc. |
Soluble epidermal growth factor receptor isoforms
|
US20080213878A1
(en)
*
|
1999-10-19 |
2008-09-04 |
Gregory Donoho |
Novel human membrane proteins and polynucleotides encoding the same
|
AU783948B2
(en)
*
|
1999-11-12 |
2006-01-05 |
Lexicon Genetics Incorporated |
Novel human proteases and polynucleotides encoding the same
|
AU1920601A
(en)
*
|
1999-11-19 |
2001-05-30 |
Lexicon Genetics Incorporated |
Novel human secreted proteins and polynucleotides encoding the same
|
ES2170622B1
(en)
*
|
1999-12-03 |
2004-05-16 |
Consejo Superior De Investigaciones Cientificas |
CLONES AND INFECTIVE VECTORS DERIVED FROM CORONAVIRUS AND ITS APPLICATIONS.
|
AU785082B2
(en)
*
|
1999-12-07 |
2006-09-14 |
Lexicon Pharmaceuticals, Inc. |
Novel human kinase proteins and polynucleotides encoding the same
|
AU2070701A
(en)
*
|
1999-12-07 |
2001-06-18 |
Lexicon Genetics Incorporated |
Novel human membrane proteins and polynucleotides encoding the same
|
EP1263966A1
(en)
*
|
1999-12-13 |
2002-12-11 |
Lexicon Genetics Incorporated |
Novel human transferase proteins and polynucleotides encoding the same
|
US20030008813A1
(en)
*
|
1999-12-17 |
2003-01-09 |
Felgner Philip L. |
Intracellular protein delivery compositions and methods of use
|
AU783901B2
(en)
*
|
1999-12-22 |
2005-12-22 |
Lexicon Pharmaceuticals, Inc. |
Human membrane proteins and polynucleotides encoding the same having Homology to CD20 Proteins and IGE Receptors
|
WO2001046407A1
(en)
*
|
1999-12-22 |
2001-06-28 |
Lexicon Genetics Incorporated |
Polynucleotides encoding human protease homologs
|
FR2802925B1
(en)
*
|
1999-12-23 |
2002-03-22 |
Commissariat Energie Atomique |
CATIONIC AMPHIPHILES, THEIR APPLICATIONS AND THEIR SYNTHESIS METHOD
|
CN1433478A
(en)
*
|
1999-12-30 |
2003-07-30 |
诺瓦提斯公司 |
Novel colloid synthetic vectors for gene therapy
|
EP1244795A1
(en)
*
|
2000-01-06 |
2002-10-02 |
Lexicon Genetics Incorporated |
Novel human proteases and polynucleotides encoding the same
|
US20020055479A1
(en)
|
2000-01-18 |
2002-05-09 |
Cowsert Lex M. |
Antisense modulation of PTP1B expression
|
AU784540B2
(en)
*
|
2000-01-18 |
2006-04-27 |
Lexicon Pharmaceuticals, Inc. |
Novel human kinase protein and polynucleotides encoding the same
|
US6261840B1
(en)
|
2000-01-18 |
2001-07-17 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
US7078388B2
(en)
*
|
2000-01-21 |
2006-07-18 |
Merial |
DNA vaccines for farm animals, in particular bovines and porcines
|
US20040002472A1
(en)
*
|
2000-01-21 |
2004-01-01 |
Audonnet Jean-Christophe Francis |
Vaccination or immunization using a prime-boost regimen
|
US6852705B2
(en)
|
2000-01-21 |
2005-02-08 |
Merial |
DNA vaccines for farm animals, in particular bovines and porcines
|
DE60118703T2
(en)
*
|
2000-01-26 |
2006-12-14 |
Lexicon Genetics Inc., The Woodlands |
HUMAN NEUREXIN-SIMILAR PROTEINS AND POLYNUCLEOTIDES THAT CODE
|
AU9256001A
(en)
*
|
2000-01-28 |
2001-12-17 |
Lexicon Genetics Incorporated |
Novel human enzymes and polynucleotides encoding the same
|
US20020115837A1
(en)
*
|
2000-01-28 |
2002-08-22 |
Turner C. Alexander |
Novel human membrane proteins and polynucleotides encoding the same
|
CA2399663A1
(en)
*
|
2000-02-04 |
2001-08-09 |
Lexicon Genetics Incorporated |
Novel human enzymes and polynucleotides encoding the same
|
WO2001057086A2
(en)
*
|
2000-02-04 |
2001-08-09 |
Lexicon Genetics Incorporated |
Novel human g protein coupled receptor proteins and polynucleotides encoding the same
|
US6689558B2
(en)
|
2000-02-08 |
2004-02-10 |
Sangamo Biosciences, Inc. |
Cells for drug discovery
|
JP2003522530A
(en)
|
2000-02-11 |
2003-07-29 |
レキシコン・ジェネティクス・インコーポレーテッド |
Novel human protease and polynucleotide encoding the protease
|
KR100388332B1
(en)
|
2000-02-16 |
2003-06-25 |
세이코 엡슨 가부시키가이샤 |
Ink cartridge for ink jet recording device, connection unit and ink jet recording device
|
AU2001238503A1
(en)
*
|
2000-02-17 |
2001-08-27 |
Lexicon Genetics Incorporated |
Novel human thrombospondin repeat proteins and polynucleotides encoding the same
|
WO2001064903A2
(en)
*
|
2000-02-29 |
2001-09-07 |
Lexicon Genetics Incorporated |
Novel human transferase proteins and polynucleotides encoding the same
|
JP2003531582A
(en)
*
|
2000-02-29 |
2003-10-28 |
レキシコン・ジェネティクス・インコーポレーテッド |
Human transporter protein and polynucleotide encoding the same
|
AU2001247283A1
(en)
*
|
2000-03-06 |
2001-09-17 |
Lexicon Genetics Incorporated |
Human transporter proteins and polynucleotides encoding the same
|
CA2402227A1
(en)
|
2000-03-10 |
2001-09-20 |
Lexicon Genetics Incorporated |
Human g-coupled protein receptor kinases and polynucleotides encoding the same
|
EP1317551B1
(en)
*
|
2000-03-13 |
2007-02-28 |
Lexicon Genetics Incorporated |
Human phospholipases and polynucleotides encoding the same
|
ATE511856T1
(en)
|
2000-03-13 |
2011-06-15 |
Cornell Res Foundation Inc |
BLOCKING LEUKOCYTE EMIGRATION AND INFLAMMATION DUE TO DISRUPTION WITH CD99/HEC2
|
CN102151337B
(en)
|
2000-03-13 |
2014-03-12 |
恩根尼公司 |
Compositions and methods for regulated protein expression in gut
|
EP1268538A2
(en)
*
|
2000-03-20 |
2003-01-02 |
Lexicon Genetics Incorporated |
Human secreted proteins and polynucleotides encoding the same
|
US20040033600A1
(en)
*
|
2001-03-21 |
2004-02-19 |
Palli Subba Reddy |
Ecdysone receptor-based inducible gene expression system
|
WO2001070763A1
(en)
*
|
2000-03-22 |
2001-09-27 |
The Children's Hospital Of Philadelphia |
Modified blood clotting factors and methods of use
|
GB0018307D0
(en)
|
2000-07-26 |
2000-09-13 |
Aventis Pharm Prod Inc |
Polypeptides
|
WO2001075108A1
(en)
*
|
2000-04-03 |
2001-10-11 |
Lexicon Genetics Incorporated |
Human ion channel protein and polynucleotides encoding the same
|
CA2405729A1
(en)
*
|
2000-04-12 |
2001-10-25 |
Lexicon Genetics Incorporated |
Human metalloprotease and polynucleotides encoding the same
|
EP1832599A3
(en)
|
2000-04-12 |
2007-11-21 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
JP2003531149A
(en)
|
2000-04-13 |
2003-10-21 |
ザ・ロツクフエラー・ユニバーシテイ |
Enhancement of antibody-derived immune response
|
US7189705B2
(en)
|
2000-04-20 |
2007-03-13 |
The University Of British Columbia |
Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
|
CA2407074A1
(en)
*
|
2000-04-21 |
2001-11-01 |
Jukka Hartikka |
Compositions and methods for in vivo delivery of polynucleotide-based therapeutics
|
EP1276873A2
(en)
|
2000-04-25 |
2003-01-22 |
Lexicon Genetics Incorporated |
Human kinase proteins and polynucleotides encoding the same
|
JP2003533205A
(en)
*
|
2000-05-12 |
2003-11-11 |
レキシコン・ジェネティクス・インコーポレーテッド |
Novel human lipocalin homologs and polynucleotides encoding the same
|
US6680172B1
(en)
|
2000-05-16 |
2004-01-20 |
Regents Of The University Of Michigan |
Treatments and markers for cancers of the central nervous system
|
WO2001088133A2
(en)
|
2000-05-18 |
2001-11-22 |
Lexicon Genetics Incorporated |
Human semaphorin homologs and polynucleotides encoding the same
|
WO2001090179A2
(en)
*
|
2000-05-23 |
2001-11-29 |
Lexicon Genetics Incorporated |
Novel human thrombospondin-like proteins and polynucleotides encoding the same
|
US6790667B1
(en)
*
|
2000-05-30 |
2004-09-14 |
Lexicon Genetics Incorporated |
Human mitochondrial proteins and polynucleotides encoding the same
|
EP2230253B1
(en)
|
2000-06-05 |
2013-08-07 |
The Brigham & Women's Hospital, Inc. |
Antibodies against a homologue of the MDR p-glycoprotein on chromosome 7p15-21 and uses thereof
|
AU2001275337A1
(en)
*
|
2000-06-07 |
2001-12-17 |
Lexicon Genetics Incorporated |
Novel human transporter proteins and polynucleotides encoding the same
|
US20040204379A1
(en)
*
|
2000-06-19 |
2004-10-14 |
Cheng Seng H. |
Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
|
PT1295611E
(en)
*
|
2000-06-20 |
2010-09-14 |
Dainippon Sumitomo Pharma Co |
Oligonucleotide-transferring preparations
|
US7074591B2
(en)
*
|
2000-06-27 |
2006-07-11 |
Lexicon Genetics Incorporated |
Polynucleotides encoding human GABA receptors
|
AU2001278956B2
(en)
*
|
2000-07-18 |
2007-04-05 |
Genzyme Corporation |
Stabilized 1alpha-hydroxy vitamin d
|
EP1315800A2
(en)
*
|
2000-07-21 |
2003-06-04 |
Incyte Genomics, Inc. |
Human proteases
|
US6887685B1
(en)
|
2000-07-25 |
2005-05-03 |
Lexicon Genetics Incorporated |
Human thymosin protein and polynucleotides encoding the same
|
AU2001284672B2
(en)
*
|
2000-07-27 |
2007-05-24 |
The Trustees Of The University Of Pennsylvania |
Compositions for and methods of using herpes simplex virus glycoprotein d to suppress immune responses
|
US20020076780A1
(en)
*
|
2000-08-16 |
2002-06-20 |
Turner C. Alexander |
Novel human ion channel proteins and polynucleotides encoding the same
|
EP1311676A2
(en)
*
|
2000-08-22 |
2003-05-21 |
Lexicon Genetics Incorporated |
Human 7tm proteins and polynucleotides encoding the same
|
JP2004531201A
(en)
*
|
2000-08-22 |
2004-10-14 |
レキシコン・ジェネティクス・インコーポレーテッド |
Novel human protease and polynucleotide encoding the protease
|
EP2157183A1
(en)
|
2000-08-25 |
2010-02-24 |
BASF Plant Science GmbH |
Plant polynucleotides encoding prenyl proteases
|
WO2002018555A2
(en)
*
|
2000-08-31 |
2002-03-07 |
Lexicon Genetics Incorporated |
Human kinase proteins and polynucleotides encoding the same
|
WO2002020753A2
(en)
*
|
2000-09-01 |
2002-03-14 |
Lexicon Genetics Incorporated |
Human gaba transporter protein and polynucleotides encoding the same
|
AU2001293019B2
(en)
*
|
2000-09-27 |
2007-01-18 |
Lexicon Pharmaceuticals, Inc. |
Human ion-exchanger proteins and polynucleotides encoding the same
|
US6777232B1
(en)
*
|
2000-10-02 |
2004-08-17 |
Lexicon Genetics Incorporated |
Human membrane proteins and polynucleotides encoding the same
|
US8105825B2
(en)
|
2000-10-03 |
2012-01-31 |
Intrexon Corporation |
Multiple inducible gene regulation system
|
US20050059031A1
(en)
|
2000-10-06 |
2005-03-17 |
Quantum Dot Corporation |
Method for enhancing transport of semiconductor nanocrystals across biological membranes
|
WO2002031129A2
(en)
|
2000-10-12 |
2002-04-18 |
Lexicon Genetics Incorporated |
Human kinases and polynucleotides encoding the same
|
US7001763B1
(en)
|
2000-10-17 |
2006-02-21 |
Lexicon Genetics Incorporated |
Human semaphorin proteins and polynucleotides encoding the same
|
US6831059B2
(en)
|
2000-10-20 |
2004-12-14 |
Allergan, Inc. |
Compositions and methods for treating gonadotrophin related illnesses
|
EP1624062A3
(en)
*
|
2000-10-27 |
2006-02-22 |
Lexicon Genetics Incorporated |
Human 7tm proteins and polynucleotides encoding them
|
JP2004521614A
(en)
*
|
2000-10-27 |
2004-07-22 |
インヴィトロジェン コーポレーション |
Methods for introducing antisense oligonucleotides into eukaryotic cells
|
US7060442B2
(en)
*
|
2000-10-30 |
2006-06-13 |
Regents Of The University Of Michigan |
Modulators on Nod2 signaling
|
CA2427701A1
(en)
*
|
2000-10-30 |
2002-05-10 |
Lexicon Genetics Incorporated |
Human 7tm proteins and polynucleotides encoding the same
|
ATE336571T1
(en)
*
|
2000-11-01 |
2006-09-15 |
Lexicon Genetics Inc |
POLYNUCLEOTIDES THAT CODE FOR HUMAN MELTRIN BETA (ADAM19) METALLOENDOPEPTIDASES
|
WO2002050278A2
(en)
*
|
2000-11-15 |
2002-06-27 |
Lexicon Genetics Incorporated |
Novel human secreted proteins and polynucleotides encoding the same
|
AU2002228633A1
(en)
*
|
2000-11-20 |
2002-06-03 |
Lexicon Genetics Incorporated |
Human kinases and polynucleotides encoding the same
|
CZ301427B6
(en)
*
|
2000-11-29 |
2010-02-24 |
Pci Biotech As |
Method for introducing a molecule into a cell cytosol
|
PE20020574A1
(en)
|
2000-12-06 |
2002-07-02 |
Wyeth Corp |
HUMANIZED ANTIBODIES THAT RECOGNIZE THE AMYLOID PEPTIDE BETA
|
JP2004517622A
(en)
|
2000-12-11 |
2004-06-17 |
レキシコン・ジェネティクス・インコーポレーテッド |
Novel human kinase and polynucleotide encoding the kinase
|
JP2004530417A
(en)
*
|
2000-12-12 |
2004-10-07 |
レキシコン・ジェネティクス・インコーポレーテッド |
Novel human kinase and polynucleotide encoding it
|
US6583269B1
(en)
|
2000-12-18 |
2003-06-24 |
Lexicon Genetics Incorporated |
Human protease inhibitor and polynucleotides encoding the same
|
US6852844B1
(en)
*
|
2000-12-20 |
2005-02-08 |
Lexicon Genetics Incorporated |
Human protocadherin proteins and polynucleotides encoding the same
|
CA2432737A1
(en)
*
|
2000-12-20 |
2002-06-27 |
Lexicon Genetics Incorporated |
Human ion channel protein and polynucleotides encoding the same
|
DE10064870B4
(en)
*
|
2000-12-27 |
2004-10-07 |
G.O.T. Gesellschaft Zur Therapieoptimierung Und Targeting Entwicklungs Mbh |
Sulfur-containing amphiphiles for the transfer of biologically active molecules into cells
|
MXPA03005386A
(en)
|
2000-12-28 |
2004-04-20 |
Wyeth Corp |
Recombinant protective protein from $i(streptococcus pneumoniae).
|
WO2002053753A2
(en)
*
|
2001-01-05 |
2002-07-11 |
Lexicon Genetics Incorporated |
Novel human lipase and polynucleotides encoding the same
|
AU2002241911B9
(en)
*
|
2001-01-19 |
2007-01-25 |
Celmed Oncology (Usa), Inc. |
Methods to treat autoimmune and inflammatory conditions
|
JP2004524835A
(en)
*
|
2001-01-23 |
2004-08-19 |
レキシコン・ジェネティクス・インコーポレーテッド |
Novel human kinase and polynucleotide encoding it
|
CA2434897A1
(en)
*
|
2001-01-24 |
2002-08-01 |
Lexicon Genetics Incorporated |
Human lipase and polynucleotides encoding the same
|
US20020132257A1
(en)
*
|
2001-01-31 |
2002-09-19 |
Tony Giordano |
Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
|
WO2002063002A2
(en)
*
|
2001-02-02 |
2002-08-15 |
Lexicon Genetics Incorporated |
Novel human transporter protein and polynucleotides encoding the same
|
DK1373470T3
(en)
|
2001-02-20 |
2013-07-29 |
Intrexon Corp |
HIS UNKNOWN SUBSTITUTION MUTANTE RECEPTORS AND THEIR USE IN A CELL CEREAL RECEPTOR-BASED INDUCTIONAL Gene EXPRESSION SYSTEM
|
DK1456346T3
(en)
|
2001-02-20 |
2012-05-29 |
Intrexon Corp |
NEW INDUCERABLE Gene EXPRESSION SYSTEM BASED ON ECDYSON RECEPTOR / INVERTEBRATE-RETINOID-X RECEPTOR
|
EP1572862B1
(en)
|
2001-02-20 |
2012-08-01 |
Intrexon Corporation |
Chimeric retinoid x receptors and their use in a novel ecdysone receptor-based inducible gene expression system
|
JP4994563B2
(en)
|
2001-02-20 |
2012-08-08 |
イントレキソン コーポレーション |
Novel substitution mutant receptors and their use in nuclear receptor-based inducible gene expression systems
|
US20030039660A1
(en)
|
2001-03-02 |
2003-02-27 |
The Rockefeller University |
Recombinant hybrid allergen constructs with reduced allergenicity that retain immunogenicity of the natural allergen
|
JP3929250B2
(en)
*
|
2001-03-08 |
2007-06-13 |
株式会社ルネサステクノロジ |
Semiconductor device
|
US7252990B2
(en)
*
|
2001-03-12 |
2007-08-07 |
Lexicon Genetics Incorporated |
Human dectin proteins and polynucleotides encoding the same
|
US20020164627A1
(en)
*
|
2001-03-12 |
2002-11-07 |
Wilganowski Nathaniel L. |
Novel human transporter proteins and polynucleotides encoding the same
|
AU2002306696B2
(en)
*
|
2001-03-12 |
2007-12-20 |
Lexicon Pharmaceuticals, Inc. |
Novel human EGF-family proteins and polynucleotides encoding the same
|
WO2002072019A2
(en)
*
|
2001-03-13 |
2002-09-19 |
Vical Incorporated |
Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases
|
US6994995B1
(en)
*
|
2001-03-16 |
2006-02-07 |
Lexicon Genetics Incorporated |
Human synaptotagmin and polynucleotides encoding the same
|
US6613534B2
(en)
|
2001-03-20 |
2003-09-02 |
Wake Forest University Health Sciences |
MAP-2 as a determinant of metastatic potential
|
US7294511B2
(en)
|
2001-03-22 |
2007-11-13 |
Chromos Molecular Systems, Inc. |
Methods for delivering nucleic acid molecules into cells and assessment thereof
|
US20030186390A1
(en)
*
|
2001-03-22 |
2003-10-02 |
De Jong Gary |
Methods for delivering nucleic acid molecules into cells and assessment thereof
|
US6936469B2
(en)
*
|
2001-03-22 |
2005-08-30 |
Chromos Molecular Systems Inc. |
Methods for delivering nucleic acid molecules into cells and assessment thereof
|
US20030096414A1
(en)
|
2001-03-27 |
2003-05-22 |
Invitrogen Corporation |
Culture medium for cell growth and transfection
|
US20040028651A1
(en)
*
|
2001-03-29 |
2004-02-12 |
Karrupiah Muthumani |
Composition and methods of using hiv vpr
|
EP1383879A4
(en)
*
|
2001-04-06 |
2005-05-11 |
Lexicon Genetics Inc |
Novel human kinases and polynucleotides encoding the same
|
US8034791B2
(en)
|
2001-04-06 |
2011-10-11 |
The University Of Chicago |
Activation of Egr-1 promoter by DNA damaging chemotherapeutics
|
ATE541937T1
(en)
*
|
2001-04-06 |
2012-02-15 |
Univ Chicago |
CHEMOTHERAPEUTIC INTRODUCTION OF EGR-1 PROMOTER ACTIVITY IN GENE THERAPY
|
US20040242523A1
(en)
*
|
2003-03-06 |
2004-12-02 |
Ana-Farber Cancer Institue And The Univiersity Of Chicago |
Chemo-inducible cancer gene therapy
|
US6644173B2
(en)
*
|
2001-04-11 |
2003-11-11 |
Keuring, Incorporated |
Beverage filter cartridge holder
|
US20070128229A1
(en)
*
|
2002-04-12 |
2007-06-07 |
Wyeth |
Surface proteins of Streptococcus pyogenes
|
JP2004533236A
(en)
*
|
2001-04-13 |
2004-11-04 |
ワイエス |
Surface protein of Streptococcus pyogenes
|
EP2228389B1
(en)
|
2001-04-13 |
2015-07-08 |
Human Genome Sciences, Inc. |
Antibodies against vascular endothelial growth factor 2
|
US6607895B2
(en)
*
|
2001-04-16 |
2003-08-19 |
Lexicon Genetics Incorporated |
Human adenylsuccinate synthetase and polynucleotides encoding the same
|
US20020165175A1
(en)
*
|
2001-04-17 |
2002-11-07 |
Xiaowu Liang |
Fast and enzymeless cloning of nucleic acid fragments
|
US20030203865A1
(en)
*
|
2001-04-30 |
2003-10-30 |
Pierrot Harvie |
Lipid-comprising drug delivery complexes and methods for their production
|
US20030077829A1
(en)
*
|
2001-04-30 |
2003-04-24 |
Protiva Biotherapeutics Inc.. |
Lipid-based formulations
|
WO2002088313A2
(en)
*
|
2001-04-30 |
2002-11-07 |
Lexicon Genetics Incorporated |
Novel human nuclear transporters and polynucleotides encoding the same
|
US20020193585A1
(en)
*
|
2001-05-25 |
2002-12-19 |
Walke D. Wade |
Novel human transporter proteins and polynucleotides encoding the same
|
EP1461425B1
(en)
|
2001-05-29 |
2008-02-13 |
Lexicon Pharmaceuticals, Inc. |
Novel human hydroxylases and polynucleotides encoding the same
|
US7745398B2
(en)
*
|
2001-05-31 |
2010-06-29 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 and treatment of cancer
|
US7744882B2
(en)
|
2001-05-31 |
2010-06-29 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 methods of detection and antibodies
|
JP2004531268A
(en)
*
|
2001-06-14 |
2004-10-14 |
レキシコン・ジェネティクス・インコーポレーテッド |
Novel human transporter protein and polynucleotide encoding the same
|
WO2003000297A1
(en)
*
|
2001-06-20 |
2003-01-03 |
Sumitomo Pharmaceuticals Company, Limited |
Method of promoting nucleic acid transfer
|
DK2000545T3
(en)
|
2001-06-20 |
2011-11-28 |
Genentech Inc |
Compositions and methods for diagnosis and treatment of lung tumor
|
US7803915B2
(en)
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
CA2451643C
(en)
|
2001-06-21 |
2012-11-13 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of superoxide dismutase 1, soluble expression
|
EP1397154B1
(en)
|
2001-06-22 |
2006-08-02 |
Vlaams Interuniversitair Instituut voor Biotechnologie vzw. |
Abin-mediated hepatitis protection
|
CA2452088A1
(en)
*
|
2001-06-26 |
2003-01-03 |
Elka Touitou |
Compositions and methods for intracellular delivery
|
AU2002318186A1
(en)
*
|
2001-07-03 |
2003-01-21 |
Lexicon Genetics Incorporated |
Novel human kielin-like proteins and polynucleotides encoding the same
|
EP1414841B1
(en)
|
2001-07-10 |
2012-11-14 |
Lakewood-Amedex, Inc |
Oligonucleotide-containing pharmacological compositions and their use
|
WO2003062370A2
(en)
|
2001-07-19 |
2003-07-31 |
Perlan Therapeutics, Inc. |
Multimeric proteins and methods of making and using same
|
US7425545B2
(en)
|
2001-07-25 |
2008-09-16 |
Isis Pharmaceuticals, Inc. |
Modulation of C-reactive protein expression
|
US6964950B2
(en)
|
2001-07-25 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of C-reactive protein expression
|
US20030096772A1
(en)
|
2001-07-30 |
2003-05-22 |
Crooke Rosanne M. |
Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
|
US7407943B2
(en)
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
US7227014B2
(en)
|
2001-08-07 |
2007-06-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein (a) expression
|
AU2002327430A1
(en)
*
|
2001-08-08 |
2003-02-24 |
Genzyme Corporation |
Methods for treating diabetes and other blood sugar disorders
|
US20040143104A1
(en)
*
|
2001-08-08 |
2004-07-22 |
Wadsworth Samuel C. |
Methods of treating diabetes and other blood sugar disorders
|
JP2005500060A
(en)
*
|
2001-08-14 |
2005-01-06 |
レキシコン・ジェネティクス・インコーポレーテッド |
Novel human collagen protein and polynucleotide encoding the same
|
CA2460120A1
(en)
|
2001-09-18 |
2003-03-27 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
WO2003027247A2
(en)
|
2001-09-24 |
2003-04-03 |
Sangamo Biosciences, Inc. |
Modulation of stem cells using zinc finger proteins
|
WO2003030125A1
(en)
*
|
2001-09-25 |
2003-04-10 |
Werner Keber |
Method and device for preventing unpermitted approach of airplanes to objects on the ground which are to be protected
|
WO2003027266A2
(en)
*
|
2001-09-26 |
2003-04-03 |
Rheogene Holdings, Inc. |
Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof
|
WO2003027289A1
(en)
|
2001-09-26 |
2003-04-03 |
Rheo Gene Holdings, Inc. |
Leafhopper ecdysone receptor nucleic acids, polypeptides, and uses thereof
|
US20040023910A1
(en)
*
|
2001-09-28 |
2004-02-05 |
Zhiming Zhang |
Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
|
US7906102B2
(en)
|
2001-10-03 |
2011-03-15 |
Vanderbilt University |
Ligands to radiation-induced molecules
|
CA2462876A1
(en)
*
|
2001-10-05 |
2003-04-17 |
The Trustees Of The University Of Pennsylvania |
Compositions for and methods of treating and preventing sirs/sepsis
|
US6750019B2
(en)
|
2001-10-09 |
2004-06-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
ATE516364T1
(en)
|
2001-10-09 |
2011-07-15 |
Isis Pharmaceuticals Inc |
ANTISENSE MODULATION OF EXPRESSION OF THE INSULIN-LIKE GROWTH FACTOR BINDING PROTEY S 5
|
MX339524B
(en)
|
2001-10-11 |
2016-05-30 |
Wyeth Corp |
Novel immunogenic compositions for the prevention and treatment of meningococcal disease.
|
US20030138407A1
(en)
*
|
2001-11-02 |
2003-07-24 |
Patrick Lu |
Therapeutic methods for nucleic acid delivery vehicles
|
AU2002368202B2
(en)
|
2001-11-02 |
2008-06-05 |
Insert Therapeutics, Inc |
Methods and compositions for therapeutic use of RNA interference
|
US7488313B2
(en)
*
|
2001-11-29 |
2009-02-10 |
Boston Scientific Scimed, Inc. |
Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
US20050152959A1
(en)
*
|
2001-12-14 |
2005-07-14 |
Transgene S. A. |
Use of a lysolipid for the preparation of a composition for transfection of a polynucleotide into a cell
|
TR201910060T4
(en)
*
|
2001-12-20 |
2019-07-22 |
Merck Sharp & Dohme |
SYN3 compositions and methods.
|
US7255874B1
(en)
|
2001-12-21 |
2007-08-14 |
Closure Medical Corporation |
Biocompatible polymers and adhesives: compositions, methods of making and uses related thereto
|
DK1463751T3
(en)
|
2001-12-21 |
2013-08-26 |
Human Genome Sciences Inc |
Albumin Fusion Proteins.
|
JP2005525095A
(en)
|
2002-01-02 |
2005-08-25 |
ジェネンテック・インコーポレーテッド |
Compositions and methods for tumor diagnosis and treatment
|
AU2003205615B2
(en)
|
2002-01-10 |
2008-09-25 |
Universiteit Gent |
A novel splice variant of MyD88 and uses thereof
|
EP2128248B2
(en)
|
2002-02-01 |
2017-01-11 |
Life Technologies Corporation |
Oligonucleotide compositions with enhanced efficiency
|
US20060009409A1
(en)
|
2002-02-01 |
2006-01-12 |
Woolf Tod M |
Double-stranded oligonucleotides
|
WO2003070905A2
(en)
*
|
2002-02-15 |
2003-08-28 |
Zycos, Inc. |
Electroporation methods for introducing bioactive agents into cells
|
DE10207177A1
(en)
*
|
2002-02-19 |
2003-09-04 |
Novosom Ag |
Optionally cationic lipids
|
EP1490027A4
(en)
*
|
2002-03-05 |
2010-11-10 |
Transave Inc |
Methods for entrapment of bioactive agent in a liposome or lipid complex
|
US8116860B2
(en)
*
|
2002-03-11 |
2012-02-14 |
Altea Therapeutics Corporation |
Transdermal porator and patch system and method for using same
|
ES2612779T3
(en)
*
|
2002-03-11 |
2017-05-18 |
Nitto Denko Corporation |
System of transdermal patches of drug administration, method of manufacture thereof and method of use thereof
|
US9918665B2
(en)
|
2002-03-11 |
2018-03-20 |
Nitto Denko Corporation |
Transdermal porator and patch system and method for using same
|
US20030180712A1
(en)
|
2002-03-20 |
2003-09-25 |
Biostratum Ab |
Inhibition of the beta3 subunit of L-type Ca2+ channels
|
AU2003230874A1
(en)
|
2002-04-16 |
2003-11-03 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US20040180438A1
(en)
*
|
2002-04-26 |
2004-09-16 |
Pachuk Catherine J. |
Methods and compositions for silencing genes without inducing toxicity
|
US7519418B2
(en)
*
|
2002-04-30 |
2009-04-14 |
Boston Scientific Scimed, Inc. |
Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment
|
WO2003093469A2
(en)
*
|
2002-05-01 |
2003-11-13 |
Chromos Molecular Systems, Inc. |
Methods for delivering nucleic acid molecules into cells and assessment thereof
|
EP1549352A4
(en)
*
|
2002-05-06 |
2005-07-27 |
Nucleonics Inc |
Methods for delivery of nucleic acids
|
US7598421B2
(en)
*
|
2002-05-08 |
2009-10-06 |
Ucl Biomedica Plc |
Materials for the delivery of biologically-active material to cells
|
US20040013649A1
(en)
*
|
2002-05-10 |
2004-01-22 |
Inex Pharmaceuticals Corporation |
Cancer vaccines and methods of using the same
|
US7199107B2
(en)
|
2002-05-23 |
2007-04-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of kinesin-like 1 expression
|
EP2316922B1
(en)
|
2002-05-24 |
2013-05-22 |
Merck Sharp & Dohme Corp. |
Neutralizing human anti-IGFR antibody
|
EA200401565A1
(en)
*
|
2002-05-24 |
2005-04-28 |
Неофарм, Инк. |
METHOD FOR OBTAINING CARDIOLYPINE OR ANALOGUE OF CARDIOLIPINE (OPTIONS), METHOD FOR OBTAINING LIPOSOME AND COMPOSITION OF CARDIOLIPINE FOR TREATING DISEASES (OPTIONS)
|
WO2003099830A2
(en)
*
|
2002-05-24 |
2003-12-04 |
Neopharm, Inc. |
Cardiolipin compositions, methods of preparation and use
|
AU2003245160B2
(en)
|
2002-06-28 |
2009-09-24 |
Arbutus Biopharma Corporation |
Method and apparatus for producing liposomes
|
AU2003261103A1
(en)
*
|
2002-07-02 |
2004-01-23 |
Uab Research Foundation |
Compounds promoting delivery of genes
|
ES2279127T3
(en)
|
2002-07-05 |
2007-08-16 |
Lipoxen Technologies Limited |
PROCEDURE TO INCREASE AN IMMUNE RESPONSE OF NUCLEIC ACID VACCINATION.
|
US7375093B2
(en)
|
2002-07-05 |
2008-05-20 |
Intrexon Corporation |
Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
|
EP1540004A4
(en)
*
|
2002-07-31 |
2007-10-03 |
Nucleonics Inc |
Double stranded rna structures and constructs, and methods for generating and using the same
|
US20040034336A1
(en)
*
|
2002-08-08 |
2004-02-19 |
Neal Scott |
Charged liposomes/micelles with encapsulted medical compounds
|
US7785608B2
(en)
*
|
2002-08-30 |
2010-08-31 |
Wyeth Holdings Corporation |
Immunogenic compositions for the prevention and treatment of meningococcal disease
|
US7135324B2
(en)
|
2002-09-04 |
2006-11-14 |
The University Of Connecticut |
Viral recombinases, related articles, and methods of use thereof
|
AU2003273271A1
(en)
*
|
2002-09-09 |
2004-03-29 |
The Brigham And Women's Hospital, Inc. |
Genes and proteins altering tau-related neurodegeneration
|
WO2004024067A2
(en)
*
|
2002-09-10 |
2004-03-25 |
Vical Incorporated |
Codon-optimized polynucleotide-based vaccines against bacillus anthracis infection
|
BR0314236A
(en)
|
2002-09-13 |
2005-08-09 |
Replicor Inc |
Oligonucleotide formulation, pharmaceutical composition, kit, antiviral compound, preparation of oligonucleotide and methods for selection of an antiviral oligonucleotide for use as an antiviral agent, for prophylaxis or treatment of a viral infection in a patient, for prophylactic treatment of cancer caused by oncoviruses. for identifying a compound that alters the binding of an oligonucleotide to at least one viral component, for purifying oligonucleotide binding to at least one viral component and for enriching oligonucleotides from an oligonucleotide cluster
|
US20040053895A1
(en)
*
|
2002-09-18 |
2004-03-18 |
Bone Care International, Inc. |
Multi-use vessels for vitamin D formulations
|
US7148211B2
(en)
*
|
2002-09-18 |
2006-12-12 |
Genzyme Corporation |
Formulation for lipophilic agents
|
US20060189554A1
(en)
*
|
2002-09-24 |
2006-08-24 |
Russell Mumper |
Nanoparticle-Based vaccine delivery system containing adjuvant
|
EP2272958A1
(en)
|
2002-09-26 |
2011-01-12 |
ISIS Pharmaceuticals, Inc. |
Modulation of forkhead box O1A expression
|
US9809654B2
(en)
|
2002-09-27 |
2017-11-07 |
Vaccinex, Inc. |
Targeted CD1d molecules
|
US20050277611A1
(en)
*
|
2002-10-16 |
2005-12-15 |
Neopharm, Inc. |
Cationic cardiolipin analoges and its use thereof
|
US6863731B2
(en)
*
|
2002-10-18 |
2005-03-08 |
Controls Corporation Of America |
System for deposition of inert barrier coating to increase corrosion resistance
|
CN1747738B
(en)
*
|
2002-10-29 |
2010-11-24 |
川塞夫有限公司 |
Sustained release of antifectives
|
US7718189B2
(en)
*
|
2002-10-29 |
2010-05-18 |
Transave, Inc. |
Sustained release of antiinfectives
|
JP3447009B1
(en)
*
|
2002-10-29 |
2003-09-16 |
實 平垣 |
Construct structure and method for producing the same
|
US7879351B2
(en)
*
|
2002-10-29 |
2011-02-01 |
Transave, Inc. |
High delivery rates for lipid based drug formulations, and methods of treatment thereof
|
TW200509968A
(en)
|
2002-11-01 |
2005-03-16 |
Elan Pharm Inc |
Prevention and treatment of synucleinopathic disease
|
WO2008103472A2
(en)
|
2007-02-23 |
2008-08-28 |
Elan Pharmaceuticals, Inc. |
Prevention and treatment of synucleinopathic and amyloidogenic disease
|
US8506959B2
(en)
|
2002-11-01 |
2013-08-13 |
Neotope Biosciences Limited |
Prevention and treatment of synucleinopathic and amyloidogenic disease
|
CA2504929C
(en)
|
2002-11-05 |
2014-07-22 |
Charles Allerson |
Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
|
WO2004044138A2
(en)
|
2002-11-05 |
2004-05-27 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
JP4986109B2
(en)
|
2002-11-13 |
2012-07-25 |
ジェンザイム・コーポレーション |
Antisense regulation of apolipoprotein B expression
|
DK1569695T3
(en)
|
2002-11-13 |
2013-08-05 |
Genzyme Corp |
ANTISENSE MODULATION OF APOLIPOPROTEIN-B EXPRESSION
|
US7144999B2
(en)
|
2002-11-23 |
2006-12-05 |
Isis Pharmaceuticals, Inc. |
Modulation of hypoxia-inducible factor 1 alpha expression
|
EP1903056A3
(en)
|
2002-12-10 |
2008-05-07 |
Idm Pharma, Inc. |
HLA-A1, -A2 -A3, -A24, -B7, and -B44 binding peptides comprising tumor associated antigen epitopes, and compositions thereof
|
CA2508228C
(en)
|
2002-12-23 |
2013-12-17 |
Vical Incorporated |
Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
|
EP1578193A4
(en)
*
|
2002-12-23 |
2011-06-15 |
Vical Inc |
Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes
|
CA2508281C
(en)
*
|
2002-12-23 |
2011-08-09 |
Vical Incorporated |
Method for producing sterile polynucleotide based medicaments
|
US20040138154A1
(en)
*
|
2003-01-13 |
2004-07-15 |
Lei Yu |
Solid surface for biomolecule delivery and high-throughput assay
|
US20070269891A9
(en)
*
|
2003-01-13 |
2007-11-22 |
Yasunobu Tanaka |
Solid surface with immobilized degradable cationic polymer for transfecting eukaryotic cells
|
WO2004065551A2
(en)
*
|
2003-01-21 |
2004-08-05 |
Bristol-Myers Squibb Company |
Polynucleotide encoding a novel acyl coenzyme a, monoacylglycerol acyltransferase-3 (mgat3), and uses thereof
|
US7304161B2
(en)
|
2003-02-10 |
2007-12-04 |
Intrexon Corporation |
Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex
|
DK1597366T3
(en)
|
2003-02-11 |
2013-02-25 |
Antisense Therapeutics Ltd |
Modulation of expression of insulin-like growth factor receptor I
|
CA2516188C
(en)
*
|
2003-02-14 |
2012-04-17 |
University Of South Florida |
Chitosan-derivatives for gene delivery and expression
|
US7803781B2
(en)
|
2003-02-28 |
2010-09-28 |
Isis Pharmaceuticals, Inc. |
Modulation of growth hormone receptor expression and insulin-like growth factor expression
|
US7456315B2
(en)
|
2003-02-28 |
2008-11-25 |
Intrexon Corporation |
Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
|
EP2216407B1
(en)
|
2003-03-07 |
2016-01-13 |
Alnylam Pharmaceuticals, Inc. |
Therapeutic compositions
|
US20040185559A1
(en)
|
2003-03-21 |
2004-09-23 |
Isis Pharmaceuticals Inc. |
Modulation of diacylglycerol acyltransferase 1 expression
|
US20040242502A1
(en)
*
|
2003-04-08 |
2004-12-02 |
Galenica Pharmaceuticals, Inc. |
Semi-synthetic saponin analogs with carrier and immune stimulatory activities for DNA and RNA vaccines
|
CA2522751A1
(en)
*
|
2003-04-16 |
2004-11-04 |
Wyeth Holdings Corporation |
Novel immunogenic compositions for the prevention and treatment of meningococcal disease
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
WO2004094595A2
(en)
|
2003-04-17 |
2004-11-04 |
Alnylam Pharmaceuticals Inc. |
MODIFIED iRNA AGENTS
|
EP1620112A4
(en)
*
|
2003-04-17 |
2007-04-25 |
Univ Columbia |
Desmoglein 4 is a novel gene involved in hair growth
|
US7399853B2
(en)
|
2003-04-28 |
2008-07-15 |
Isis Pharmaceuticals |
Modulation of glucagon receptor expression
|
US8080642B2
(en)
*
|
2003-05-16 |
2011-12-20 |
Vical Incorporated |
Severe acute respiratory syndrome DNA compositions and methods of use
|
JP4846588B2
(en)
*
|
2003-05-22 |
2011-12-28 |
モレキュラー、トランスファー、インコーポレイテッド |
Novel lipids for nucleic acid transfection
|
AU2004253455B2
(en)
|
2003-06-03 |
2011-03-03 |
Eli Lilly And Company |
Modulation of survivin expression
|
CN101396555A
(en)
*
|
2003-06-04 |
2009-04-01 |
坎基股份有限公司 |
Methods and compositions for interferon therapy
|
EP2284268A3
(en)
|
2003-06-12 |
2012-05-30 |
Alnylam Pharmaceuticals Inc. |
Conserved HBV and HCV sequences useful for gene silencing
|
US20060078560A1
(en)
*
|
2003-06-23 |
2006-04-13 |
Neopharm, Inc. |
Method of inducing apoptosis and inhibiting cardiolipin synthesis
|
US7261882B2
(en)
|
2003-06-23 |
2007-08-28 |
Reagents Of The University Of Colorado |
Methods for treating neuropathic pain by administering IL-10 polypeptides
|
JP4951338B2
(en)
*
|
2003-07-16 |
2012-06-13 |
プロチバ バイオセラピューティクス インコーポレイティッド |
Interfering RNA encapsulated in lipid
|
CA2533701A1
(en)
|
2003-07-31 |
2005-02-17 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding rnas
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
WO2005014791A2
(en)
|
2003-08-08 |
2005-02-17 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
US7330851B2
(en)
*
|
2003-08-18 |
2008-02-12 |
Eaglehawk, Limited |
Data security through dissembly of data elements or connections between elements
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
EP1656453A2
(en)
*
|
2003-08-22 |
2006-05-17 |
Nucleonics, Inc. |
Eukaryotic expression systems for expression of inhibitory rna in multiple intracellular compartments
|
US7291604B2
(en)
*
|
2003-09-03 |
2007-11-06 |
The General Hospital Corporation |
Methods of treating restenosis
|
AU2004272646B2
(en)
*
|
2003-09-15 |
2011-11-24 |
Arbutus Biopharma Corporation |
Polyethyleneglycol-modified lipid compounds and uses thereof
|
SG146682A1
(en)
|
2003-09-18 |
2008-10-30 |
Isis Pharmaceuticals Inc |
Modulation of eif4e expression
|
CA2539439C
(en)
|
2003-09-19 |
2012-10-23 |
Sangamo Biosciences, Inc. |
Engineered zinc finger proteins for regulation of gene expression
|
US7662929B2
(en)
|
2003-10-10 |
2010-02-16 |
Alchemia Oncology Pty Limited |
Antibody that specifically binds hyaluronan synthase
|
DE10347710B4
(en)
|
2003-10-14 |
2006-03-30 |
Johannes-Gutenberg-Universität Mainz |
Recombinant vaccines and their use
|
AU2003284327A1
(en)
*
|
2003-10-22 |
2005-06-08 |
Neal Scott |
Charged liposomes/micelles with encapsulated medical compounds
|
US8016811B2
(en)
|
2003-10-24 |
2011-09-13 |
Altea Therapeutics Corporation |
Method for transdermal delivery of permeant substances
|
US20050191653A1
(en)
|
2003-11-03 |
2005-09-01 |
Freier Susan M. |
Modulation of SGLT2 expression
|
ITMI20032185A1
(en)
*
|
2003-11-12 |
2005-05-13 |
Chemi Spa |
PROCESS FOR THE SYNTHESIS OF CATIONIC LIPIDS.
|
US20050107318A1
(en)
*
|
2003-11-17 |
2005-05-19 |
Samuel Wadsworth |
Methods of treating diabetes and other blood sugar disorders
|
CA2747871C
(en)
|
2003-11-17 |
2018-04-10 |
Genentech, Inc. |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
EP1696034A4
(en)
*
|
2003-12-19 |
2006-12-27 |
Dainippon Sumitomo Pharma Co |
Novel method of nucleic acid transfer
|
SE0303588D0
(en)
|
2003-12-30 |
2003-12-30 |
Bioactive Polymers Ab C O Lund |
Surface protection of exposed biological tissues
|
WO2005071080A2
(en)
|
2004-01-20 |
2005-08-04 |
Isis Pharmaceuticals, Inc. |
Modulation of glucocorticoid receptor expression
|
US7468431B2
(en)
|
2004-01-22 |
2008-12-23 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP2 expression
|
US7432057B2
(en)
*
|
2004-01-30 |
2008-10-07 |
Michigan State University |
Genetic test for PSE-susceptible turkeys
|
AU2005214091B2
(en)
*
|
2004-02-24 |
2010-08-12 |
Abbvie B.V. |
Method for determining the risk of developing a neurological disease
|
US8569474B2
(en)
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
EP2700720A3
(en)
|
2004-03-15 |
2015-01-28 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for optimizing cleavage of RNA by RNASE H
|
ATE480550T1
(en)
*
|
2004-03-25 |
2010-09-15 |
California Inst Of Techn |
HYBRIDIZATION CHAIN REACTION
|
CA2561221C
(en)
*
|
2004-03-26 |
2016-09-20 |
Curis, Inc. |
Rna interference modulators of hedgehog signaling and uses thereof
|
US20050244869A1
(en)
|
2004-04-05 |
2005-11-03 |
Brown-Driver Vickie L |
Modulation of transthyretin expression
|
JP4564052B2
(en)
|
2004-04-08 |
2010-10-20 |
サンガモ バイオサイエンシズ インコーポレイテッド |
Methods and compositions for modulating myocardial contractility
|
US20050260652A1
(en)
*
|
2004-04-15 |
2005-11-24 |
The General Hospital Corporation |
Compositions and methods that modulate RNA interference
|
WO2005103713A2
(en)
|
2004-04-20 |
2005-11-03 |
Galapagos N.V. |
Methods, compositions and compound assays for inhibiting amyloid-beta protein production
|
ES2427177T3
(en)
|
2004-04-27 |
2013-10-29 |
Galapagos N.V. |
Methods, agents and tests for the detection of compounds to induce differentiation of undifferentiated mammalian cells to give rise to osteoblasts
|
US7303881B2
(en)
*
|
2004-04-30 |
2007-12-04 |
Pds Biotechnology Corporation |
Antigen delivery compositions and methods of use
|
US7935510B2
(en)
|
2004-04-30 |
2011-05-03 |
Intrexon Corporation |
Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
|
KR101462819B1
(en)
|
2004-05-03 |
2014-11-21 |
헤르메스 바이오사이언스, 인코포레이티드 |
Liposomes useful for drug delivery
|
JP5331340B2
(en)
*
|
2004-05-18 |
2013-10-30 |
バイカル インコーポレイテッド |
Influenza virus vaccine composition and method of use thereof
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
EP1766035B1
(en)
*
|
2004-06-07 |
2011-12-07 |
Protiva Biotherapeutics Inc. |
Lipid encapsulated interfering rna
|
ATE537263T1
(en)
|
2004-06-07 |
2011-12-15 |
Protiva Biotherapeutics Inc |
CATIONIC LIPIDS AND METHODS OF USE
|
US7306923B2
(en)
|
2004-06-14 |
2007-12-11 |
Galapagos N.V. |
Methods for identification, and compounds useful for the treatment of degenerative & inflammatory diseases
|
EP1759203A2
(en)
|
2004-06-21 |
2007-03-07 |
Galapagos N.V. |
Methods and means for treatment of osteoarthritis
|
US7094775B2
(en)
|
2004-06-30 |
2006-08-22 |
Bone Care International, Llc |
Method of treating breast cancer using a combination of vitamin D analogues and other agents
|
JP2008504827A
(en)
*
|
2004-07-02 |
2008-02-21 |
プロチバ バイオセラピューティクス インコーポレイティッド |
Immunostimulatory siRNA molecules and methods of use thereof
|
CA2573176A1
(en)
*
|
2004-07-09 |
2006-01-19 |
Bc Cancer Agency |
Nup98-hox fusions for expansion of hemopoietic stem cells
|
US7604798B2
(en)
*
|
2004-07-15 |
2009-10-20 |
Northwestern University |
Methods and compositions for importing nucleic acids into cell nuclei
|
EP1784416B1
(en)
|
2004-07-16 |
2011-10-05 |
GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Vaccines against aids comprising cmv/r nucleic acid constructs
|
WO2006007712A1
(en)
*
|
2004-07-19 |
2006-01-26 |
Protiva Biotherapeutics, Inc. |
Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents
|
EA013752B1
(en)
|
2004-08-09 |
2010-06-30 |
Элан Фармасьютикалз, Инк. |
Prevention and treatment of synucleinopathic and amyloidogenic disease
|
JP4804467B2
(en)
|
2004-08-23 |
2011-11-02 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Multiple RNA polymerase III promoter expression construct
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
EP1789095A2
(en)
|
2004-09-16 |
2007-05-30 |
Sangamo Biosciences Inc. |
Compositions and methods for protein production
|
DE602005027479D1
(en)
|
2004-09-24 |
2011-05-26 |
Alnylam Pharmaceuticals Inc |
TARGETING OF INTERMEDIATE PRODUCTS TO REPRODUCTION OF INDIVIDUAL VIRUSES BY RNAI
|
ATE514776T1
(en)
|
2004-10-05 |
2011-07-15 |
California Inst Of Techn |
APTAMER-REGULATED NUCLEIC ACIDS AND USES THEREOF
|
US7485468B2
(en)
|
2004-10-15 |
2009-02-03 |
Galapagos Bv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
|
ATE435025T1
(en)
*
|
2004-10-18 |
2009-07-15 |
Sinai School Medicine |
INHIBITION OF TUMOR GROWTH AND METASTASIS FORMATION WITH PEPTIDES DERIVED FROM ATF2
|
CN101048139A
(en)
*
|
2004-10-28 |
2007-10-03 |
艾德克斯实验室公司 |
Compositions for controlled delivery of pharmaceutically active compounds
|
US20060147449A1
(en)
*
|
2004-11-15 |
2006-07-06 |
Brass Lawrence F |
Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses
|
WO2006053430A1
(en)
*
|
2004-11-17 |
2006-05-26 |
Protiva Biotherapeutics, Inc. |
Sirna silencing of apolipoprotein b
|
DE102004057303A1
(en)
*
|
2004-11-26 |
2006-06-01 |
Merck Patent Gmbh |
Stable crystal modifications of DOTAP chloride
|
WO2006060723A2
(en)
*
|
2004-12-03 |
2006-06-08 |
Vical Incorporated |
Methods for producing block copolymer/amphiphilic particles
|
EP2316942B1
(en)
|
2004-12-22 |
2021-04-21 |
Alnylam Pharmaceuticals, Inc. |
Conserved hbv and hcv sequences useful for gene silencing
|
US9034650B2
(en)
|
2005-02-02 |
2015-05-19 |
Intrexon Corporation |
Site-specific serine recombinases and methods of their use
|
CA2596506C
(en)
|
2005-02-09 |
2021-04-06 |
Avi Biopharma, Inc. |
Antisense composition and method for treating muscle atrophy
|
JP4988606B2
(en)
|
2005-02-28 |
2012-08-01 |
サンガモ バイオサイエンシズ インコーポレイテッド |
Anti-angiogenic methods and compositions
|
US7727721B2
(en)
*
|
2005-03-08 |
2010-06-01 |
California Institute Of Technology |
Hybridization chain reaction amplification for in situ imaging
|
RU2007137489A
(en)
|
2005-03-10 |
2009-04-20 |
Дженентек, Инк. (Us) |
METHODS AND COMPOSITIONS FOR MODULATION OF VESSEL INTEGRITY
|
US20090062184A1
(en)
*
|
2005-03-24 |
2009-03-05 |
Dainippon Sumitomo Pharma Co., Ltd. |
Fine particulate preparation comprising complex of nucleic acid molecule and collagen
|
ATE541928T1
(en)
|
2005-03-31 |
2012-02-15 |
Calando Pharmaceuticals Inc |
RIBONUCLEOTIDE REDUCTASE SUBUNITY 2 INHIBITORS AND USES THEREOF
|
US20070026061A1
(en)
*
|
2005-05-25 |
2007-02-01 |
Nahid Ali |
Liposomal formulation and use thereof
|
LT2816118T
(en)
|
2005-05-31 |
2018-12-10 |
The Regents Of The University Of Colorado, A Body Corporate |
Methods for delivering genes
|
CA2610791C
(en)
|
2005-06-08 |
2015-12-01 |
Cangene Corporation |
Hyaluronic acid binding peptides enhance host defense against pathogenic bacteria
|
CN101437539B
(en)
*
|
2005-07-05 |
2013-10-02 |
康奈尔研究基金会(有限公司) |
Blocking leukocyte emigration and inflammation by interfering with CD99l2
|
SG10201508995QA
(en)
|
2005-07-26 |
2015-11-27 |
Sangamo Biosciences Inc |
Targeted integration and expression of exogenous nucleic acid sequences
|
US20070054873A1
(en)
*
|
2005-08-26 |
2007-03-08 |
Protiva Biotherapeutics, Inc. |
Glucocorticoid modulation of nucleic acid-mediated immune stimulation
|
US7666584B2
(en)
*
|
2005-09-01 |
2010-02-23 |
Philadelphia Health & Education Coporation |
Identification of a pin specific gene and protein (PIN-1) useful as a diagnostic treatment for prostate cancer
|
CN101268194A
(en)
|
2005-09-20 |
2008-09-17 |
巴斯福植物科学有限公司 |
Methods for controlling gene expression using ta-siRNA
|
DE102005046490A1
(en)
|
2005-09-28 |
2007-03-29 |
Johannes-Gutenberg-Universität Mainz |
New nucleic acid molecule comprising promoter, a transcriptable nucleic acid sequence, a first and second nucleic acid sequence for producing modified RNA with transcriptional stability and translational efficiency
|
US7312079B1
(en)
|
2005-10-06 |
2007-12-25 |
Lexicon Pharmaceuticals, Inc. |
Variants of FAM3C
|
ATE526975T1
(en)
|
2005-10-07 |
2011-10-15 |
California Inst Of Techn |
PKR ACTIVATION USING HYBRIDIZATION CHAIN REACTION
|
JP5671206B2
(en)
|
2005-10-21 |
2015-02-18 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Mutation of c-KIT oncogene in melanoma
|
WO2007051303A1
(en)
|
2005-11-02 |
2007-05-10 |
Protiva Biotherapeutics, Inc. |
MODIFIED siRNA MOLECULES AND USES THEREOF
|
US8114440B2
(en)
|
2005-11-16 |
2012-02-14 |
Idexx Laboratories Inc. |
Pharmaceutical compositions for the administration of aptamers
|
US7754679B2
(en)
*
|
2005-11-16 |
2010-07-13 |
Idexx Laboratories, Inc. |
Pharmaceutical compositions for the administration of aptamers
|
CA2630602A1
(en)
|
2005-11-21 |
2007-05-31 |
Isis Pharmaceuticals, Inc. |
Modulation of eif4e-bp2 expression
|
TWI461436B
(en)
|
2005-11-25 |
2014-11-21 |
Kyowa Hakko Kirin Co Ltd |
Human monoclonal antibody human cd134 (ox40) and methods of making and using same
|
DK1962805T3
(en)
|
2005-12-08 |
2016-09-26 |
Insmed Inc |
Lipid-based compositions of the anti-infective agents for the treatment of lung infections
|
US10647960B2
(en)
*
|
2005-12-13 |
2020-05-12 |
The Trustees Of The University Of Pennsylvania |
Transcriptome transfer produces cellular phenotype conversion
|
US9149543B2
(en)
|
2005-12-15 |
2015-10-06 |
The Trustees Of The University Of Pennsylvania |
Methods and models for rapid, widespread delivery of genetic material to the CNS using non-viral, cationic lipid-mediated vectors
|
US8669418B2
(en)
|
2005-12-22 |
2014-03-11 |
Vib Vzw |
Means and methods for mediating protein interference
|
WO2007073489A2
(en)
*
|
2005-12-22 |
2007-06-28 |
Trustees Of Boston University |
Molecules for gene delivery and gene therapy, and methods of use thereof
|
WO2007071789A1
(en)
|
2005-12-22 |
2007-06-28 |
Vib Vzw |
Means and methods for mediating protein interference
|
SI2161038T1
(en)
|
2006-01-26 |
2014-05-30 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to Huntingtin
|
WO2008001166A2
(en)
*
|
2006-02-07 |
2008-01-03 |
Council Of Scientific & Industrial Research |
Process for synthesis of glycomimicking cationic amphiphiles
|
JP2009525757A
(en)
|
2006-02-10 |
2009-07-16 |
ザ ユニバーシティ オブ シンシナティ |
Phosphatase inhibitor protein-1 as a regulator of cardiac function
|
EP2614839A3
(en)
|
2006-04-05 |
2015-01-28 |
Genentech, Inc. |
Method for using BOC/CDO to modulate hedgehog signaling
|
AU2007243442A1
(en)
*
|
2006-04-24 |
2007-11-08 |
Shantha West, Inc. |
AgRM2 antigen
|
CN101437943A
(en)
|
2006-05-03 |
2009-05-20 |
波罗的科技发展有限公司 |
Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease
|
EP2015780B1
(en)
|
2006-05-05 |
2012-12-12 |
Molecular Transfer, Inc. |
Novel reagents for transfection of eukaryotic cells
|
EP2027262B1
(en)
|
2006-05-25 |
2010-03-31 |
Sangamo Biosciences Inc. |
Variant foki cleavage half-domains
|
GB0610636D0
(en)
|
2006-05-30 |
2006-07-05 |
Univ London |
Materials and complexes for the delivery of biologically-active material to cells
|
WO2008042024A2
(en)
|
2006-06-01 |
2008-04-10 |
Elan Pharmaceuticals, Inc. |
Neuroactive fragments of app
|
US7915399B2
(en)
*
|
2006-06-09 |
2011-03-29 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
US20080004410A1
(en)
*
|
2006-06-30 |
2008-01-03 |
Yu-Chin Lai |
Hydrophilic macromonomers having alpha,beta-conjugated carboxylic terminal group and medical devices incorporating same
|
JP5072275B2
(en)
|
2006-07-03 |
2012-11-14 |
テルモ株式会社 |
Method for separating closed vesicles, method for producing preparation and evaluation method
|
WO2008011473A2
(en)
|
2006-07-19 |
2008-01-24 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to hbxip
|
JP2009544731A
(en)
*
|
2006-07-28 |
2009-12-17 |
サノフィ−アベンティス |
Compositions and methods for tumor therapy
|
PL2068922T3
(en)
|
2006-10-19 |
2012-11-30 |
Csl Ltd |
Anti-il-13r alpha 1 antibodies and their uses thereof
|
ES2658239T3
(en)
|
2006-10-19 |
2018-03-08 |
Csl Limited |
Interleukin-13 alpha 1 receptor high affinity antibody antagonists
|
US8466154B2
(en)
*
|
2006-10-27 |
2013-06-18 |
The Board Of Regents Of The University Of Texas System |
Methods and compositions related to wrapping of dehydrons
|
WO2008058291A2
(en)
|
2006-11-09 |
2008-05-15 |
California Institute Of Technology |
Modular aptamer-regulated ribozymes
|
AU2007355108B2
(en)
|
2006-11-27 |
2013-07-11 |
Patrys Limited |
Novel glycosylated peptide target in neoplastic cells
|
EP1938843A1
(en)
*
|
2006-12-19 |
2008-07-02 |
Novosom AG |
Lipids and lipid assemblies comrising transfection enhancer elements
|
AR064642A1
(en)
*
|
2006-12-22 |
2009-04-15 |
Wyeth Corp |
POLINUCLEOTIDE VECTOR THAT INCLUDES IT RECOMBINATING CELL THAT UNDERSTANDS THE VECTOR POLYPEPTIDE, ANTIBODY, COMPOSITION THAT UNDERSTANDS THE POLINUCLEOTIDE, VECTOR, RECOMBINATING CELL POLYPEPTIDE OR ANTIBODY, USE OF THE COMPOSITION AND A COMPOSITION AND A METHOD
|
EP2118118B1
(en)
*
|
2007-01-19 |
2017-09-27 |
Exiqon A/S |
Mediated cellular delivery of lna oligonucleotides
|
WO2008094945A2
(en)
|
2007-01-29 |
2008-08-07 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating protein expression
|
US9603922B2
(en)
|
2007-02-21 |
2017-03-28 |
Vaccinex, Inc. |
Modulation of NKT cell activity with antigen-loaded CD1d molecules
|
CN101663407B
(en)
|
2007-02-22 |
2017-08-08 |
健泰科生物技术公司 |
method for detecting inflammatory bowel disease
|
ES2570182T3
(en)
|
2007-02-23 |
2016-05-17 |
Prothena Biosciences Ltd |
Prevention and treatment of synucleinopathic and amyloidogenic disease
|
WO2008106658A2
(en)
|
2007-03-01 |
2008-09-04 |
California Institute Of Technology |
TRIGGERED RNAi
|
WO2008106646A2
(en)
*
|
2007-03-01 |
2008-09-04 |
Introgen Therapeutics, Inc |
Methods and formulations for topical gene therapy
|
US8877206B2
(en)
|
2007-03-22 |
2014-11-04 |
Pds Biotechnology Corporation |
Stimulation of an immune response by cationic lipids
|
DE102007015598A1
(en)
*
|
2007-03-29 |
2008-10-02 |
Heinrich-Heine-Universität Düsseldorf |
Use of fluorochemical compounds for diagnostic purposes using imaging techniques
|
WO2008124768A1
(en)
|
2007-04-09 |
2008-10-16 |
The General Hospital Corporation |
Hemojuvelin fusion proteins and uses thereof
|
WO2008137717A1
(en)
|
2007-05-04 |
2008-11-13 |
Transave, Inc. |
Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
|
EP2157982B1
(en)
|
2007-05-04 |
2014-12-17 |
Marina Biotech, Inc. |
Amino acid lipids and uses thereof
|
US9333214B2
(en)
|
2007-05-07 |
2016-05-10 |
Insmed Incorporated |
Method for treating pulmonary disorders with liposomal amikacin formulations
|
US9119783B2
(en)
|
2007-05-07 |
2015-09-01 |
Insmed Incorporated |
Method of treating pulmonary disorders with liposomal amikacin formulations
|
US9114081B2
(en)
|
2007-05-07 |
2015-08-25 |
Insmed Incorporated |
Methods of treating pulmonary disorders with liposomal amikacin formulations
|
EP2155770B1
(en)
|
2007-05-16 |
2013-10-16 |
California Institute of Technology |
A versatile nucleic acid hairpin motif for programming biomolecular self-assembly pathways
|
BRPI0811870A2
(en)
*
|
2007-05-16 |
2014-10-21 |
Mat Malta Advanced Technologies Ltd |
INFLUENCE TREATMENT AND PREVENTION
|
CA2688346A1
(en)
|
2007-05-23 |
2008-12-04 |
Vical Incorporated |
Compositions and methods for enhancing immune responses to vaccines
|
DK2167458T3
(en)
|
2007-05-29 |
2018-06-18 |
Intrexon Corp |
CHIRAL DIACYL HYDRAZINE LIGANDS FOR MODULATING EXPRESSION OF EXOGENEOUS GENES OF AN ECDYSON RECEPTOR COMPLEX
|
US20080312174A1
(en)
*
|
2007-06-05 |
2008-12-18 |
Nitto Denko Corporation |
Water soluble crosslinked polymers
|
MX2009013766A
(en)
|
2007-06-20 |
2010-02-01 |
Galapagos Nv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of bone and joint degenerative diseases.
|
US20090069266A1
(en)
*
|
2007-06-27 |
2009-03-12 |
Northwestern University |
Methods and compositions for nucleic acid transfer into cells
|
KR101510778B1
(en)
|
2007-07-12 |
2015-04-10 |
상가모 바이오사이언스 인코포레이티드 |
Methods and compositions for inactivating alpha 1,6 fucosyltransferase (fut8) gene expression
|
WO2009011855A2
(en)
*
|
2007-07-16 |
2009-01-22 |
California Institute Of Technology |
Selection of nucleic acid-based sensor domains within nucleic acid switch platform
|
US8828960B2
(en)
*
|
2007-07-17 |
2014-09-09 |
Idexx Laboratories, Inc. |
Amino acid vitamin ester compositions for controlled delivery of pharmaceutically active compounds
|
KR20100049084A
(en)
|
2007-08-23 |
2010-05-11 |
인트렉손 코포레이션 |
Methods and compositions for diagnosing disease
|
US8367815B2
(en)
|
2007-08-28 |
2013-02-05 |
California Institute Of Technology |
Modular polynucleotides for ligand-controlled regulatory systems
|
US20120165387A1
(en)
|
2007-08-28 |
2012-06-28 |
Smolke Christina D |
General composition framework for ligand-controlled RNA regulatory systems
|
US8865667B2
(en)
|
2007-09-12 |
2014-10-21 |
California Institute Of Technology |
Higher-order cellular information processing devices
|
AU2008302504B2
(en)
*
|
2007-09-17 |
2014-08-14 |
Agrofresh Inc. |
Compositions and methods for the modification of physiological responses in plants
|
US8563314B2
(en)
|
2007-09-27 |
2013-10-22 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating PD1
|
NZ584848A
(en)
|
2007-09-28 |
2012-09-28 |
Intrexon Corp |
Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
|
JP2010539978A
(en)
|
2007-10-02 |
2010-12-24 |
アムジェン インコーポレイテッド |
Increased erythropoietin using nucleic acids that can hybridize to micro-RNA and its precursors
|
AU2008308509B2
(en)
|
2007-10-04 |
2014-10-23 |
Zymogenetics, Inc. |
B7 family member zB7H6 and related compositions and methods
|
BRPI0818287A2
(en)
|
2007-10-08 |
2015-11-03 |
Intrexon Corp |
manipulated dendritic cells and uses for cancer treatment.
|
GB0720486D0
(en)
*
|
2007-10-19 |
2007-11-28 |
Univ Edinburgh |
Cationic lipids
|
WO2009058881A1
(en)
*
|
2007-10-29 |
2009-05-07 |
The University Of California |
Osteoarthritis gene therapy
|
US8097712B2
(en)
|
2007-11-07 |
2012-01-17 |
Beelogics Inc. |
Compositions for conferring tolerance to viral disease in social insects, and the use thereof
|
DE102007056488A1
(en)
|
2007-11-22 |
2009-07-23 |
Biontex Laboratories Gmbh |
Composition, useful e.g. transfection comprises a non-viral gene delivery system containing e.g. cationic lipid, and an agent for partial suppression and/or activation of innate intracellular and/or intercellular immune defense
|
WO2009065618A2
(en)
|
2007-11-22 |
2009-05-28 |
Biontex Laboratories Gmbh |
Improvement of transfection results of non-viral gene delivery systems by influencing the congenital immune system
|
DE102008016275A1
(en)
|
2008-03-28 |
2009-11-19 |
Biontex Laboratories Gmbh |
Composition, useful e.g. transfection comprises a non-viral gene delivery system containing e.g. cationic lipid, and an agent for partial suppression and/or activation of innate intracellular and/or intercellular immune defense
|
DE102008023913A1
(en)
|
2008-05-16 |
2009-11-19 |
Biontex Laboratories Gmbh |
Composition, useful e.g. transfection comprises a non-viral gene delivery system containing e.g. cationic lipid, and an agent for partial suppression and/or activation of innate intracellular and/or intercellular immune defense
|
AU2008340355B2
(en)
|
2007-12-04 |
2015-01-22 |
Tekmira Pharmaceuticals Corporation |
Targeting lipids
|
US9029524B2
(en)
|
2007-12-10 |
2015-05-12 |
California Institute Of Technology |
Signal activated RNA interference
|
EP2610341B1
(en)
|
2007-12-11 |
2014-09-17 |
The Scripps Research Institute |
Compositions and methods related to mRNA translational enhancer elements
|
WO2009078799A1
(en)
|
2007-12-17 |
2009-06-25 |
Marfl Ab |
New vaccine for the treatment of mycobacterium related disorders
|
EP2238251B1
(en)
|
2007-12-27 |
2015-02-11 |
Protiva Biotherapeutics Inc. |
Silencing of polo-like kinase expression using interfering rna
|
HUE025560T2
(en)
|
2007-12-28 |
2016-03-29 |
Prothena Biosciences Ltd |
Treatment and prophylaxis of amyloidosis
|
CN102016036B
(en)
|
2008-02-11 |
2015-04-08 |
阿克赛医药公司 |
Modified RNAi polynucleotides and uses thereof
|
US8497364B2
(en)
*
|
2008-02-27 |
2013-07-30 |
California Institute Of Technology |
Triggered RNAi
|
US20110045001A1
(en)
*
|
2008-03-28 |
2011-02-24 |
Biontex Laboratories Gmbh |
Transfection results of non-viral gene delivery systems by influencing of the innate immune system
|
EP2283133A2
(en)
|
2008-04-04 |
2011-02-16 |
Calando Pharmaceuticals, Inc. |
Compositions and use of epas1 inhibitors
|
JP5788312B2
(en)
|
2008-04-11 |
2015-09-30 |
アルニラム ファーマスーティカルズ インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
Site-specific delivery of nucleic acids by combining targeting ligands with endosomal degradable components
|
NZ588583A
(en)
|
2008-04-15 |
2012-08-31 |
Protiva Biotherapeutics Inc |
Novel lipid formulations for nucleic acid delivery
|
CA2721380A1
(en)
|
2008-04-15 |
2009-10-22 |
Protiva Biotherapeutics, Inc. |
Silencing of csn5 gene expression using interfering rna
|
CN102137675A
(en)
|
2008-04-17 |
2011-07-27 |
Pds生物科技公司 |
Stimulation of an immune response by enantiomers of cationic lipids
|
US20100021904A1
(en)
*
|
2008-05-21 |
2010-01-28 |
Pierce Niles A |
Shielded cross-linking probes
|
US8241854B2
(en)
*
|
2008-05-22 |
2012-08-14 |
California Institute Of Technology |
Triggered RNAi
|
US20100021901A1
(en)
*
|
2008-05-22 |
2010-01-28 |
Peng Yin |
Compositions and methods for detecting analytes
|
EP2296669B1
(en)
|
2008-05-30 |
2012-03-21 |
Yale University |
Targeted oligonucleotide compositions for modifying gene expression
|
EP2910568B1
(en)
|
2008-06-10 |
2018-08-22 |
Sangamo Therapeutics, Inc. |
Methods and compositions for generation of BAX- and BAK-deficient cell lines
|
RU2010151562A
(en)
|
2008-06-20 |
2012-07-27 |
ВАЙЕТ ЭлЭлСи (US) |
COMPOSITIONS AND METHODS OF APPLICATION OF ORF1358 FROM BETA-HEMOLYTIC STRAPTOCOK STRAINS
|
WO2010008582A2
(en)
|
2008-07-18 |
2010-01-21 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell drug delivery system
|
KR20160015400A
(en)
|
2008-08-22 |
2016-02-12 |
상가모 바이오사이언스 인코포레이티드 |
Methods and compositions for targeted single-stranded cleavage and targeted integration
|
JP5420668B2
(en)
|
2008-08-25 |
2014-02-19 |
エクスカリアード・ファーマシューティカルズ,インコーポレイテッド |
Antisense oligonucleotides for connective tissue growth factor and uses thereof
|
EP2816113A3
(en)
|
2008-09-11 |
2015-03-25 |
Galapagos N.V. |
Method for identifying compounds useful for increasing the functional activity and cell surface expression of cf-associated mutant cystic fibrosis transmembrane conductance regulator
|
CA2753338A1
(en)
|
2008-09-22 |
2010-03-25 |
Rxi Pharmaceuticals Corporation |
Neutral nanotransporters
|
CA2740000C
(en)
|
2008-10-09 |
2017-12-12 |
Tekmira Pharmaceuticals Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
JP2012505913A
(en)
|
2008-10-16 |
2012-03-08 |
マリーナ バイオテック,インコーポレイテッド |
Processes and compositions for efficient delivery by liposomes in therapy to suppress gene expression
|
AU2009313615B2
(en)
|
2008-11-05 |
2012-11-29 |
Regents Of The University Of Minnesota |
Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (BHS) disease
|
WO2010059226A2
(en)
|
2008-11-19 |
2010-05-27 |
Rxi Pharmaceuticals Corporation |
Inhibition of map4k4 through rnai
|
WO2010065662A2
(en)
|
2008-12-04 |
2010-06-10 |
Curna, Inc. |
Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1
|
RU2746478C2
(en)
|
2008-12-04 |
2021-04-14 |
КьюРНА, Инк. |
Treatment of tumors of diseases related to the genom-suppressor by therapy of natural transcript inhibition in anti-significant orientation regarding this gene
|
KR101829469B1
(en)
|
2008-12-04 |
2018-03-30 |
큐알엔에이, 인크. |
Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo
|
US9206404B2
(en)
|
2008-12-04 |
2015-12-08 |
Sangamo Biosciences, Inc. |
Method of deleting an IgM gene in an isolated rat cell
|
WO2010078536A1
(en)
|
2009-01-05 |
2010-07-08 |
Rxi Pharmaceuticals Corporation |
Inhibition of pcsk9 through rnai
|
US20100233270A1
(en)
|
2009-01-08 |
2010-09-16 |
Northwestern University |
Delivery of Oligonucleotide-Functionalized Nanoparticles
|
FR2941152B1
(en)
*
|
2009-01-20 |
2013-10-18 |
Centre Nat Rech Scient |
VECTORS COMPRISING ANIONIC MACROMOLECULE AND CATIONIC LIPID FOR THE ADMINISTRATION OF SMALL NUCLEIC ACIDS
|
JP5827132B2
(en)
|
2009-02-04 |
2015-12-02 |
サンガモ バイオサイエンシズ インコーポレイテッド |
Methods and compositions for treating neuropathy
|
WO2010090762A1
(en)
|
2009-02-04 |
2010-08-12 |
Rxi Pharmaceuticals Corporation |
Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
ES2658626T3
(en)
|
2009-02-12 |
2018-03-12 |
Curna, Inc. |
Treatment of diseases related to glial cell-derived neurotrophic factor (GDNF) by inhibition of natural antisense transcript to GDNF
|
KR101682735B1
(en)
|
2009-02-12 |
2016-12-06 |
큐알엔에이, 인크. |
Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
|
WO2010096561A1
(en)
|
2009-02-18 |
2010-08-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Synthetic hiv/siv gag proteins and uses thereof
|
US8329882B2
(en)
|
2009-02-18 |
2012-12-11 |
California Institute Of Technology |
Genetic control of mammalian cells with synthetic RNA regulatory systems
|
JP2012517821A
(en)
|
2009-02-19 |
2012-08-09 |
ガラパゴス・ナムローゼ・フェンノートシャップ |
Identification method and compound useful for diagnosis and treatment of diseases including inflammation
|
US20120035245A1
(en)
|
2009-02-19 |
2012-02-09 |
Richard Antonius Jozef Janssen |
Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
|
JP2012517822A
(en)
|
2009-02-19 |
2012-08-09 |
ガラパゴス・ナムローゼ・フェンノートシャップ |
Identification method and compound useful for diagnosis and treatment of diseases including inflammation
|
JP6250263B2
(en)
|
2009-03-04 |
2017-12-20 |
クルナ・インコーポレーテッド |
Treatment of SIRT1-related diseases by suppression of natural antisense transcripts against sirtuin 1 (SIRT1)
|
ES2656290T3
(en)
|
2009-03-16 |
2018-02-26 |
Curna, Inc. |
Treatment of diseases related to nuclear factor (derived from erythroid 2) similar to 2 (NRF2) by inhibition of natural antisense transcript to NRF2
|
EP2408920B1
(en)
|
2009-03-17 |
2017-03-08 |
CuRNA, Inc. |
Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
|
US8993509B2
(en)
|
2009-03-31 |
2015-03-31 |
Robert Zimmerman |
Method for treatment of cachexia by administering inhibitors of adipose triglyceride lipase expression or activity
|
WO2010112569A1
(en)
|
2009-03-31 |
2010-10-07 |
Robert Zimmermann |
Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor
|
EP2414829A1
(en)
|
2009-04-01 |
2012-02-08 |
Galapagos N.V. |
Methods and means for treatment of osteoarthritis
|
US9145555B2
(en)
|
2009-04-02 |
2015-09-29 |
California Institute Of Technology |
Integrated—ligand-responsive microRNAs
|
CA2756833C
(en)
|
2009-04-09 |
2019-11-19 |
Sangamo Biosciences, Inc. |
Targeted integration into stem cells
|
JP5748653B2
(en)
|
2009-04-10 |
2015-07-15 |
協和発酵キリン株式会社 |
Hematological tumor therapy using anti-TIM-3 antibody
|
CN102724993B
(en)
|
2009-04-17 |
2016-04-27 |
纽约大学 |
Targeting TNF family receptors the peptide, compositions, method and uses thereof of antagonism TNF effect
|
EP3524275A1
(en)
|
2009-04-22 |
2019-08-14 |
Massachusetts Institute Of Technology |
Innate immune supression enables repeated delivery of long rna molecules
|
US20100273203A1
(en)
*
|
2009-04-23 |
2010-10-28 |
Board Of Trustees Of The University Of Arkansas |
Methods and compositions for detecting metabolites
|
KR101732201B1
(en)
|
2009-04-27 |
2017-05-02 |
교와 핫꼬 기린 가부시키가이샤 |
Anti-il-3r antibody for use in treatment of blood tumor
|
US8044215B2
(en)
*
|
2009-04-29 |
2011-10-25 |
Juvaris Biotherapeutics, Inc. |
Methods for the preparation of amphillic nitrogen containing imidazolinium derivative compounds
|
EP2424987B1
(en)
|
2009-05-01 |
2017-11-15 |
CuRNA, Inc. |
Treatment of hemoglobin (hbf/hbg) related diseases by inhibition of natural antisense transcript to hbf/hbg
|
JP5883782B2
(en)
|
2009-05-06 |
2016-03-15 |
クルナ・インコーポレーテッド |
Treatment of lipid transport metabolism gene-related diseases by suppression of natural antisense transcripts on lipid transport metabolism genes
|
WO2010129746A2
(en)
|
2009-05-06 |
2010-11-11 |
Curna, Inc. |
Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
|
WO2010135207A1
(en)
|
2009-05-16 |
2010-11-25 |
Agave Pharma, Incorporated |
Compositions comprising cationic amphiphiles and colipids for delivering therapeutics molecules
|
DK2432881T3
(en)
|
2009-05-18 |
2018-02-26 |
Curna Inc |
TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR
|
KR101703695B1
(en)
|
2009-05-22 |
2017-02-08 |
큐알엔에이, 인크. |
Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3
|
CN103221541B
(en)
|
2009-05-28 |
2017-03-01 |
库尔纳公司 |
Antiviral gene relevant disease is treated by the natural antisense transcript suppressing antiviral gene
|
BRPI1011236A2
(en)
|
2009-06-15 |
2019-07-09 |
4S3 Bioscience Inc |
methods and compositions for treating myotubular myopathy using chimeric polypeptides comprising miotubularih1 (mtm1) polypeptides
|
WO2010148050A2
(en)
|
2009-06-16 |
2010-12-23 |
Curna, Inc. |
Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
|
JP6128846B2
(en)
|
2009-06-16 |
2017-05-17 |
クルナ・インコーポレーテッド |
Treatment of PON1 gene-related diseases by suppression of natural antisense transcripts against paraoxonase (PON1)
|
US8859515B2
(en)
|
2009-06-24 |
2014-10-14 |
Curna, Inc. |
Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2
|
EP2446037B1
(en)
|
2009-06-26 |
2016-04-20 |
CuRNA, Inc. |
Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
|
CA2767127A1
(en)
|
2009-07-01 |
2011-01-06 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for delivery of therapeutic agents to solid tumors
|
US9018187B2
(en)
|
2009-07-01 |
2015-04-28 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods for the delivery of therapeutic agents
|
WO2011000106A1
(en)
|
2009-07-01 |
2011-01-06 |
Protiva Biotherapeutics, Inc. |
Improved cationic lipids and methods for the delivery of therapeutic agents
|
WO2011003834A1
(en)
|
2009-07-09 |
2011-01-13 |
Marina Biotech, Inc. |
Amphoteric liposomes comprising imino lipids
|
WO2011011447A1
(en)
|
2009-07-20 |
2011-01-27 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing ebola virus gene expression
|
EP2461819A4
(en)
|
2009-07-28 |
2013-07-31 |
Sangamo Biosciences Inc |
Methods and compositions for treating trinucleotide repeat disorders
|
WO2011015573A1
(en)
|
2009-08-03 |
2011-02-10 |
Galapagos Nv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
|
AU2010279572B2
(en)
|
2009-08-03 |
2017-02-02 |
Recombinetics, Inc. |
Methods and compositions for targeted gene modification
|
WO2011015572A1
(en)
|
2009-08-03 |
2011-02-10 |
Galapagos Nv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
|
CA2769665A1
(en)
|
2009-08-05 |
2011-02-10 |
Opko Curna, Llc |
Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
|
US8586526B2
(en)
|
2010-05-17 |
2013-11-19 |
Sangamo Biosciences, Inc. |
DNA-binding proteins and uses thereof
|
US8410064B2
(en)
*
|
2009-08-24 |
2013-04-02 |
The Board Of Trustees Of The University Of Arkansas |
Classical cannabinoid metabolites and methods of use thereof
|
CN102482671B
(en)
|
2009-08-25 |
2017-12-01 |
库尔纳公司 |
IQGAP relevant diseases are treated by suppressing the natural antisense transcript of ' gtpase activating protein containing IQ die bodys ' (IQGAP)
|
CA2772715C
(en)
|
2009-09-02 |
2019-03-26 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
EP2480668A2
(en)
|
2009-09-23 |
2012-08-01 |
Protiva Biotherapeutics Inc. |
Compositions and methods for silencing genes expressed in cancer
|
CA2780741C
(en)
|
2009-10-12 |
2023-04-04 |
Smith Holdings, Llc |
Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
|
US8962584B2
(en)
|
2009-10-14 |
2015-02-24 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. |
Compositions for controlling Varroa mites in bees
|
WO2011050194A1
(en)
|
2009-10-22 |
2011-04-28 |
Genentech, Inc. |
Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
|
WO2011056682A1
(en)
|
2009-10-27 |
2011-05-12 |
The University Of British Columbia |
Reverse head group lipids, lipid particle compositions comprising reverse headgroup lipids, and methods for the delivery of nucleic acids
|
WO2011056234A1
(en)
|
2009-11-06 |
2011-05-12 |
Fibrogen, Inc. |
Treatment for radiation-induced disorders
|
WO2011060233A1
(en)
|
2009-11-11 |
2011-05-19 |
The Trustees Of The University Of Pennsylvania |
Anti-tem1 antibodies and uses thereof
|
TWI507524B
(en)
|
2009-11-30 |
2015-11-11 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of tumor
|
NZ733634A
(en)
|
2009-12-01 |
2022-10-28 |
Translate Bio Inc |
Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
|
AU2010329847A1
(en)
|
2009-12-11 |
2012-07-26 |
Genecode As |
Methods of facilitating neural cell survival using GDNF family ligand (GFL) mimetics or RET signaling pathway activators
|
WO2011084455A2
(en)
|
2009-12-16 |
2011-07-14 |
Opko Curna, Llc. |
Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
|
KR101891352B1
(en)
|
2009-12-23 |
2018-08-24 |
큐알엔에이, 인크. |
Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf
|
RU2619185C2
(en)
|
2009-12-23 |
2017-05-12 |
Курна, Инк. |
Treatment of diseases associated with uncoupling proteins 2 (ucp2), by inhibiting of natural antisense transcript to ucp2
|
EP2519633B1
(en)
|
2009-12-29 |
2017-10-25 |
CuRNA, Inc. |
Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
|
JP5982288B2
(en)
|
2009-12-29 |
2016-08-31 |
カッパーアールエヌエー,インコーポレイテッド |
Treatment of tumor protein 63-related diseases by inhibition of natural antisense transcripts against tumor protein 63 (p63)
|
NO2521784T3
(en)
|
2010-01-04 |
2018-05-05 |
|
|
EP2521785B1
(en)
|
2010-01-06 |
2022-03-09 |
CuRNA, Inc. |
Inhibition of natural antisense transcript to a pancreatic developmental gene for use in a treatment of pancreatic developmental gene related diseases
|
ES2664866T3
(en)
|
2010-01-11 |
2018-04-23 |
Curna, Inc. |
Treatment of diseases related to sex hormone binding globulin (shbg) by inhibition of the natural antisense transcript to shbg
|
US8883739B2
(en)
|
2010-01-19 |
2014-11-11 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for male reproductive disorders
|
WO2011090804A1
(en)
|
2010-01-22 |
2011-07-28 |
Dow Agrosciences Llc |
Targeted genomic alteration
|
CA2786568A1
(en)
|
2010-01-25 |
2011-07-28 |
Curna, Inc. |
Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1
|
EP4328304A2
(en)
|
2010-02-08 |
2024-02-28 |
Sangamo Therapeutics, Inc. |
Engineered cleavage half-domains
|
AU2011215557B2
(en)
|
2010-02-09 |
2016-03-10 |
Sangamo Therapeutics, Inc. |
Targeted genomic modification with partially single-stranded donor molecules
|
JP5976548B2
(en)
|
2010-02-22 |
2016-08-23 |
カッパーアールエヌエー,インコーポレイテッド |
Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcripts against PYCR1
|
SG183335A1
(en)
|
2010-02-23 |
2012-09-27 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of tumor
|
WO2011109427A2
(en)
|
2010-03-01 |
2011-09-09 |
Alnylam Pharmaceuticals, Inc. |
Improving the biological activity of sirna through modulation of its thermodynamic profile
|
AU2011224570B2
(en)
|
2010-03-08 |
2014-08-14 |
Monsanto Technology Llc |
Polynucleotide molecules for gene regulation in plants
|
EP2547368A4
(en)
|
2010-03-19 |
2014-08-06 |
Univ South Alabama |
Methods and compositions for the treatment of cancer
|
EP3284821B1
(en)
|
2010-03-23 |
2022-01-05 |
Precigen, Inc. |
Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
|
US9247720B2
(en)
|
2010-03-24 |
2016-02-02 |
Institut National de la Santé et de la Recherche Médicale |
Primate model from the family cercopithecidae infected by a HBV strain of human genotype
|
CA2794189C
(en)
|
2010-03-24 |
2022-01-11 |
Rxi Pharmaceuticals Corporation |
Rna interference in dermal and fibrotic indications
|
CN106074591B
(en)
|
2010-03-24 |
2020-01-14 |
菲奥医药公司 |
RNA interference in ocular symptoms
|
EP2550000A4
(en)
|
2010-03-24 |
2014-03-26 |
Advirna Inc |
Reduced size self-delivering rnai compounds
|
AU2011230619C1
(en)
|
2010-03-25 |
2016-06-23 |
Oregon Health & Science University |
CMV glycoproteins and recombinant vectors
|
US8883218B2
(en)
*
|
2010-03-26 |
2014-11-11 |
The Board Of Trustees Of The University Of Arkansas |
Anti-cancer nanoparticle compositions and methods of use
|
WO2011120023A1
(en)
|
2010-03-26 |
2011-09-29 |
Marina Biotech, Inc. |
Nucleic acid compounds for inhibiting survivin gene expression uses thereof
|
WO2011127337A2
(en)
|
2010-04-09 |
2011-10-13 |
Opko Curna Llc |
Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
|
US8790621B2
(en)
*
|
2010-04-12 |
2014-07-29 |
Iowa State University Research Foundation, Inc. |
Nanoparticles and nanoparticle compositions
|
AU2011239386B2
(en)
|
2010-04-16 |
2015-03-19 |
Salk Institute For Biological Studies |
Methods for treating metabolic disorders using FGF
|
WO2011133584A2
(en)
|
2010-04-19 |
2011-10-27 |
Marina Biotech, Inc. |
Nucleic acid compounds for inhibiting hras gene expression and uses thereof
|
WO2011139843A2
(en)
|
2010-04-28 |
2011-11-10 |
Marina Biotech, Inc. |
Multi-sirna compositions for reducing gene expression
|
US9408914B2
(en)
|
2010-04-28 |
2016-08-09 |
Kyowa Hakko Kirin Co., Ltd. |
Cationic lipid
|
US20130129811A1
(en)
|
2010-04-28 |
2013-05-23 |
Takeshi Kuboyama |
Cationic lipid
|
SI2563920T1
(en)
|
2010-04-29 |
2017-05-31 |
Ionis Pharmaceuticals, Inc. |
Modulation of transthyretin expression
|
SG185027A1
(en)
|
2010-05-03 |
2012-11-29 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of tumor
|
WO2011139387A1
(en)
|
2010-05-03 |
2011-11-10 |
Opko Curna, Llc |
Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
|
JP5866106B2
(en)
|
2010-05-12 |
2016-02-17 |
コロンビア ユニヴァーシティ |
Method for producing enteroendocrine cells that produce and secrete insulin
|
CA2799091A1
(en)
|
2010-05-12 |
2011-11-17 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods of use thereof
|
WO2011141704A1
(en)
|
2010-05-12 |
2011-11-17 |
Protiva Biotherapeutics, Inc |
Novel cyclic cationic lipids and methods of use
|
TWI586356B
(en)
|
2010-05-14 |
2017-06-11 |
可娜公司 |
Treatment of par4 related diseases by inhibition of natural antisense transcript to par4
|
US8658780B2
(en)
|
2010-05-18 |
2014-02-25 |
California Institute Of Technology |
Triggered covalent probes for imaging and silencing genetic expression
|
RU2585229C2
(en)
|
2010-05-26 |
2016-05-27 |
Курна, Инк. |
Treatment of diseases associated with atonal homolog 1 (aton1) by inhibiting natural antisense transcript of gene aton1
|
CA2802017A1
(en)
|
2010-06-09 |
2011-12-15 |
Zymogenetics, Inc. |
Dimeric vstm3 fusion proteins and related compositions and methods
|
EP2582387A2
(en)
|
2010-06-17 |
2013-04-24 |
The United States Of America As Represented By The Secretary, National Institutes Of Health |
Compositions and methods for treating inflammatory conditions
|
US9006417B2
(en)
|
2010-06-30 |
2015-04-14 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
US10487332B2
(en)
|
2010-07-06 |
2019-11-26 |
Glaxosmithkline Biologicals Sa |
Immunisation of large mammals with low doses of RNA
|
US20130171241A1
(en)
|
2010-07-06 |
2013-07-04 |
Novartis Ag |
Liposomes with lipids having an advantageous pka-value for rna delivery
|
AU2011276236B2
(en)
|
2010-07-06 |
2016-03-10 |
Glaxosmithkline Biologicals S.A. |
Cationic oil-in-water emulsions
|
HUE047796T2
(en)
|
2010-07-06 |
2020-05-28 |
Glaxosmithkline Biologicals Sa |
Delivery of rna to trigger multiple immune pathways
|
RU2611190C2
(en)
|
2010-07-14 |
2017-02-21 |
Курна, Инк. |
Treatment of diseases related with gene dlg by inhibition of natural antisense transcript of dlg gene
|
US8962241B2
(en)
|
2010-07-20 |
2015-02-24 |
California Institute Of Technology |
Triggered molecular geometry based bioimaging probes
|
US8877438B2
(en)
|
2010-07-20 |
2014-11-04 |
California Institute Of Technology |
Self-assembled polynucleotide structure
|
US9834439B2
(en)
|
2010-07-20 |
2017-12-05 |
California Institute Of Technology |
Biomolecular self-assembly
|
US9057057B2
(en)
|
2010-07-27 |
2015-06-16 |
The Johns Hopkins University |
Obligate heterodimer variants of foki cleavage domain
|
HUE052850T2
(en)
|
2010-08-23 |
2021-05-28 |
Wyeth Llc |
Stable formulations of neisseria meningitidis rlp2086 antigens
|
SI3970742T1
(en)
|
2010-08-31 |
2022-08-31 |
Glaxosmithkline Biologicals S.A. |
Pegylated liposomes for delivery of immunogen-encoding rna
|
MX362802B
(en)
|
2010-09-10 |
2019-02-13 |
Wyeth Llc Star |
Non-lipidated variants of neisseria meningitidis orf2086 antigens.
|
US8703824B2
(en)
|
2010-09-14 |
2014-04-22 |
Council Of Scientific & Industrial Research |
Cationic amphiphiles with mannose-mimicking head-groups and a process for the preparation thereof
|
EP3511420B1
(en)
|
2010-09-27 |
2021-04-07 |
Sangamo Therapeutics, Inc. |
Compositions for inhibiting viral entry into cells
|
JP5974012B2
(en)
|
2010-10-05 |
2016-08-23 |
ジェネンテック, インコーポレイテッド |
Mutant smoothened and method of using the same
|
ES2640755T3
(en)
|
2010-10-06 |
2017-11-06 |
Curna, Inc. |
Treatment of diseases related to Sialidase 4 (neu4) by inhibition of the natural antisense transcript to the neu4 gene
|
MX363307B
(en)
|
2010-10-11 |
2019-03-20 |
Novartis Ag Star |
Antigen delivery platforms.
|
WO2012054723A2
(en)
|
2010-10-22 |
2012-04-26 |
Opko Curna Llc |
Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
|
RU2611195C2
(en)
|
2010-10-27 |
2017-02-21 |
Курна, Инк. |
Treatment of interferon-related developmental regulator 1 (ifrd1) associated diseases by inhibition of natural antisense transcript to ifrd1
|
US20140134181A1
(en)
|
2010-11-05 |
2014-05-15 |
Kenneth E. Lipson |
Treatment Method For Lung Remodeling Diseases
|
CA2818824A1
(en)
|
2010-11-23 |
2012-05-31 |
Joseph Collard |
Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
|
AU2011336467A1
(en)
|
2010-12-01 |
2013-07-04 |
Spinal Modulation, Inc. |
Agent delivery systems for selective neuromodulation
|
AU2011338548B2
(en)
|
2010-12-06 |
2016-09-29 |
The Penn State Research Foundation |
Compositions and methods relating to proliferative diseases
|
WO2012076715A1
(en)
|
2010-12-09 |
2012-06-14 |
Institut Pasteur |
Mgmt-based method for obtaining high yield of recombinant protein expression
|
US9095598B2
(en)
|
2010-12-28 |
2015-08-04 |
The Board Of Trustees Of The University Of Arkansas |
Stilbenoid derivatives and their uses
|
WO2012106281A2
(en)
|
2011-01-31 |
2012-08-09 |
The General Hospital Corporation |
Multimodal trail molecules and uses in cellular therapies
|
KR101697396B1
(en)
|
2011-02-02 |
2017-01-17 |
엑스칼리아드 파마슈티컬즈, 인코포레이티드 |
Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf)
|
WO2012109495A1
(en)
|
2011-02-09 |
2012-08-16 |
Metabolic Solutions Development Company, Llc |
Cellular targets of thiazolidinediones
|
EP2492279A1
(en)
|
2011-02-25 |
2012-08-29 |
Laboratorios Del. Dr. Esteve, S.A. |
Rapid immunogen selection method using lentiviral display
|
EP2681327B1
(en)
|
2011-03-04 |
2018-11-21 |
Intrexon Corporation |
Vectors conditionally expressing protein
|
AU2012236099A1
(en)
|
2011-03-31 |
2013-10-03 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
US9458456B2
(en)
|
2011-04-01 |
2016-10-04 |
University Of South Alabama |
Methods and compositions for the diagnosis, classification, and treatment of cancer
|
WO2012142458A1
(en)
|
2011-04-13 |
2012-10-18 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of ptp1b expression
|
WO2012149515A2
(en)
*
|
2011-04-29 |
2012-11-01 |
Northwestern University |
Novel vegf mimetic peptide-based scaffolds for therapeutic angiogenesis and methods for their use
|
PT2709981T
(en)
*
|
2011-05-20 |
2019-05-30 |
Merck Patent Gmbh |
Preparation of stable crystal modifications of dotap chloride
|
SG193553A1
(en)
|
2011-05-24 |
2013-10-30 |
Biontech Ag |
Individualized vaccines for cancer
|
RS59037B1
(en)
|
2011-06-08 |
2019-08-30 |
Translate Bio Inc |
Lipid nanoparticle compositions and methods for mrna delivery
|
ES2653247T3
(en)
|
2011-06-09 |
2018-02-06 |
Curna, Inc. |
Treatment of frataxin-related diseases (FXN) by inhibiting the natural antisense transcript to the FXN gene
|
LT2691530T
(en)
|
2011-06-10 |
2018-08-10 |
Oregon Health & Science University |
Cmv glycoproteins and recombinant vectors
|
CA2839437A1
(en)
|
2011-06-16 |
2012-12-20 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of fibroblast growth factor receptor 4 expression
|
CN103890000B
(en)
|
2011-06-21 |
2017-09-01 |
阿尔尼拉姆医药品有限公司 |
(ANGPTL3) the iRNA compositions of angiopoietin-like 3 and its application method
|
MX350198B
(en)
|
2011-07-06 |
2017-08-30 |
Novartis Ag |
Oil-in-water emulsions that contain nucleic acids.
|
CA2840989A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic combination compositions and uses thereof
|
SG10201605500TA
(en)
|
2011-07-06 |
2016-08-30 |
Novartis Ag |
Cationic oil-in-water emulsions
|
US20140274812A1
(en)
|
2011-07-15 |
2014-09-18 |
The General Hospital Corporation |
Methods of Transcription Activator Like Effector Assembly
|
EP2546358A1
(en)
|
2011-07-15 |
2013-01-16 |
Laboratorios Del. Dr. Esteve, S.A. |
Methods and reagents for efficient control of HIV progression
|
AU2012216792A1
(en)
|
2011-09-12 |
2013-03-28 |
International Aids Vaccine Initiative |
Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
|
EP2755466A4
(en)
|
2011-09-13 |
2015-04-15 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
US10806146B2
(en)
|
2011-09-13 |
2020-10-20 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
US10760086B2
(en)
|
2011-09-13 |
2020-09-01 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
US10829828B2
(en)
|
2011-09-13 |
2020-11-10 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
DK2758433T3
(en)
|
2011-09-19 |
2018-01-15 |
Axon Neuroscience Se |
PROTEIN-BASED THERAPY AND DIAGNOSIS OF TAU-MEDIATED PATHOLOGY OF ALZHEIMER'S DISEASE
|
PT2760463T
(en)
|
2011-09-20 |
2019-02-27 |
Univ North Carolina Chapel Hill |
Regulation of sodium channels by plunc proteins
|
WO2013043569A1
(en)
|
2011-09-20 |
2013-03-28 |
Vical Incorporated |
Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
|
CN108410868A
(en)
|
2011-09-20 |
2018-08-17 |
Ionis制药公司 |
The antisense of GCGR expression is adjusted
|
CA2848417C
(en)
|
2011-09-21 |
2023-05-02 |
Sangamo Biosciences, Inc. |
Methods and compositions for regulation of transgene expression
|
US20130085139A1
(en)
|
2011-10-04 |
2013-04-04 |
Royal Holloway And Bedford New College |
Oligomers
|
WO2013053765A1
(en)
|
2011-10-11 |
2013-04-18 |
Proyecto De Biomedicina Cima, S.L. |
A non-human animal model of mucosa-associated lymphoid tissue (malt) lymphoma
|
KR20140084232A
(en)
|
2011-10-25 |
2014-07-04 |
아이시스 파마수티컬즈 인코포레이티드 |
Antisense modulation of gccr expression
|
EP2586461A1
(en)
|
2011-10-27 |
2013-05-01 |
Christopher L. Parks |
Viral particles derived from an enveloped virus
|
JP2013095755A
(en)
|
2011-11-02 |
2013-05-20 |
Kyowa Hakko Kirin Co Ltd |
Cationic lipid
|
MX359548B
(en)
|
2011-11-18 |
2018-10-02 |
Alnylam Pharmaceuticals Inc |
Modified rnai agents.
|
KR102385013B1
(en)
|
2011-11-18 |
2022-04-12 |
알닐람 파마슈티칼스 인코포레이티드 |
RNAi AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES
|
EP2788316B1
(en)
*
|
2011-12-07 |
2019-04-24 |
Alnylam Pharmaceuticals, Inc. |
Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents
|
ES2921724T1
(en)
|
2011-12-07 |
2022-08-31 |
Alnylam Pharmaceuticals Inc |
Biodegradable lipids for the administration of active agents
|
KR102007061B1
(en)
|
2011-12-09 |
2019-08-02 |
앵스띠뛰 파스퇴르 |
Multiplex immuno screening assay
|
AU2012353463B2
(en)
|
2011-12-12 |
2017-08-24 |
Kyowa Hakko Kirin Co., Ltd. |
Lipid nanoparticles containing combinations of cationic lipids
|
US9839616B2
(en)
|
2011-12-12 |
2017-12-12 |
Kyowa Hakko Kirin Co., Ltd. |
Lipid nano particles comprising cationic lipid for drug delivery system
|
WO2013090648A1
(en)
*
|
2011-12-16 |
2013-06-20 |
modeRNA Therapeutics |
Modified nucleoside, nucleotide, and nucleic acid compositions
|
US9035039B2
(en)
|
2011-12-22 |
2015-05-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing SMAD4
|
PL2794627T3
(en)
|
2011-12-22 |
2019-04-30 |
Alios Biopharma Inc |
Substituted nucleosides, nucleotides and analogs thereof
|
US9464291B2
(en)
|
2012-01-06 |
2016-10-11 |
University Of South Alabama |
Methods and compositions for the treatment of cancer
|
EP2802338B1
(en)
|
2012-01-09 |
2018-03-07 |
Serpin Pharma, LLC |
Peptides and methods of using same
|
KR102384791B1
(en)
|
2012-02-24 |
2022-04-08 |
아뷰터스 바이오파마 코포레이션 |
Trialkyl cationic lipids and methods of use thereof
|
RU2639277C2
(en)
|
2012-02-29 |
2017-12-20 |
Сангамо Байосайенсиз, Инк. |
Methods and compositions for huntington disease treatment
|
MY198910A
(en)
|
2012-03-09 |
2023-10-02 |
Pfizer |
Neisseria meningitidis compositions and methods thereof
|
SA115360586B1
(en)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
Neisseria meningitidis compositions and methods thereof
|
CA2867262C
(en)
|
2012-03-15 |
2021-03-16 |
Curna, Inc. |
Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
|
US9441007B2
(en)
|
2012-03-21 |
2016-09-13 |
Alios Biopharma, Inc. |
Substituted nucleosides, nucleotides and analogs thereof
|
USRE48171E1
(en)
|
2012-03-21 |
2020-08-25 |
Janssen Biopharma, Inc. |
Substituted nucleosides, nucleotides and analogs thereof
|
WO2013143555A1
(en)
|
2012-03-26 |
2013-10-03 |
Biontech Ag |
Rna formulation for immunotherapy
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
US9878056B2
(en)
|
2012-04-02 |
2018-01-30 |
Modernatx, Inc. |
Modified polynucleotides for the production of cosmetic proteins and peptides
|
AU2013243948A1
(en)
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins associated with human disease
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
US9783610B2
(en)
|
2012-04-27 |
2017-10-10 |
The Trustees Of The University Of Pennsylvania |
Anti-tumor endothelial marker-1 (TEM1) antibody variants and uses thereof
|
LT2852391T
(en)
|
2012-05-21 |
2022-03-10 |
Insmed Incorporated |
Systems for treating pulmonary infections
|
AU2013264742B2
(en)
|
2012-05-24 |
2018-10-04 |
A.B. Seeds Ltd. |
Compositions and methods for silencing gene expression
|
US9890364B2
(en)
|
2012-05-29 |
2018-02-13 |
The General Hospital Corporation |
TAL-Tet1 fusion proteins and methods of use thereof
|
EP3536787A1
(en)
|
2012-06-08 |
2019-09-11 |
Translate Bio, Inc. |
Nuclease resistant polynucleotides and uses thereof
|
RS62288B9
(en)
*
|
2012-06-08 |
2021-12-31 |
Nitto Denko Corp |
Lipids for therapeutic agent delivery formulations
|
ES2631608T3
(en)
|
2012-06-27 |
2017-09-01 |
International Aids Vaccine Initiative |
Env-glycoprotein variant of HIV-1
|
TW201726599A
(en)
|
2012-07-06 |
2017-08-01 |
協和醱酵麒麟有限公司 |
Cationic lipid
|
EP3196301B1
(en)
|
2012-07-11 |
2018-10-17 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of monogenic diseases
|
CA2878037C
(en)
|
2012-07-11 |
2021-08-31 |
Sangamo Biosciences, Inc. |
Methods and compositions for delivery of biologics
|
US9913907B2
(en)
|
2012-07-16 |
2018-03-13 |
Kyowa Hakko Kirin Co., Ltd. |
RNAi pharmaceutical composition for suppressing expression of KRAS gene
|
US9708607B2
(en)
|
2012-08-03 |
2017-07-18 |
Alnylam Pharmaceuticals, Inc. |
Modified RNAi agents
|
EP2698377A1
(en)
|
2012-08-17 |
2014-02-19 |
Laboratorios Del. Dr. Esteve, S.A. |
Enhanced rapid immunogen selection method for HIV gp120 variants
|
CA2882499C
(en)
|
2012-08-29 |
2023-09-26 |
Sangamo Biosciences, Inc. |
Cells genetically modified within the bcl11a gene by a nuclease and various aspects related thereto
|
EP2890720B1
(en)
|
2012-08-30 |
2019-07-17 |
The General Hospital Corporation |
Compositions and methods for treating cancer
|
US9365856B2
(en)
|
2012-09-14 |
2016-06-14 |
The Board Of Trustees Of The University Of Arkansas |
Methods of using a serum response factor isoform
|
WO2014041179A1
(en)
|
2012-09-17 |
2014-03-20 |
Chemedest Ltd. |
Treatment of peripheral neuropathy using gfr(alpha)3 type receptor agonists
|
AU2013317805B2
(en)
|
2012-09-21 |
2018-07-26 |
Pds Biotechnology Corporation |
Improved vaccine compositions and methods of use
|
EP3763810A3
(en)
|
2012-10-10 |
2021-07-14 |
Sangamo Therapeutics, Inc. |
T cell modifying compounds and uses thereof
|
EP3483185B1
(en)
|
2012-10-12 |
2020-09-09 |
The General Hospital Corporation |
Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
|
CA2892391C
(en)
|
2012-11-28 |
2023-10-17 |
Biontech Rna Pharmaceuticals Gmbh |
Individualized vaccines for cancer
|
AU2013352259B2
(en)
|
2012-11-29 |
2018-06-14 |
Insmed Incorporated |
Stabilized vancomycin formulations
|
WO2014089313A1
(en)
|
2012-12-05 |
2014-06-12 |
Alnylam Pharmaceuticals |
PCSK9 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
US10272163B2
(en)
|
2012-12-07 |
2019-04-30 |
The Regents Of The University Of California |
Factor VIII mutation repair and tolerance induction
|
US20140179770A1
(en)
|
2012-12-12 |
2014-06-26 |
Massachusetts Institute Of Technology |
Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
|
CA2894684A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Engineering and optimization of improved crispr-cas systems, methods and enzyme compositions for sequence manipulation in eukaryotes
|
DK2931898T3
(en)
|
2012-12-12 |
2016-06-20 |
Massachusetts Inst Technology |
CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS
|
US20140310830A1
(en)
|
2012-12-12 |
2014-10-16 |
Feng Zhang |
CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
|
EP4279588A3
(en)
|
2012-12-12 |
2024-01-17 |
The Broad Institute, Inc. |
Engineering of systems, methods and optimized guide compositions for sequence manipulation
|
DK2896697T3
(en)
|
2012-12-12 |
2015-12-07 |
Broad Inst Inc |
Design of systems, methods and optimized sequence manipulation guide compositions
|
JP2016505256A
(en)
|
2012-12-12 |
2016-02-25 |
ザ・ブロード・インスティテュート・インコーポレイテッ |
CRISPR-Cas component system, method and composition for sequence manipulation
|
EP2931899A1
(en)
|
2012-12-12 |
2015-10-21 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
BR112015015976A2
(en)
|
2013-01-01 |
2018-04-10 |
A. B. Seeds Ltd. |
method for introducing dsrna into seeds to modulate gene expression
|
US10683505B2
(en)
|
2013-01-01 |
2020-06-16 |
Monsanto Technology Llc |
Methods of introducing dsRNA to plant seeds for modulating gene expression
|
WO2014107739A1
(en)
|
2013-01-07 |
2014-07-10 |
Eleven Biotherapeutics, Inc. |
Antibodies against pcsk9
|
AU2014207618A1
(en)
|
2013-01-16 |
2015-08-06 |
Emory University |
Cas9-nucleic acid complexes and uses related thereto
|
AU2014214719B2
(en)
|
2013-02-07 |
2020-02-13 |
The General Hospital Corporation |
Tale transcriptional activators
|
EP2953970A4
(en)
|
2013-02-08 |
2016-06-29 |
Misfolding Diagnostics Inc |
Transthyretin antibodies and uses thereof
|
US9371352B2
(en)
|
2013-02-08 |
2016-06-21 |
Vaccinex, Inc. |
Modified glycolipids and methods of making and using the same
|
WO2014130723A1
(en)
|
2013-02-20 |
2014-08-28 |
Valerion Therapeutics, Llc |
Methods and compositions for treatment of pompe disease
|
CA2903716C
(en)
|
2013-03-08 |
2019-04-09 |
Pfizer Inc. |
Immunogenic fusion polypeptides
|
CA2940513C
(en)
|
2013-03-11 |
2023-08-15 |
University Of Florida Research Foundation, Inc. |
Delivery of card protein as therapy for ocular inflammation
|
JP6698015B2
(en)
|
2013-03-12 |
2020-05-27 |
ザ ジェネラル ホスピタル コーポレイション |
Modified mullerian inhibitory substance (MIS) protein and use thereof for the treatment of diseases
|
WO2014164761A1
(en)
|
2013-03-13 |
2014-10-09 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
MX2015012334A
(en)
|
2013-03-13 |
2016-02-05 |
Monsanto Technology Llc |
Methods and compositions for weed control.
|
BR112015022260B1
(en)
|
2013-03-13 |
2023-05-16 |
Prothena Biosciences Limited |
MONOCLONAL ANTIBODY THAT BINDS TO TAU, POLYNUCLEOTIDE, PHARMACEUTICAL COMPOSITION AND USE OF AN ANTIBODY
|
WO2014139883A1
(en)
|
2013-03-14 |
2014-09-18 |
Galapagos Nv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of fibrotic diseases
|
PE20160046A1
(en)
|
2013-03-14 |
2016-02-14 |
Alnylam Pharmaceuticals Inc |
COMPOSITION OF RNAi AGAINST THE C5 COMPONENT OF THE COMPLEMENT AND METHODS FOR ITS USE
|
KR20210122917A
(en)
|
2013-03-14 |
2021-10-12 |
샤이어 휴먼 지네틱 테라피즈 인크. |
Cftr mrna compositions and related methods and uses
|
EP2971010B1
(en)
|
2013-03-14 |
2020-06-10 |
ModernaTX, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
JP2016518812A
(en)
|
2013-03-14 |
2016-06-30 |
ガラパゴス・ナムローゼ・フェンノートシャップGalapagos N.V. |
Molecular targets useful in the treatment of fibrosis and inhibitors of said targets
|
DK2970955T3
(en)
|
2013-03-14 |
2019-02-11 |
Translate Bio Inc |
METHODS FOR CLEANING MESSENGER RNA
|
JP2016522675A
(en)
|
2013-03-14 |
2016-08-04 |
ガラパゴス・ナムローゼ・フェンノートシャップGalapagos N.V. |
Molecular targets useful in the treatment of diseases associated with epithelial-mesenchymal transition and inhibitors of said targets
|
US9127024B2
(en)
|
2013-03-15 |
2015-09-08 |
Intrexon Corporation |
Boron-containing diacylhydrazines
|
US10010504B2
(en)
|
2013-03-15 |
2018-07-03 |
The Penn State Research Foundation |
Compositions and methods including celecoxib and plumbagin relating to treatment of cancer
|
US9999603B2
(en)
|
2013-03-15 |
2018-06-19 |
The Penn State Research Foundation |
Compositions and methods including leelamine and arachidonyl trifluoromethyl ketone relating to treatment of cancer
|
WO2014145042A1
(en)
|
2013-03-15 |
2014-09-18 |
Loma Linda University |
Treatment of autoimmune diseases
|
US10052364B2
(en)
|
2013-03-15 |
2018-08-21 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for cognitive disorders
|
US10568328B2
(en)
|
2013-03-15 |
2020-02-25 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
WO2014180490A1
(en)
|
2013-05-10 |
2014-11-13 |
Biontech Ag |
Predicting immunogenicity of t cell epitopes
|
WO2014186585A2
(en)
|
2013-05-15 |
2014-11-20 |
Sangamo Biosciences, Inc. |
Methods and compositions for treatment of a genetic condition
|
SG10201913872XA
(en)
|
2013-05-22 |
2020-03-30 |
Alnylam Pharmaceuticals Inc |
SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
SG11201510565TA
(en)
|
2013-05-22 |
2016-01-28 |
Alnylam Pharmaceuticals Inc |
Tmprss6 irna compositions and methods of use thereof
|
WO2014190181A1
(en)
|
2013-05-22 |
2014-11-27 |
Northwestern University |
Rna-directed dna cleavage and gene editing by cas9 enzyme from neisseria meningitidis
|
US20160130585A1
(en)
|
2013-05-28 |
2016-05-12 |
The Johns Hopkins University |
Aptamers for the treatment of sickle cell disease
|
EP3007704B1
(en)
|
2013-06-13 |
2021-01-06 |
Antisense Therapeutics Ltd |
Combination therapy for acromegaly
|
EP3011030B1
(en)
|
2013-06-17 |
2023-11-08 |
The Broad Institute, Inc. |
Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
|
CN106062197A
(en)
|
2013-06-17 |
2016-10-26 |
布罗德研究所有限公司 |
Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
|
CN114015726A
(en)
|
2013-06-17 |
2022-02-08 |
布罗德研究所有限公司 |
Delivery, use and therapeutic applications of CRISPR-CAS systems and compositions for targeting disorders and diseases with viral components
|
BR112015031608A2
(en)
|
2013-06-17 |
2017-08-22 |
Massachusetts Inst Technology |
APPLICATION AND USE OF CRISPR-CAS SYSTEMS, VECTORS AND COMPOSITIONS FOR LIVER TARGETING AND THERAPY
|
MX2015017311A
(en)
|
2013-06-17 |
2017-04-10 |
Broad Inst Inc |
Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells.
|
EP3011033B1
(en)
|
2013-06-17 |
2020-02-19 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
US20160152952A1
(en)
|
2013-06-25 |
2016-06-02 |
Temple University-Of The Commonwealth System Of Higher Education |
Cortical Bone-Derived Stem Cells
|
US9856472B2
(en)
|
2013-07-01 |
2018-01-02 |
California Institute Of Technology |
Small conditional RNAs
|
EP3030663B1
(en)
|
2013-07-19 |
2019-09-04 |
Monsanto Technology LLC |
Compositions and methods for controlling leptinotarsa
|
US9850496B2
(en)
|
2013-07-19 |
2017-12-26 |
Monsanto Technology Llc |
Compositions and methods for controlling Leptinotarsa
|
CA2919226A1
(en)
|
2013-07-23 |
2015-01-29 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for delivering messenger rna
|
US10894963B2
(en)
|
2013-07-25 |
2021-01-19 |
Exicure, Inc. |
Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
US10568898B2
(en)
*
|
2013-08-13 |
2020-02-25 |
Northwestern University |
Lipophilic nanoparticles for drug delivery
|
WO2015031645A1
(en)
|
2013-08-28 |
2015-03-05 |
Washington University |
Monoclonal antibodies to human 14-3-3 epsilon and human 14-3-3 epsilon sv
|
CA3131284C
(en)
|
2013-08-28 |
2023-09-19 |
David Paschon |
Compositions for linking dna-binding domains and cleavage domains
|
US11236338B2
(en)
|
2013-09-05 |
2022-02-01 |
Sarepta Therapeutics, Inc. |
Antisense-induced exon2 inclusion in acid alpha-glucosidase
|
US20150065381A1
(en)
|
2013-09-05 |
2015-03-05 |
International Aids Vaccine Initiative |
Methods of identifying novel hiv-1 immunogens
|
US9340799B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
MRNA-sensing switchable gRNAs
|
RU2662968C2
(en)
|
2013-09-08 |
2018-07-31 |
Пфайзер Инк. |
Immunogenic composition for neisseria meningitidis (options)
|
EP3047023B1
(en)
|
2013-09-19 |
2019-09-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Compositions and methods for inhibiting jc virus (jcv)
|
WO2015042564A1
(en)
|
2013-09-23 |
2015-03-26 |
Alnylam Pharmaceuticals, Inc. |
Methods for treating or preventing transthyretin (ttr) associated diseases
|
JP6821429B2
(en)
|
2013-09-25 |
2021-01-27 |
ゾエティス・サービシーズ・エルエルシー |
PCV2B branched vaccine composition and usage
|
EP2873423B1
(en)
|
2013-10-07 |
2017-05-31 |
International Aids Vaccine Initiative |
Soluble hiv-1 envelope glycoprotein trimers
|
AU2014337248B2
(en)
|
2013-10-17 |
2020-09-24 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
AU2014340083B2
(en)
|
2013-10-22 |
2019-08-15 |
Translate Bio, Inc. |
mRNA therapy for phenylketonuria
|
CN106413811A
(en)
|
2013-10-22 |
2017-02-15 |
夏尔人类遗传性治疗公司 |
Mrna therapy for argininosuccinate synthetase deficiency
|
EP3066200A1
(en)
|
2013-11-04 |
2016-09-14 |
Monsanto Technology LLC |
Compositions and methods for controlling arthropod parasite and pest infestations
|
US9469650B2
(en)
|
2013-11-08 |
2016-10-18 |
Board Of Trustees Of The University Of Arkansas |
Melampomagnolide B derivatives
|
US9487536B2
(en)
|
2013-11-08 |
2016-11-08 |
Board Of Trustees Of The University Of Arkansas |
Melampomagnolide B derivatives
|
NZ719477A
(en)
|
2013-11-11 |
2022-05-27 |
Sangamo Therapeutics Inc |
Methods and compositions for treating huntington’s disease
|
RS58671B1
(en)
|
2013-11-13 |
2019-06-28 |
Childrens Medical Center |
Nuclease-mediated regulation of gene expression
|
CN112107693B
(en)
|
2013-12-03 |
2023-05-26 |
西北大学 |
Liposome particles, method for preparing said liposome particles and use thereof
|
JP6883987B2
(en)
|
2013-12-04 |
2021-06-09 |
フィオ ファーマシューティカルズ コーポレーションPhio Pharmaceuticals Corp. |
Methods for wound healing procedures utilizing chemically modified oligonucleotides
|
DK3080274T3
(en)
|
2013-12-09 |
2020-08-31 |
Sangamo Therapeutics Inc |
Methods and compositions for genome manipulation
|
UA119253C2
(en)
|
2013-12-10 |
2019-05-27 |
Біолоджикс, Інк. |
Compositions and methods for virus control in varroa mite and bees
|
ES2912283T3
(en)
|
2013-12-11 |
2022-05-25 |
Massachusetts Gen Hospital |
Use of müllerian inhibitory substance (MIS)-type proteins for contraception and preservation of ovarian reserve
|
AU2014361781B2
(en)
|
2013-12-12 |
2021-04-01 |
Massachusetts Institute Of Technology |
Delivery, use and therapeutic applications of the CRISPR -Cas systems and compositions for genome editing
|
KR20160089530A
(en)
|
2013-12-12 |
2016-07-27 |
더 브로드 인스티튜트, 인코퍼레이티드 |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders
|
CA2931090A1
(en)
|
2013-12-12 |
2015-06-18 |
Alnylam Pharmaceuticals, Inc. |
Complement component irna compositions and methods of use thereof
|
WO2015089486A2
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
|
WO2015089419A2
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
|
WO2015106128A2
(en)
|
2014-01-09 |
2015-07-16 |
Alnylam Pharmaceuticals, Inc. |
MODIFIED RNAi AGENTS
|
UA121462C2
(en)
|
2014-01-15 |
2020-06-10 |
Монсанто Текнолоджі Елелсі |
Methods and compositions for weed control using epsps polynucleotides
|
WO2015116902A1
(en)
|
2014-01-31 |
2015-08-06 |
Genentech, Inc. |
G-protein coupled receptors in hedgehog signaling
|
PL3102673T3
(en)
|
2014-02-03 |
2020-11-02 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treatment of a beta thalessemia
|
AU2015214264B2
(en)
|
2014-02-04 |
2018-12-20 |
Curis, Inc. |
Mutant Smoothened and methods of using the same
|
WO2015123264A1
(en)
|
2014-02-11 |
2015-08-20 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
WO2015127094A1
(en)
|
2014-02-19 |
2015-08-27 |
University Of Florida Research Foundation, Inc. |
Delivery of nrf2 as therapy for protection against reactive oxygen species
|
EP3110401A4
(en)
|
2014-02-25 |
2017-10-25 |
Merck Sharp & Dohme Corp. |
Lipid nanoparticle vaccine adjuvants and antigen delivery systems
|
KR101605421B1
(en)
|
2014-03-05 |
2016-03-23 |
국립암센터 |
A monoclonal antibody which specifically recognizes B cell lymphoma and use thereof
|
US9624498B2
(en)
|
2014-03-18 |
2017-04-18 |
Sangamo Biosciences, Inc. |
Methods and compositions for regulation of zinc finger protein expression
|
US11091770B2
(en)
|
2014-04-01 |
2021-08-17 |
Monsanto Technology Llc |
Compositions and methods for controlling insect pests
|
EP3134506B1
(en)
|
2014-04-25 |
2019-08-07 |
Translate Bio, Inc. |
Methods for purification of messenger rna
|
CA2947270A1
(en)
|
2014-04-28 |
2015-11-05 |
Rxi Pharmaceuticals Corporation |
Methods for treating cancer using nucleic acids targeting mdm2 or mycn
|
US20170051290A1
(en)
|
2014-05-01 |
2017-02-23 |
Rxi Pharmaceuticals Corporation |
Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules
|
CN106456699B
(en)
|
2014-05-05 |
2021-07-02 |
生物风险投资有限责任公司 |
Compositions and methods for inhibiting anti-apoptotic Bcl-2 proteins as anti-aging agents
|
WO2015171918A2
(en)
|
2014-05-07 |
2015-11-12 |
Louisiana State University And Agricultural And Mechanical College |
Compositions and uses for treatment thereof
|
US11110154B2
(en)
|
2014-05-08 |
2021-09-07 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treating Huntington's Disease
|
ES2926985T3
(en)
|
2014-05-15 |
2022-10-31 |
Insmed Inc |
Methods for treating nontuberculous mycobacterial lung infections
|
EA201692370A1
(en)
|
2014-05-22 |
2017-03-31 |
Элнилэм Фармасьютикалз, Инк. |
COMPOSITIONS of mRNA ANGIOTENZINOGENA (AGT) AND METHODS OF THEIR USE
|
AU2015266767A1
(en)
|
2014-05-30 |
2016-12-08 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods to treat latent viral infections
|
PL3164113T3
(en)
|
2014-06-04 |
2019-09-30 |
Exicure, Inc. |
Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
|
CA2952697A1
(en)
|
2014-06-16 |
2015-12-23 |
The Johns Hopkins University |
Compositions and methods for the expression of crispr guide rnas using the h1 promoter
|
AU2015280252A1
(en)
|
2014-06-23 |
2017-01-12 |
Monsanto Technology Llc |
Compositions and methods for regulating gene expression via RNA interference
|
US11807857B2
(en)
|
2014-06-25 |
2023-11-07 |
Monsanto Technology Llc |
Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression
|
US10487314B2
(en)
|
2014-06-26 |
2019-11-26 |
The Trustees Of Columbia University In The City Of New York |
Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells
|
EP3169773B1
(en)
|
2014-07-15 |
2023-07-12 |
Juno Therapeutics, Inc. |
Engineered cells for adoptive cell therapy
|
US10195280B2
(en)
|
2014-07-15 |
2019-02-05 |
Life Technologies Corporation |
Compositions and methods for efficient delivery of molecules to cells
|
WO2016014625A1
(en)
|
2014-07-22 |
2016-01-28 |
Board Of Trustees Of The University Of Arkansas |
Compositions and methods for selectively depleting senescent cells
|
US10449261B2
(en)
|
2014-07-24 |
2019-10-22 |
Washington University |
Compositions targeting radiation-induced molecules and methods of use thereof
|
KR102330593B1
(en)
|
2014-07-28 |
2021-11-26 |
에스케이이노베이션 주식회사 |
Novel Isoprene Synthase and Method of Preparing Isoprene Using Thereof
|
CA2955842A1
(en)
|
2014-07-29 |
2016-02-04 |
Monsanto Technology Llc |
Compositions and methods for controlling insect pests
|
EP4079847A1
(en)
|
2014-07-30 |
2022-10-26 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
EP3686279B1
(en)
|
2014-08-17 |
2023-01-04 |
The Broad Institute, Inc. |
Genome editing using cas9 nickases
|
EP3186377A1
(en)
|
2014-08-20 |
2017-07-05 |
Alnylam Pharmaceuticals, Inc. |
Modified double-stranded rna agents
|
WO2016033424A1
(en)
|
2014-08-29 |
2016-03-03 |
Genzyme Corporation |
Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
|
US10900039B2
(en)
|
2014-09-05 |
2021-01-26 |
Phio Pharmaceuticals Corp. |
Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1
|
CN107073017A
(en)
|
2014-09-10 |
2017-08-18 |
华盛顿大学 |
Composition and method for treating precancerous dermatosis change
|
WO2016040589A1
(en)
|
2014-09-12 |
2016-03-17 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting complement component c5 and methods of use thereof
|
PT3194570T
(en)
|
2014-09-16 |
2021-08-06 |
Sangamo Therapeutics Inc |
Methods and compositions for nuclease-mediated genome engineering and correction in hematopoietic stem cells
|
MX2017003403A
(en)
|
2014-09-17 |
2017-06-19 |
Intrexon Corp |
Boron-containing diacylhydrazine compounds.
|
WO2016049024A2
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling competition of multiple cancer mutations in vivo
|
WO2016049251A1
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes
|
WO2016049163A2
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
|
WO2016045732A1
(en)
|
2014-09-25 |
2016-03-31 |
Biontech Rna Pharmaceuticals Gmbh |
Stable formulations of lipids and liposomes
|
AU2015328012A1
(en)
|
2014-10-02 |
2017-05-11 |
Arbutus Biopharma Corporation |
Compositions and methods for silencing Hepatitis B virus gene expression
|
MX2017004448A
(en)
|
2014-10-06 |
2017-10-23 |
Exicure Inc |
Anti-tnf compounds.
|
US20170304459A1
(en)
|
2014-10-10 |
2017-10-26 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhalation delivery of conjugated oligonucleotide
|
JOP20200115A1
(en)
|
2014-10-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
Compositions And Methods For Inhibition Of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression
|
WO2016061487A1
(en)
|
2014-10-17 |
2016-04-21 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
US10918629B2
(en)
|
2014-10-20 |
2021-02-16 |
The Curators Of The University Of Missouri |
Method for treating lymphedema
|
WO2016069694A2
(en)
|
2014-10-30 |
2016-05-06 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
|
JOP20200092A1
(en)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
HEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
CN113846101A
(en)
|
2014-11-17 |
2021-12-28 |
阿尔尼拉姆医药品有限公司 |
Apolipoprotein C3(APOC3) iRNA compositions and methods of use thereof
|
JP7175608B2
(en)
|
2014-11-19 |
2022-11-21 |
ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク |
Osteocalcin as a treatment for age-related frailty
|
WO2016085986A1
(en)
|
2014-11-24 |
2016-06-02 |
Northwestern University |
High density lipoprptein nanoparticles for inflammation
|
WO2016090166A1
(en)
|
2014-12-03 |
2016-06-09 |
Board Of Trustees Of The University Of Arkansas |
Melampomagnolide b dimers
|
CN107001238B
(en)
*
|
2014-12-08 |
2019-04-26 |
日油株式会社 |
The manufacturing method of cation lipid
|
WO2016094872A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Dead guides for crispr transcription factors
|
WO2016094874A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Escorted and functionalized guides for crispr-cas systems
|
WO2016094867A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Protected guide rnas (pgrnas)
|
US10793613B2
(en)
|
2014-12-15 |
2020-10-06 |
Washington University |
Compositions and methods for targeted cytokine delivery
|
WO2016106236A1
(en)
|
2014-12-23 |
2016-06-30 |
The Broad Institute Inc. |
Rna-targeting system
|
EP3237615B2
(en)
|
2014-12-24 |
2023-07-26 |
The Broad Institute, Inc. |
Crispr having or associated with destabilization domains
|
WO2016108926A1
(en)
|
2014-12-30 |
2016-07-07 |
The Broad Institute Inc. |
Crispr mediated in vivo modeling and genetic screening of tumor growth and metastasis
|
PL3256589T3
(en)
|
2015-01-22 |
2022-02-21 |
Monsanto Technology Llc |
Compositions and methods for controlling leptinotarsa
|
KR20220159498A
(en)
|
2015-01-28 |
2022-12-02 |
카리부 바이오사이언시스 인코포레이티드 |
Crispr hybrid dna/rna polynucleotides and methods of use
|
WO2016128060A1
(en)
|
2015-02-12 |
2016-08-18 |
Biontech Ag |
Predicting t cell epitopes useful for vaccination
|
CA2976445A1
(en)
|
2015-02-13 |
2016-08-18 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
US10888611B2
(en)
|
2015-02-19 |
2021-01-12 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
US10736845B2
(en)
*
|
2015-03-03 |
2020-08-11 |
Cureport Inc. |
Dual loaded liposomal pharmaceutical formulations
|
US9895313B2
(en)
|
2015-03-03 |
2018-02-20 |
Cureport, Inc. |
Combination liposomal pharmaceutical formulations
|
MA41795A
(en)
|
2015-03-18 |
2018-01-23 |
Sarepta Therapeutics Inc |
EXCLUSION OF AN EXON INDUCED BY ANTISENSE COMPOUNDS IN MYOSTATIN
|
US10174292B2
(en)
|
2015-03-20 |
2019-01-08 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
EP3072901A1
(en)
|
2015-03-23 |
2016-09-28 |
International Aids Vaccine Initiative |
Soluble hiv-1 envelope glycoprotein trimers
|
EP4335918A2
(en)
|
2015-04-03 |
2024-03-13 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of genome editing of b-cells
|
US10745702B2
(en)
|
2015-04-08 |
2020-08-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the LECT2 gene
|
US20180112006A1
(en)
|
2015-04-17 |
2018-04-26 |
The General Hospital Corporation |
Agents, systems and methods for treating cancer
|
MX2017014075A
(en)
|
2015-05-01 |
2018-07-06 |
Onl Therapeutics Inc |
Peptide compositions and methods of use.
|
CN115322991A
(en)
|
2015-05-06 |
2022-11-11 |
阿尔尼拉姆医药品有限公司 |
Factor XII, kallikrein B, plasma Freuey factor 1 and kininogen 1 iRNA compositions and methods of use thereof
|
RU2021132397A
(en)
|
2015-05-16 |
2022-02-24 |
Джензим Корпорейшн |
GENE EDITING OF DEEP INRON MUTATIONS
|
US10716827B2
(en)
|
2015-05-20 |
2020-07-21 |
Syracuse University |
Compositions and methods for enhancing peptide stability against protease digestion
|
WO2016187499A1
(en)
|
2015-05-20 |
2016-11-24 |
Syracuse University |
Improved glycemic control using intrinsic factor bound to a vitamin b12 conjugate of a glucagon-like peptide- 1 receptor agonist
|
JP6949728B2
(en)
|
2015-05-29 |
2021-10-13 |
ジュノー セラピューティクス インコーポレイテッド |
Compositions and Methods for Modulating Inhibitory Interactions in Genetically Engineered Cells
|
US10117911B2
(en)
|
2015-05-29 |
2018-11-06 |
Agenovir Corporation |
Compositions and methods to treat herpes simplex virus infections
|
EP3302497A4
(en)
|
2015-06-01 |
2019-01-16 |
Sarepta Therapeutics, Inc. |
Antisense-induced exon exclusion in type vii collagen
|
EP3302053B1
(en)
|
2015-06-02 |
2021-03-17 |
Monsanto Technology LLC |
Compositions and methods for delivery of a polynucleotide into a plant
|
EP3302030A4
(en)
|
2015-06-03 |
2019-04-24 |
Monsanto Technology LLC |
Methods and compositions for introducing nucleic acids into plants
|
WO2016197132A1
(en)
|
2015-06-04 |
2016-12-08 |
Protiva Biotherapeutics Inc. |
Treating hepatitis b virus infection using crispr
|
TW201710503A
(en)
|
2015-06-12 |
2017-03-16 |
長庚醫療財團法人林口長庚紀念醫院 |
Novel polynucleotides, vactor, pharmaceutical compositions and use thereof
|
EP3307316A1
(en)
|
2015-06-12 |
2018-04-18 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions and methods of use thereof
|
WO2016205728A1
(en)
|
2015-06-17 |
2016-12-22 |
Massachusetts Institute Of Technology |
Crispr mediated recording of cellular events
|
EP3430134B1
(en)
|
2015-06-18 |
2022-09-21 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
WO2016205749A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
WO2016205323A1
(en)
|
2015-06-18 |
2016-12-22 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
WO2017007813A1
(en)
|
2015-07-06 |
2017-01-12 |
Rxi Pharmaceuticals Corporation |
Nucleic acid molecules targeting superoxide dismutase 1 (sod1)
|
WO2017007825A1
(en)
|
2015-07-06 |
2017-01-12 |
Rxi Pharmaceuticals Corporation |
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
|
WO2017011286A1
(en)
|
2015-07-10 |
2017-01-19 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
|
CA2991301A1
(en)
|
2015-07-13 |
2017-01-19 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
MA42895A
(en)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
MODIFIED CELLS FOR ADOPTIVE CELL THERAPY
|
WO2017011728A1
(en)
|
2015-07-15 |
2017-01-19 |
Washington University |
ANTIBODIES TO TUMOR ASSOCIATED COMPLEX N-GLYCANS WITH TERMINAL GlcNAcBeta RESIDUES AND METHODS OF USE THEREOF
|
US20180208932A1
(en)
|
2015-07-29 |
2018-07-26 |
Arbutus Biopharma Corporation |
Compositions and methods for silencing hepatitis b virus gene expression
|
WO2017024317A2
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
WO2017035278A1
(en)
|
2015-08-24 |
2017-03-02 |
Halo-Bio Rnai Therapeutics, Inc. |
Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
|
US11020462B2
(en)
|
2015-08-28 |
2021-06-01 |
Serpin Pharma |
Methods for treatment of diseases
|
US10889813B2
(en)
|
2015-09-02 |
2021-01-12 |
Alnylam Pharmaceuticals, Inc. |
Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof
|
EP3350328A1
(en)
|
2015-09-14 |
2018-07-25 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof
|
CN108289966A
(en)
|
2015-09-24 |
2018-07-17 |
北卡罗来纳-查佩尔山大学 |
Method and composition for reducing transfer
|
WO2017058881A1
(en)
|
2015-09-28 |
2017-04-06 |
The Trustees Of Columbia University In The City Of New York |
Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
|
WO2017059902A1
(en)
|
2015-10-07 |
2017-04-13 |
Biontech Rna Pharmaceuticals Gmbh |
3' utr sequences for stabilization of rna
|
CN108513579B
(en)
|
2015-10-09 |
2022-10-04 |
孟山都技术公司 |
Novel RNA-guided nucleases and uses thereof
|
MA45819A
(en)
|
2015-10-09 |
2018-08-15 |
Sarepta Therapeutics Inc |
COMPOSITIONS AND METHODS FOR TREATING DUCHENNE MUSCLE DYSTROPHY AND RELATED DISORDERS
|
WO2017062953A1
(en)
|
2015-10-10 |
2017-04-13 |
Intrexon Corporation |
Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
|
MA42991A
(en)
|
2015-10-16 |
2018-08-22 |
Ipsen Biopharm Ltd |
STABILIZATION OF PHARMACEUTICAL COMPOSITIONS OF CAMPTOTHECIN
|
CA3002744A1
(en)
|
2015-10-19 |
2017-04-27 |
Rxi Pharmaceuticals Corporation |
Reduced size self-delivering nucleic acid compounds targeting long non-coding rna
|
US20170211142A1
(en)
|
2015-10-22 |
2017-07-27 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
CN108513575A
(en)
|
2015-10-23 |
2018-09-07 |
哈佛大学的校长及成员们 |
Nucleobase editing machine and application thereof
|
WO2017079429A1
(en)
|
2015-11-05 |
2017-05-11 |
Board Of Trustees Of The University Of Arkansas |
Hetero-substituted cyclic lactone analogues and uses thereof
|
AU2016349954B2
(en)
|
2015-11-05 |
2022-08-25 |
Antisense Therapeutics Ltd |
Mobilizing leukemia cells
|
EP3374496A4
(en)
|
2015-11-13 |
2019-07-10 |
PDS Biotechnology Corporation |
Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
|
AU2016367712B2
(en)
|
2015-12-09 |
2021-10-07 |
Jingang Medicine (Australia) Pty Ltd |
Immunomodulating composition for treatment
|
EP3387129A1
(en)
|
2015-12-10 |
2018-10-17 |
Alnylam Pharmaceuticals, Inc. |
STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) CHAPERONE (SCAP) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
CN108778297B
(en)
|
2015-12-18 |
2024-02-09 |
桑格摩生物治疗股份有限公司 |
Targeted disruption of T cell receptors
|
US20190233814A1
(en)
|
2015-12-18 |
2019-08-01 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
KR20180088911A
(en)
|
2015-12-18 |
2018-08-07 |
상가모 테라퓨틱스, 인코포레이티드 |
Targeted Collapse of MHC Cell Receptors
|
CA3009131A1
(en)
|
2015-12-25 |
2017-06-29 |
Kyowa Hakko Kirin Co., Ltd. |
Compounds as cationic lipids and their use in nucleic acid delivery compositions
|
US11938193B2
(en)
|
2016-01-08 |
2024-03-26 |
Washington University |
Compositions comprising chemerin and methods of use thereof
|
CA3010738A1
(en)
|
2016-01-15 |
2017-07-20 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of neurologic disease
|
WO2017132528A1
(en)
|
2016-01-29 |
2017-08-03 |
Bioventures, Llc |
Triazole derivatives of melampomagnolide b and methods of use thereof
|
CN109069568B
(en)
|
2016-02-02 |
2023-07-07 |
桑格摩生物治疗股份有限公司 |
Compositions for linking DNA binding domains and cleavage domains
|
CN109071625A
(en)
|
2016-02-04 |
2018-12-21 |
柯瑞斯公司 |
Smooth mutant and its application method
|
JP7220458B2
(en)
|
2016-02-05 |
2023-02-10 |
ワシントン・ユニバーシティ |
Compositions and methods for targeted cytokine delivery
|
EP3653709B1
(en)
|
2016-02-22 |
2020-12-09 |
Caribou Biosciences, Inc. |
Methods for modulating dna repair outcomes
|
GB201604235D0
(en)
|
2016-03-11 |
2016-04-27 |
Ucl Business Plc |
Lipids and complexes for the delivery of biologically-active material to cells
|
CA3018572A1
(en)
|
2016-03-24 |
2017-09-28 |
Marquette University |
Quantitative flagellar fluorescent markers and standards
|
US10213448B2
(en)
|
2016-03-25 |
2019-02-26 |
Novazoi Theranostics |
Ethanolamine-based lipid biosynthetic compounds, method of making and use thereof
|
EP3445405A4
(en)
|
2016-04-18 |
2019-12-18 |
Sarepta Therapeutics, Inc. |
Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
|
AU2017253089B2
(en)
|
2016-04-19 |
2023-07-20 |
Massachusetts Institute Of Technology |
Novel CRISPR enzymes and systems
|
US20200263190A1
(en)
|
2016-04-19 |
2020-08-20 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
WO2017184786A1
(en)
|
2016-04-19 |
2017-10-26 |
The Broad Institute Inc. |
Cpf1 complexes with reduced indel activity
|
WO2017184995A1
(en)
|
2016-04-21 |
2017-10-26 |
Bioventures, Llc |
Compounds that induce degradation of anti-apoptotic bcl-2 family proteins and the uses thereof
|
UA124148C2
(en)
|
2016-05-02 |
2021-07-28 |
Протена Біосайенсіс Лімітед |
Antibodies recognizing tau
|
KR102533675B1
(en)
|
2016-05-02 |
2023-05-22 |
프로테나 바이오사이언시즈 리미티드 |
Tau recognition antibody
|
CN109415432B
(en)
|
2016-05-02 |
2022-07-08 |
普罗塞纳生物科学有限公司 |
TAU immunotherapy
|
JP7186094B2
(en)
|
2016-05-06 |
2022-12-08 |
イグジキュア オペレーティング カンパニー |
Liposomal Spherical Nucleic Acid (SNA) Constructs Presenting Antisense Oligonucleotides (ASOs) for Specific Knockdown of Interleukin 17 Receptor mRNA
|
US20190256845A1
(en)
|
2016-06-10 |
2019-08-22 |
Alnylam Pharmaceuticals, Inc. |
COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
|
CA3028074A1
(en)
|
2016-06-16 |
2018-12-20 |
Oslo Universitetssykehus Hf |
Improved gene editing
|
KR20230156150A
(en)
|
2016-06-17 |
2023-11-13 |
더 브로드 인스티튜트, 인코퍼레이티드 |
Type vi crispr orthologs and systems
|
US20210222164A1
(en)
|
2016-06-29 |
2021-07-22 |
The Broad Institute, Inc. |
Crispr-cas systems having destabilization domain
|
JP7086870B2
(en)
|
2016-06-30 |
2022-06-20 |
アルブータス・バイオファーマー・コーポレイション |
Compositions and Methods for Delivering Messenger RNA
|
EP3943613A1
(en)
|
2016-07-05 |
2022-01-26 |
California Institute of Technology |
Fractional initiator hybridization chain reaction
|
CA3029860A1
(en)
|
2016-07-05 |
2018-01-11 |
The Johns Hopkins University |
Compositions and methods comprising improvements of crispr guide rnas using the h1 promoter
|
AU2017295720B2
(en)
|
2016-07-13 |
2021-07-22 |
Vertex Pharmaceuticals Incorporated |
Methods, compositions and kits for increasing genome editing efficiency
|
JP2019524098A
(en)
|
2016-07-15 |
2019-09-05 |
ソーク インスティテュート フォー バイオロジカル スタディーズ |
Methods and compositions for genome editing of non-dividing cells
|
CA2937157A1
(en)
|
2016-07-25 |
2018-01-25 |
Ucl Business Plc |
Protein-based t-cell receptor knockdown
|
KR20230095129A
(en)
|
2016-08-03 |
2023-06-28 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
Adenosine nucleobase editors and uses thereof
|
EP3493834A1
(en)
|
2016-08-07 |
2019-06-12 |
Novartis AG |
Mrna-mediated immunization methods
|
EP3497214B1
(en)
|
2016-08-09 |
2023-06-28 |
President and Fellows of Harvard College |
Programmable cas9-recombinase fusion proteins and uses thereof
|
CN110312799A
(en)
|
2016-08-17 |
2019-10-08 |
博德研究所 |
Novel C RISPR enzyme and system
|
WO2018035388A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
SG10202007392SA
(en)
|
2016-08-24 |
2020-09-29 |
Sangamo Therapeutics Inc |
Engineered target specific nucleases
|
DK3504229T3
(en)
|
2016-08-24 |
2021-12-20 |
Sangamo Therapeutics Inc |
REGULATION OF GENEPRESSION USING MANIPULATED NUCLEASES
|
WO2018039438A1
(en)
|
2016-08-24 |
2018-03-01 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
AU2017321492A1
(en)
|
2016-08-30 |
2019-03-14 |
California Institute Of Technology |
Immunohistochemistry via hybridization chain reaction
|
EP3519578B1
(en)
*
|
2016-10-03 |
2021-12-22 |
Precision Nanosystems Inc |
Compositions for transfecting resistant cell types
|
CA3038690A1
(en)
|
2016-10-05 |
2018-04-12 |
FUJIFILM Cellular Dynamics, Inc. |
Generating mature lineages from induced pluripotent stem cells with mecp2 disruption
|
CA3037387A1
(en)
|
2016-10-13 |
2018-04-19 |
Juno Therapeutics, Inc. |
Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
|
SG11201903089RA
(en)
|
2016-10-14 |
2019-05-30 |
Harvard College |
Aav delivery of nucleobase editors
|
US11219695B2
(en)
|
2016-10-20 |
2022-01-11 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of Fabry disease
|
EP3528827A4
(en)
|
2016-10-21 |
2020-11-04 |
Merck Sharp & Dohme Corp. |
Influenza hemagglutinin protein vaccines
|
WO2018081388A1
(en)
|
2016-10-26 |
2018-05-03 |
Washington University |
Compositions comprising desaminotyrosine and uses thereof to enhance type i interferon stimulation
|
WO2018081775A1
(en)
|
2016-10-31 |
2018-05-03 |
Sangamo Therapeutics, Inc. |
Gene correction of scid-related genes in hematopoietic stem and progenitor cells
|
US10011848B2
(en)
|
2016-11-09 |
2018-07-03 |
City University Of Hong Kong |
System and method for delivery of substance into mammalian cells
|
EA201990864A1
(en)
|
2016-11-09 |
2019-11-29 |
|
STRUCTURES FOR EXPRESSION OF FRATAXIN
|
TW202313978A
(en)
|
2016-11-23 |
2023-04-01 |
美商阿尼拉製藥公司 |
Serpina1 irna compositions and methods of use thereof
|
AU2017367695A1
(en)
|
2016-12-02 |
2019-06-13 |
Juno Therapeutics, Inc. |
Engineered B cells and related compositions and methods
|
MA49610A
(en)
|
2016-12-08 |
2020-05-27 |
Univ Case Western Reserve |
METHODS AND COMPOSITIONS FOR IMPROVING FUNCTIONAL MYELIN PRODUCTION
|
TWI790217B
(en)
|
2016-12-16 |
2023-01-21 |
美商阿尼拉製藥公司 |
METHODS FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES USING TRANSTHYRETIN (TTR) iRNA COMPOSITIONS
|
JP2020510443A
(en)
|
2016-12-20 |
2020-04-09 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
Method for increasing the efficiency of homologous recombination repair (HDR) in a cell genome
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
KR102567845B1
(en)
|
2017-01-31 |
2023-08-17 |
화이자 인코포레이티드 |
Neisseria meningitidis compositions and methods thereof
|
WO2018148595A1
(en)
|
2017-02-10 |
2018-08-16 |
Washington University |
Antibodies to tip1 and methods of use thereof
|
EA201991747A1
(en)
|
2017-02-27 |
2020-06-04 |
Транслейт Био, Инк. |
NEW CODON-OPTIMIZED CFTR mRNA
|
US11898179B2
(en)
|
2017-03-09 |
2024-02-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
JP2020510439A
(en)
|
2017-03-10 |
2020-04-09 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
Base-editing factor from cytosine to guanine
|
EP3596207B1
(en)
|
2017-03-15 |
2023-12-20 |
The Broad Institute, Inc. |
Novel cas13b orthologues crispr enzymes and systems
|
US11268082B2
(en)
|
2017-03-23 |
2022-03-08 |
President And Fellows Of Harvard College |
Nucleobase editors comprising nucleic acid programmable DNA binding proteins
|
US10876101B2
(en)
|
2017-03-28 |
2020-12-29 |
Locanabio, Inc. |
CRISPR-associated (Cas) protein
|
US11840711B2
(en)
|
2017-04-12 |
2023-12-12 |
The Broad Institute, Inc. |
Type VI CRISPR orthologs and systems
|
TWI801377B
(en)
|
2017-04-18 |
2023-05-11 |
美商阿尼拉製藥公司 |
Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
|
WO2018201091A1
(en)
|
2017-04-27 |
2018-11-01 |
Washington University |
Chemokine decoy receptors of rodent gammaherpesviruses and uses thereof
|
WO2018201088A1
(en)
|
2017-04-27 |
2018-11-01 |
Washington University |
Activation of natural cytotoxicity receptor 2 (ncr2)
|
WO2018201090A1
(en)
|
2017-04-28 |
2018-11-01 |
Exicure, Inc. |
Synthesis of spherical nucleic acids using lipophilic moieties
|
CA3058848A1
(en)
|
2017-05-09 |
2018-11-15 |
Vib Vzw |
Means and methods for treating bacterial infections
|
WO2018208910A1
(en)
|
2017-05-09 |
2018-11-15 |
The Broad Institute Inc. |
Gut microbiome function predicts response to anti-integrin biologic therapy in inflammatory bowel diseases
|
WO2018209320A1
(en)
|
2017-05-12 |
2018-11-15 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
|
US10994025B2
(en)
|
2017-05-12 |
2021-05-04 |
Massachusetts Institute Of Technology |
Argonaute protein-double stranded RNA complexes and uses related thereto
|
WO2018213476A1
(en)
|
2017-05-16 |
2018-11-22 |
Translate Bio, Inc. |
Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
|
WO2018231690A1
(en)
|
2017-06-12 |
2018-12-20 |
Washington University |
Zika virus strains for treatment of glioblastoma
|
RS61691B1
(en)
|
2017-06-20 |
2021-05-31 |
Inst Curie |
Immune cells defective for suv39h1
|
CN111511906A
(en)
|
2017-06-23 |
2020-08-07 |
因思科瑞普特公司 |
Nucleic acid-guided nucleases
|
WO2019005884A1
(en)
|
2017-06-26 |
2019-01-03 |
The Broad Institute, Inc. |
Crispr/cas-adenine deaminase based compositions, systems, and methods for targeted nucleic acid editing
|
JP2020526558A
(en)
|
2017-07-13 |
2020-08-31 |
ノースウェスタン ユニバーシティ |
Common and direct methods for preparing oligonucleotide functionalized metal-organic framework nanoparticles
|
US11732274B2
(en)
|
2017-07-28 |
2023-08-22 |
President And Fellows Of Harvard College |
Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
|
JP7360171B2
(en)
|
2017-07-31 |
2023-10-12 |
ワシントン・ユニバーシティ |
Pirfenidone derivatives for regulation of B lymphocyte activity and organ protection
|
US20200375929A1
(en)
|
2017-08-14 |
2020-12-03 |
Washington University |
Methods and compositions for the treatment of diseases associated with cancer, inflammation, or immune response
|
WO2019139645A2
(en)
|
2017-08-30 |
2019-07-18 |
President And Fellows Of Harvard College |
High efficiency base editors comprising gam
|
US11097018B2
(en)
|
2017-09-06 |
2021-08-24 |
Washington University |
Organomedicinals for imaging and treatment of neurodegenerative disorders
|
CA3073848A1
(en)
|
2017-09-21 |
2019-03-28 |
The Broad Institute, Inc. |
Systems, methods, and compositions for targeted nucleic acid editing
|
US11795443B2
(en)
|
2017-10-16 |
2023-10-24 |
The Broad Institute, Inc. |
Uses of adenosine base editors
|
US11555189B2
(en)
|
2017-10-18 |
2023-01-17 |
Sarepta Therapeutics, Inc. |
Antisense oligomer compounds
|
US11851679B2
(en)
|
2017-11-01 |
2023-12-26 |
Juno Therapeutics, Inc. |
Method of assessing activity of recombinant antigen receptors
|
AU2018360697A1
(en)
|
2017-11-01 |
2020-05-14 |
Alnylam Pharmaceuticals, Inc. |
Complement component C3 iRNA compositions and methods of use thereof
|
CN107827762B
(en)
*
|
2017-11-14 |
2020-10-02 |
苏州东南药业股份有限公司 |
(2, 3-dioleoyl-propyl) trimethyl ammonium chloride and preparation method and application thereof
|
BR112020009663A2
(en)
|
2017-11-17 |
2020-11-10 |
Iovance Biotherapeutics, Inc. |
method for the expansion of tumor infiltrating lymphocytes (tils) in a therapeutic population of tils, method for the treatment of an individual with cancer, composition
|
WO2019100039A1
(en)
|
2017-11-20 |
2019-05-23 |
Alnylam Pharmaceuticals, Inc. |
Serum amyloid p component (apcs) irna compositions and methods of use thereof
|
JP2021503885A
(en)
|
2017-11-22 |
2021-02-15 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
Expanded culture of peripheral blood lymphocytes (PBL) from peripheral blood
|
WO2019118806A1
(en)
|
2017-12-14 |
2019-06-20 |
Solid Biosciences Inc. |
Non-viral production and delivery of genes
|
AU2018392782B2
(en)
|
2017-12-21 |
2023-08-31 |
Alnylam Pharmaceuticals, Inc. |
Chirally-enriched double-stranded RNA agents
|
US11713446B2
(en)
|
2018-01-08 |
2023-08-01 |
Iovance Biotherapeutics, Inc. |
Processes for generating TIL products enriched for tumor antigen-specific T-cells
|
CA3087771A1
(en)
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
WO2019136459A1
(en)
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
BR112020014315A2
(en)
|
2018-01-17 |
2020-12-08 |
Vertex Pharmaceuticals Incorporated |
DNA-PK INHIBITORS
|
IL276082B2
(en)
|
2018-01-17 |
2024-01-01 |
Vertex Pharma |
Dna-pk inhibitor compounds, compositions comprising same and uses thereof
|
CN111770921B
(en)
|
2018-01-17 |
2024-03-22 |
沃泰克斯药物股份有限公司 |
Quinoxalinone compounds, compositions, methods and kits for improving genome editing efficiency
|
EP3743069A4
(en)
|
2018-01-22 |
2021-06-09 |
BioVentures, LLC |
Bcl-2 proteins degraders for cancer treatment
|
JP2021511356A
(en)
|
2018-01-29 |
2021-05-06 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
Stabilized RSVF protein and its use
|
CN108129338A
(en)
*
|
2018-02-01 |
2018-06-08 |
爱斯特(成都)生物制药股份有限公司 |
A kind of preparation method of cationic liposome DOTAP
|
WO2019160383A1
(en)
|
2018-02-19 |
2019-08-22 |
고려대학교 산학협력단 |
Vaccine comprising epitope of heat shock protein, and use thereof
|
EP3539975A1
(en)
|
2018-03-15 |
2019-09-18 |
Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron |
Micropeptides and uses thereof
|
EP3773505A4
(en)
|
2018-03-30 |
2021-12-22 |
Insmed Incorporated |
Methods for continuous manufacture of liposomal drug products
|
JP2021520781A
(en)
|
2018-04-06 |
2021-08-26 |
チルドレンズ メディカル センター コーポレーションChildren’S Medical Center Corporation |
Compositions and Methods for Somatic Cell Reprogramming and Imprinting Modulation
|
US20210198330A1
(en)
|
2018-05-23 |
2021-07-01 |
The Broad Institute, Inc. |
Base editors and uses thereof
|
MX2020013124A
(en)
|
2018-06-05 |
2021-07-15 |
Lifeedit Therapeutics Inc |
Rna-guided nucleases and active fragments and variants thereof and methods of use.
|
CN113286884A
(en)
|
2018-08-07 |
2021-08-20 |
博德研究所 |
Novel CAS12B enzymes and systems
|
US20210317461A1
(en)
|
2018-08-09 |
2021-10-14 |
Verseau Therapeutics, Inc. |
Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
|
JP2021533755A
(en)
|
2018-08-10 |
2021-12-09 |
ユーティレックス カンパニー リミテッド |
Chimeric antigen receptor and CAR-T cells that bind to HLA-DR
|
US20210317429A1
(en)
|
2018-08-20 |
2021-10-14 |
The Broad Institute, Inc. |
Methods and compositions for optochemical control of crispr-cas9
|
US11174500B2
(en)
|
2018-08-24 |
2021-11-16 |
Translate Bio, Inc. |
Methods for purification of messenger RNA
|
JP2022500003A
(en)
|
2018-09-18 |
2022-01-04 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
Ketohexokinase (KHK) iRNA composition and its usage
|
CN113015741A
(en)
|
2018-09-18 |
2021-06-22 |
桑格摩生物治疗股份有限公司 |
Programmed cell death 1(PD1) specific nucleases
|
WO2020069029A1
(en)
|
2018-09-26 |
2020-04-02 |
Emendobio Inc. |
Novel crispr nucleases
|
KR20210068485A
(en)
|
2018-09-28 |
2021-06-09 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
Cellular reprogramming to reverse aging and promote organ and tissue regeneration
|
GB201815820D0
(en)
|
2018-09-28 |
2018-11-14 |
Univ Wageningen |
Off-target activity inhibitors for guided endonucleases
|
JP2022505139A
(en)
|
2018-10-15 |
2022-01-14 |
フォンダッツィオーネ・テレソン |
Genome editing methods and constructs
|
US20220389395A1
(en)
|
2018-10-29 |
2022-12-08 |
The Broad Institute, Inc. |
Nucleobase editors comprising geocas9 and uses thereof
|
US10913951B2
(en)
|
2018-10-31 |
2021-02-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
|
JP2022506508A
(en)
|
2018-11-05 |
2022-01-17 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
Expanded culture of TIL using AKT pathway inhibitors
|
TW202039829A
(en)
|
2018-11-05 |
2020-11-01 |
美商艾歐凡斯生物治療公司 |
Selection of improved tumor reactive t-cells
|
CR20210295A
(en)
|
2018-11-05 |
2021-07-09 |
Iovance Biotherapeutics Inc |
Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
CN112969469A
(en)
|
2018-11-05 |
2021-06-15 |
艾欧凡斯生物治疗公司 |
Treatment of anti-PD-1 antibody refractory NSCLC patients
|
US20220282275A1
(en)
|
2018-11-15 |
2022-09-08 |
The Broad Institute, Inc. |
G-to-t base editors and uses thereof
|
US20220056444A1
(en)
|
2018-12-05 |
2022-02-24 |
Empirico Inc. |
Process to inhibit or eliminate eosinophilic diseases of the airway and related conditions
|
EP3898958A1
(en)
|
2018-12-17 |
2021-10-27 |
The Broad Institute, Inc. |
Crispr-associated transposase systems and methods of use thereof
|
WO2020131547A1
(en)
|
2018-12-19 |
2020-06-25 |
Iovance Biotherapeutics, Inc. |
Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
|
AU2019406186A1
(en)
|
2018-12-20 |
2021-07-15 |
Praxis Precision Medicines, Inc. |
Compositions and methods for the treatment of KCNT1 related disorders
|
EP4339286A2
(en)
|
2018-12-27 |
2024-03-20 |
LifeEDIT Therapeutics, Inc. |
Polypeptides useful for gene editing and methods of use
|
WO2020150265A1
(en)
|
2019-01-15 |
2020-07-23 |
Empirico Inc. |
Prodrugs of alox-15 inhibitors and methods of using the same
|
US20220098621A1
(en)
|
2019-02-05 |
2022-03-31 |
Emendobio Inc. |
Crispr compositions and methods for promoting gene editing of ribosomal protein s19 (rps19) gene
|
WO2020163017A1
(en)
|
2019-02-06 |
2020-08-13 |
Klogenix Llc |
Dna binding proteins and uses thereof
|
WO2020163307A1
(en)
|
2019-02-06 |
2020-08-13 |
Emendobio Inc. |
New engineered high fidelity cas9
|
WO2020172343A2
(en)
|
2019-02-19 |
2020-08-27 |
Massachusetts Institute Of Technology |
Methods for treating injuries
|
AU2020233284A1
(en)
|
2019-03-01 |
2021-09-16 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
KR20210134943A
(en)
|
2019-03-03 |
2021-11-11 |
프로테나 바이오사이언시즈 리미티드 |
Tau Recognizing Antibodies
|
WO2020181178A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through thymine alkylation
|
WO2020181195A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through adenine excision
|
US20220170013A1
(en)
|
2019-03-06 |
2022-06-02 |
The Broad Institute, Inc. |
T:a to a:t base editing through adenosine methylation
|
WO2020181202A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
A:t to t:a base editing through adenine deamination and oxidation
|
WO2020181180A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
A:t to c:g base editors and uses thereof
|
AU2020236937B2
(en)
|
2019-03-08 |
2023-06-15 |
Obsidian Therapeutics, Inc. |
CD40L compositions and methods for tunable regulation
|
GB201903499D0
(en)
|
2019-03-14 |
2019-05-01 |
Ucl Business Plc |
Minimal promoter
|
WO2020191102A1
(en)
|
2019-03-18 |
2020-09-24 |
The Broad Institute, Inc. |
Type vii crispr proteins and systems
|
WO2020191249A1
(en)
|
2019-03-19 |
2020-09-24 |
The Broad Institute, Inc. |
Methods and compositions for editing nucleotide sequences
|
CN113939586A
(en)
|
2019-04-02 |
2022-01-14 |
桑格摩生物治疗股份有限公司 |
Methods of treating beta-thalassemia
|
WO2020210542A1
(en)
|
2019-04-09 |
2020-10-15 |
The Regents Of The University Of California |
Long-lasting analgesia via targeted in vivo epigenetic repression
|
US20220204975A1
(en)
|
2019-04-12 |
2022-06-30 |
President And Fellows Of Harvard College |
System for genome editing
|
US20220307003A1
(en)
|
2019-04-17 |
2022-09-29 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
EP3958868A4
(en)
|
2019-04-22 |
2023-01-18 |
The Penn State Research Foundation |
Methods and compositions relating to inhibition of aldehyde dehydrogenases for treatment of cancer
|
US20220213469A1
(en)
|
2019-04-30 |
2022-07-07 |
The Broad Institute, Inc. |
Methods and compositions for barcoding nucleic acid libraries and cell populations
|
WO2020232029A1
(en)
|
2019-05-13 |
2020-11-19 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
WO2020232271A1
(en)
|
2019-05-14 |
2020-11-19 |
The Broad Institute, Inc. |
Compositions and methods for targeting multinucleated cells
|
EP3969052A1
(en)
|
2019-05-17 |
2022-03-23 |
Alnylam Pharmaceuticals Inc. |
Oral delivery of oligonucleotides
|
WO2020236972A2
(en)
|
2019-05-20 |
2020-11-26 |
The Broad Institute, Inc. |
Non-class i multi-component nucleic acid targeting systems
|
US20220249697A1
(en)
|
2019-05-20 |
2022-08-11 |
The Broad Institute, Inc. |
Aav delivery of nucleobase editors
|
WO2020243371A1
(en)
|
2019-05-28 |
2020-12-03 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating immune responses
|
CN114040976A
(en)
|
2019-05-29 |
2022-02-11 |
奥驰亚客户服务有限公司 |
Compositions and methods for producing tobacco plants and products with reduced or eliminated smoke branches
|
WO2020243485A1
(en)
|
2019-05-29 |
2020-12-03 |
Massachusetts Institute Of Technology |
Hiv-1 specific immunogen compositions and methods of use
|
GB201909597D0
(en)
|
2019-07-03 |
2019-08-14 |
Univ Wageningen |
Crispr type v-u1 system from mycobacterium mucogenicum and uses thereof
|
CN114222815A
(en)
|
2019-07-23 |
2022-03-22 |
记忆疗法公司 |
SUV39H1 deficient immune cells
|
WO2021025750A1
(en)
|
2019-08-08 |
2021-02-11 |
The Broad Institute, Inc. |
Base editors with diversified targeting scope
|
EP4013864A1
(en)
|
2019-08-12 |
2022-06-22 |
Lifeedit Therapeutics, Inc. |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
WO2021030522A1
(en)
|
2019-08-13 |
2021-02-18 |
Alnylam Pharmaceuticals, Inc. |
SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2021030666A1
(en)
|
2019-08-15 |
2021-02-18 |
The Broad Institute, Inc. |
Base editing by transglycosylation
|
AU2020333667A1
(en)
|
2019-08-16 |
2022-02-24 |
Massachusetts Institute Of Technology |
Targeted trans-splicing using CRISPR/Cas13
|
KR102099342B1
(en)
|
2019-09-03 |
2020-04-10 |
주식회사 제노포커스 |
Expression Method of CRM197 Protein
|
WO2021072248A2
(en)
|
2019-10-10 |
2021-04-15 |
Altria Client Services Llc |
Pale yellow locus and its applications in tobacco
|
WO2021072328A1
(en)
|
2019-10-10 |
2021-04-15 |
The Broad Institute, Inc. |
Methods and compositions for prime editing rna
|
MX2022004388A
(en)
|
2019-11-01 |
2022-05-06 |
Alnylam Pharmaceuticals Inc |
HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF.
|
US20230079440A1
(en)
|
2019-11-01 |
2023-03-16 |
Sangamo Therapeutics, Inc. |
Compositions and methods for genome engineering
|
CN115135765A
(en)
|
2019-11-08 |
2022-09-30 |
菲奥医药公司 |
Chemically modified oligonucleotides targeting bromodomain-containing protein 4(BRD4) for immunotherapy
|
US20230056569A1
(en)
|
2019-11-22 |
2023-02-23 |
Alnylam Pharmaceuticals, Inc. |
Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
|
WO2021108717A2
(en)
|
2019-11-26 |
2021-06-03 |
The Broad Institute, Inc |
Systems and methods for evaluating cas9-independent off-target editing of nucleic acids
|
US20230220341A1
(en)
|
2019-12-11 |
2023-07-13 |
lovance Biotherapeutics, Inc. |
Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same
|
EP4073251A1
(en)
|
2019-12-13 |
2022-10-19 |
Alnylam Pharmaceuticals, Inc. |
Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof
|
CA3164996A1
(en)
|
2019-12-20 |
2021-06-14 |
Novarock Biotherapeutics, Ltd. |
Anti-interleukin-23 p19 antibodies and methods of use thereof
|
CN115190912A
(en)
|
2019-12-30 |
2022-10-14 |
生命编辑制药股份有限公司 |
RNA-guided nucleases, active fragments and variants thereof, and methods of use
|
WO2021138537A1
(en)
|
2019-12-31 |
2021-07-08 |
Phio Pharmaceuticals Corp. |
Chemically modified oligonucleotides with improved systemic delivery
|
JP2023509770A
(en)
|
2020-01-08 |
2023-03-09 |
オブシディアン セラピューティクス, インコーポレイテッド |
Compositions and methods for regulatable control of transcription
|
GB202000934D0
(en)
|
2020-01-22 |
2020-03-04 |
Ucl Business Ltd |
Engineered immune cells
|
CA3166153A1
(en)
|
2020-01-28 |
2021-08-05 |
The Broad Institute, Inc. |
Base editors, compositions, and methods for modifying the mitochondrial genome
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
US20230108687A1
(en)
|
2020-02-05 |
2023-04-06 |
The Broad Institute, Inc. |
Gene editing methods for treating spinal muscular atrophy
|
US20230235309A1
(en)
|
2020-02-05 |
2023-07-27 |
The Broad Institute, Inc. |
Adenine base editors and uses thereof
|
WO2021163191A1
(en)
|
2020-02-10 |
2021-08-19 |
Board Of Regents, The University Of Texas System |
Methods for rapid cloning and expression of hla class i cells
|
PE20230493A1
(en)
|
2020-02-14 |
2023-03-23 |
Merck Sharp And Dohme Llc |
HPV VACCINE
|
US11752199B1
(en)
|
2020-02-25 |
2023-09-12 |
Mallinckrodt Ard Ip Unlimited Company |
Methods of modulating pericytes
|
EP4114947A1
(en)
|
2020-03-05 |
2023-01-11 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
|
EP3885440A1
(en)
|
2020-03-26 |
2021-09-29 |
Splicebio, S.L. |
Split inteins and their uses
|
TW202204615A
(en)
|
2020-03-26 |
2022-02-01 |
美商阿尼拉製藥公司 |
Coronavirus irna compositions and methods of use thereof
|
EP4133076A1
(en)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Angiotensin-converting enzyme 2 (ace2) irna compositions and methods of use thereof
|
EP4133077A1
(en)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
|
TW202208626A
(en)
|
2020-04-24 |
2022-03-01 |
美商生命編輯公司 |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
EP4143319A1
(en)
|
2020-04-27 |
2023-03-08 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein e (apoe) irna agent compositions and methods of use thereof
|
EP4143315A1
(en)
|
2020-04-28 |
2023-03-08 |
The Broad Institute Inc. |
<smallcaps/>? ? ?ush2a? ? ? ? ?targeted base editing of thegene
|
JP2023523855A
(en)
|
2020-05-04 |
2023-06-07 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
Method for producing tumor-infiltrating lymphocytes and their use in immunotherapy
|
CN111393595A
(en)
*
|
2020-05-06 |
2020-07-10 |
东莞市竤穗实业投资有限公司 |
Bio-based polycarbodiimide crosslinking agent with temperature-sensitive characteristic and preparation method thereof
|
CN115715203A
(en)
|
2020-05-06 |
2023-02-24 |
塞勒克提斯公司 |
Methods of genetically modifying cells to deliver therapeutic proteins
|
AU2021268253A1
(en)
|
2020-05-06 |
2022-12-08 |
Cellectis S.A. |
Methods for targeted insertion of exogenous sequences in cellular genomes
|
DE112021002672T5
(en)
|
2020-05-08 |
2023-04-13 |
President And Fellows Of Harvard College |
METHODS AND COMPOSITIONS FOR EDIT BOTH STRANDS SIMULTANEOUSLY OF A DOUBLE STRANDED NUCLEOTIDE TARGET SEQUENCE
|
WO2021231437A1
(en)
|
2020-05-11 |
2021-11-18 |
LifeEDIT Therapeutics, Inc. |
Rna-guided nucleic acid binding proteins and active fragments and variants thereof and methods of use
|
WO2021231680A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
|
EP4150086A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
|
EP4150077A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
|
WO2021231692A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of otoferlin (otof)
|
WO2021231679A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
|
EP4150078A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
|
WO2021231675A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
|
EP4150089A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of retinoschisin 1 (rs1)
|
IL298215A
(en)
|
2020-05-19 |
2023-01-01 |
Othair Prothena Ltd |
Multi-epitope vaccine for the treatment of alzheimer's disease
|
US11408000B2
(en)
|
2020-06-03 |
2022-08-09 |
Triplet Therapeutics, Inc. |
Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
|
WO2021252557A1
(en)
|
2020-06-09 |
2021-12-16 |
Alnylam Pharmaceuticals, Inc. |
Rnai compositions and methods of use thereof for delivery by inhalation
|
IL299771A
(en)
|
2020-07-10 |
2023-03-01 |
Inst Nat Sante Rech Med |
Methods and compositions for treating epilepsy
|
CA3173949A1
(en)
|
2020-07-15 |
2022-01-20 |
LifeEDIT Therapeutics, Inc. |
Uracil stabilizing proteins and active fragments and variants thereof and methods of use
|
WO2022023576A1
(en)
|
2020-07-30 |
2022-02-03 |
Institut Curie |
Immune cells defective for socs1
|
WO2022034374A2
(en)
|
2020-08-11 |
2022-02-17 |
University Of Oslo |
Improved gene editing
|
US20220064596A1
(en)
|
2020-08-25 |
2022-03-03 |
Kite Pharma, Inc. |
T cells with improved functionality
|
KR20230060509A
(en)
|
2020-09-04 |
2023-05-04 |
노바록 바이오테라퓨틱스 리미티드 |
Nectin-4 Antibodies and Uses Thereof
|
JP2023541400A
(en)
|
2020-09-11 |
2023-10-02 |
ライフエディット セラピューティクス,インコーポレイティド |
DNA modification enzymes, active fragments and variants thereof, and methods for using the same
|
US20230348892A1
(en)
|
2020-09-17 |
2023-11-02 |
Northwestern University |
Engineered mamalian genetic circuits and methods of using the same
|
EP4217489A1
(en)
|
2020-09-24 |
2023-08-02 |
Alnylam Pharmaceuticals, Inc. |
Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
|
EP3973978A1
(en)
|
2020-09-25 |
2022-03-30 |
Mallinckrodt Ard IP Unlimited Company |
Methods of modulating corticosteroid response
|
TW202229552A
(en)
|
2020-10-05 |
2022-08-01 |
美商艾拉倫製藥股份有限公司 |
G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof
|
EP4225330A1
(en)
|
2020-10-06 |
2023-08-16 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
EP4229074A1
(en)
|
2020-10-16 |
2023-08-23 |
Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis |
Anti-tumor immunity induces the presentation of aberrant peptides
|
AU2021365822A1
(en)
|
2020-10-21 |
2023-06-08 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating primary hyperoxaluria
|
EP4232582A1
(en)
|
2020-10-23 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Mucin 5b (muc5b) irna compositions and methods of use thereof
|
CA3200234A1
(en)
|
2020-11-25 |
2022-06-02 |
Daryl C. Drummond |
Lipid nanoparticles for delivery of nucleic acids, and related methods of use
|
TW202237150A
(en)
|
2020-12-01 |
2022-10-01 |
美商艾拉倫製藥股份有限公司 |
Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
|
CA3202483A1
(en)
|
2020-12-17 |
2022-06-23 |
Maria Fardis |
Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
|
JP2024500403A
(en)
|
2020-12-17 |
2024-01-09 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
Treatment of cancer with tumor-infiltrating lymphocytes
|
JP2024503437A
(en)
|
2021-01-11 |
2024-01-25 |
ザ ブロード インスティテュート,インコーポレーテッド |
Prime editing factor variants, constructs, and methods to improve prime editing efficiency and accuracy
|
WO2022164796A1
(en)
|
2021-01-26 |
2022-08-04 |
California Institute Of Technology |
Allosteric conditional guide rnas for cell-selective regulation of crispr/cas
|
WO2022164319A1
(en)
|
2021-01-29 |
2022-08-04 |
Wageningen Universiteit |
Crispr-associated base-editing of the complementary strand
|
US20220243216A1
(en)
|
2021-02-03 |
2022-08-04 |
Altria Client Services Llc |
Increasing trichome density and improving transport of metabolites in plant trichomes
|
TW202245835A
(en)
|
2021-02-04 |
2022-12-01 |
美商默沙東有限責任公司 |
Nanoemulsion adjuvant composition for pneumococcal conjugate vaccines
|
BR112023015761A2
(en)
|
2021-02-12 |
2023-11-07 |
Alnylam Pharmaceuticals Inc |
SUPEROXIDE DISMUTASE 1 (SOD1) IRNA COMPOSITIONS AND METHODS OF USE THEREOF TO TREAT OR PREVENT NEURODEGENERATIVE DISEASES ASSOCIATED WITH SUPEROXIDE DISMUTASE 1 (SOD1)
|
WO2022182864A1
(en)
|
2021-02-25 |
2022-09-01 |
Alnylam Pharmaceuticals, Inc. |
Prion protein (prnp) irna compositions and methods and methods of use thereof
|
EP4305169A1
(en)
|
2021-03-12 |
2024-01-17 |
Alnylam Pharmaceuticals, Inc. |
Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
|
AU2022233182A1
(en)
|
2021-03-12 |
2023-10-05 |
Synthego Corporation |
Genetically modified cells expressing antigen-containing fusion proteins and uses thereof
|
AU2022242754A1
(en)
|
2021-03-22 |
2023-11-02 |
LifeEDIT Therapeutics, Inc. |
Dna modifyng enzymes and active fragments and variants thereof and methods of use
|
KR20230162024A
(en)
|
2021-03-29 |
2023-11-28 |
알닐람 파마슈티칼스 인코포레이티드 |
Huntingtin (HTT) iRNA preparation composition and method of use thereof
|
KR20240037185A
(en)
|
2021-04-19 |
2024-03-21 |
이오반스 바이오테라퓨틱스, 인크. |
Chimeric costimulatory receptors, chemokine receptors, and their uses in cellular immunotherapy
|
EP4326873A1
(en)
|
2021-04-22 |
2024-02-28 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating cancer
|
WO2022232343A1
(en)
|
2021-04-29 |
2022-11-03 |
Alnylam Pharmaceuticals, Inc. |
Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof
|
EP4341401A1
(en)
|
2021-05-18 |
2024-03-27 |
Alnylam Pharmaceuticals, Inc. |
Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
|
WO2022246023A1
(en)
|
2021-05-20 |
2022-11-24 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
CA3218475A1
(en)
|
2021-05-21 |
2022-11-24 |
Shipra DAS |
Enhancing efficacy of t-cell-mediated immunotherapy by modulating cancer-associated fibroblasts in solid tumors
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
IL308743A
(en)
|
2021-06-04 |
2024-01-01 |
Alnylam Pharmaceuticals Inc |
HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2022261509A1
(en)
|
2021-06-11 |
2022-12-15 |
The Broad Institute, Inc. |
Improved cytosine to guanine base editors
|
WO2022261394A1
(en)
|
2021-06-11 |
2022-12-15 |
LifeEDIT Therapeutics, Inc. |
Rna polymerase iii promoters and methods of use
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
WO2023278410A1
(en)
|
2021-06-29 |
2023-01-05 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
WO2023288288A1
(en)
|
2021-07-15 |
2023-01-19 |
Turn Biotechnologies, Inc. |
Synthetic, persistent rna constructs with on/off mechanism for controlled expression and methods of use
|
US20230042860A1
(en)
|
2021-07-15 |
2023-02-09 |
Turn Biotechnologies, Inc. |
Polycistronic expression vectors
|
WO2023288287A2
(en)
|
2021-07-15 |
2023-01-19 |
Turn Biotechnologies, Inc. |
Synthetic, persistent rna constructs and methods of use for cell rejuvenation and for treatment
|
GB202110646D0
(en)
|
2021-07-23 |
2021-09-08 |
Sisaf Ltd |
Nucleic acid vector compositions
|
KR20240037293A
(en)
|
2021-07-23 |
2024-03-21 |
알닐람 파마슈티칼스 인코포레이티드 |
Beta-catenin (CTNNB1) iRNA composition and methods of use thereof
|
GB202110644D0
(en)
|
2021-07-23 |
2021-09-08 |
Sisaf Ltd |
Improved nucleic acid vector particles
|
CA3226942A1
(en)
|
2021-07-28 |
2023-02-02 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
|
WO2023015264A1
(en)
|
2021-08-04 |
2023-02-09 |
Phio Pharmaceuticals Corp. |
Immunotherapy of cancer utilizing natural killer cells treated with chemically modified oligonucleotides
|
WO2023015265A2
(en)
|
2021-08-04 |
2023-02-09 |
Phio Pharmaceuticals Corp. |
Chemically modified oligonucleotides
|
CA3227004A1
(en)
|
2021-08-06 |
2023-02-09 |
The Broad Institute, Inc. |
Improved prime editors and methods of use
|
WO2023023152A1
(en)
|
2021-08-19 |
2023-02-23 |
Merck Sharp & Dohme Llc |
Thermostable lipid nanoparticle and methods of use thereof
|
CA3233460A1
(en)
|
2021-10-01 |
2023-04-06 |
Jeroen Petrus Wilhelmus Maria BAKKERS |
Mammalian cardiac regeneration
|
WO2023069603A1
(en)
|
2021-10-22 |
2023-04-27 |
Korro Bio, Inc. |
Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
|
WO2023069498A1
(en)
|
2021-10-22 |
2023-04-27 |
Senda Biosciences, Inc. |
Mrna vaccine composition
|
WO2023076898A1
(en)
|
2021-10-25 |
2023-05-04 |
The Broad Institute, Inc. |
Methods and compositions for editing a genome with prime editing and a recombinase
|
US20230187042A1
(en)
|
2021-10-27 |
2023-06-15 |
Iovance Biotherapeutics, Inc. |
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
|
TW202334418A
(en)
|
2021-10-29 |
2023-09-01 |
美商艾拉倫製藥股份有限公司 |
Huntingtin (htt) irna agent compositions and methods of use thereof
|
WO2023077148A1
(en)
|
2021-11-01 |
2023-05-04 |
Tome Biosciences, Inc. |
Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
|
CN114015674A
(en)
|
2021-11-02 |
2022-02-08 |
辉二(上海)生物科技有限公司 |
Novel CRISPR-Cas12i system
|
WO2023080788A1
(en)
|
2021-11-05 |
2023-05-11 |
Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis |
Tryptophan depletion induces production and presentation of tryptophan to phenylalanine substitutions
|
WO2023086803A1
(en)
|
2021-11-10 |
2023-05-19 |
Iovance Biotherapeutics, Inc. |
Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
|
WO2023096858A1
(en)
|
2021-11-23 |
2023-06-01 |
Senda Biosciences, Inc. |
A bacteria-derived lipid composition and use thereof
|
WO2023096494A1
(en)
|
2021-11-26 |
2023-06-01 |
Synvolux Ip B.V. |
Conserved coronavirus t cell epitopes
|
WO2023122080A1
(en)
|
2021-12-20 |
2023-06-29 |
Senda Biosciences, Inc. |
Compositions comprising mrna and lipid reconstructed plant messenger packs
|
WO2023122764A1
(en)
|
2021-12-22 |
2023-06-29 |
Tome Biosciences, Inc. |
Co-delivery of a gene editor construct and a donor template
|
WO2023122762A1
(en)
|
2021-12-22 |
2023-06-29 |
Camp4 Therapeutics Corporation |
Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas
|
WO2023126458A1
(en)
|
2021-12-28 |
2023-07-06 |
Mnemo Therapeutics |
Immune cells with inactivated suv39h1 and modified tcr
|
WO2023139557A1
(en)
|
2022-01-24 |
2023-07-27 |
LifeEDIT Therapeutics, Inc. |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
WO2023141314A2
(en)
|
2022-01-24 |
2023-07-27 |
Alnylam Pharmaceuticals, Inc. |
Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
|
WO2023150637A1
(en)
|
2022-02-02 |
2023-08-10 |
Inscripta, Inc. |
Nucleic acid-guided nickase fusion proteins
|
WO2023196818A1
(en)
|
2022-04-04 |
2023-10-12 |
The Regents Of The University Of California |
Genetic complementation compositions and methods
|
WO2023196802A1
(en)
|
2022-04-04 |
2023-10-12 |
The Broad Institute, Inc. |
Cas9 variants having non-canonical pam specificities and uses thereof
|
WO2023196851A1
(en)
|
2022-04-06 |
2023-10-12 |
President And Fellows Of Harvard College |
Reversing aging of the central nervous system
|
WO2023205744A1
(en)
|
2022-04-20 |
2023-10-26 |
Tome Biosciences, Inc. |
Programmable gene insertion compositions
|
WO2023212715A1
(en)
|
2022-04-28 |
2023-11-02 |
The Broad Institute, Inc. |
Aav vectors encoding base editors and uses thereof
|
WO2023215831A1
(en)
|
2022-05-04 |
2023-11-09 |
Tome Biosciences, Inc. |
Guide rna compositions for programmable gene insertion
|
WO2023220603A1
(en)
|
2022-05-09 |
2023-11-16 |
Regeneron Pharmaceuticals, Inc. |
Vectors and methods for in vivo antibody production
|
WO2023220457A1
(en)
|
2022-05-13 |
2023-11-16 |
Northwestern University |
Receptor engagement-mediated enhancement of biologics delivery
|
WO2023220459A1
(en)
|
2022-05-13 |
2023-11-16 |
Northwestern University |
Active loading of cargo entity into lipid bilayer particles using dimerization domains
|
WO2023220392A1
(en)
|
2022-05-13 |
2023-11-16 |
Northwestern University |
Synthetic modular extracellular sensors that employ natural receptor ligand-binding domains
|
EP4279085A1
(en)
|
2022-05-20 |
2023-11-22 |
Mnemo Therapeutics |
Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
|
WO2023225670A2
(en)
|
2022-05-20 |
2023-11-23 |
Tome Biosciences, Inc. |
Ex vivo programmable gene insertion
|
WO2023230433A1
(en)
|
2022-05-23 |
2023-11-30 |
Altria Client Services Llc |
Methods and compositions for regulating alkaloids in tobacco field
|
WO2023230613A1
(en)
|
2022-05-27 |
2023-11-30 |
The Broad Institute, Inc. |
Improved mitochondrial base editors and methods for editing mitochondrial dna
|
WO2023235818A2
(en)
|
2022-06-02 |
2023-12-07 |
Scribe Therapeutics Inc. |
Engineered class 2 type v crispr systems
|
US20230392188A1
(en)
|
2022-06-02 |
2023-12-07 |
Perkinelmer Health Sciences, Inc. |
Electrophoresis-mediated characterization of dna content of adeno-associated virus capsids
|
EP4314267A1
(en)
|
2022-06-07 |
2024-02-07 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of pcsk9
|
WO2023240074A1
(en)
|
2022-06-07 |
2023-12-14 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of pcsk9
|
WO2023240137A1
(en)
|
2022-06-08 |
2023-12-14 |
The Board Institute, Inc. |
Evolved cas14a1 variants, compositions, and methods of making and using same in genome editing
|
WO2023240277A2
(en)
|
2022-06-10 |
2023-12-14 |
Camp4 Therapeutics Corporation |
Methods of modulating progranulin expression using antisense oligonucleotides targeting regulatory rnas
|
WO2024003334A1
(en)
|
2022-06-30 |
2024-01-04 |
Cellectis S.A. |
Enhancing safety of t-cell-mediated immunotherapy
|
WO2024015383A1
(en)
|
2022-07-12 |
2024-01-18 |
Northwestern University |
Engineered hypoxia biosensors and methods of using the same
|
WO2024020587A2
(en)
|
2022-07-22 |
2024-01-25 |
Tome Biosciences, Inc. |
Pleiopluripotent stem cell programmable gene insertion
|
WO2024026474A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
WO2024031038A1
(en)
|
2022-08-05 |
2024-02-08 |
Altria Client Services Llc |
Methods and compositions for regulating alkaloids in tobacco
|
WO2024033901A1
(en)
|
2022-08-12 |
2024-02-15 |
LifeEDIT Therapeutics, Inc. |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
WO2024040083A1
(en)
|
2022-08-16 |
2024-02-22 |
The Broad Institute, Inc. |
Evolved cytosine deaminases and methods of editing dna using same
|
WO2024042489A1
(en)
|
2022-08-25 |
2024-02-29 |
LifeEDIT Therapeutics, Inc. |
Chemical modification of guide rnas with locked nucleic acid for rna guided nuclease-mediated gene editing
|
WO2024047587A1
(en)
|
2022-08-31 |
2024-03-07 |
Regel Therapeutics, Inc. |
Cas-phi compositions and methods of use
|
WO2024059165A1
(en)
|
2022-09-15 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
|